Diazepino-thieno-quinoxaline compounds and their use in therapy

WO2024229401A3PCT designated stage expired Publication Date: 2024-12-05MATCHPOINT THERAPEUTICS INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/027775
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-04
Filing Date
2024-05-03
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current treatments for inflammatory disorders, such as inflammatory bowel disease and rheumatoid arthritis, are not effective for a significant percentage of patients and often have undesirable adverse effects, highlighting the need for new therapies that target mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2 or MK2) to manage inflammation effectively.

Method used

Development of diazepino-thieno-quinoxaline compounds that inhibit MK2 activity, which can be administered to treat inflammatory disorders by forming a covalently modified MK2, thereby reducing inflammatory responses.

Benefits of technology

The diazepino-thieno-quinoxaline compounds effectively inhibit MK2 activity, providing a new therapeutic approach to treat inflammatory disorders with potential for improved efficacy and reduced adverse effects compared to existing treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 000001
    Figure 000001
  • Figure 000002
    Figure 000002
  • Figure 000003
    Figure 000003
Patent Text Reader

Abstract

The invention provides diazepino-thieno-quinoxaline compounds, pharmaceutical compositions, their use for inhibiting MK2, and their use in the treatment of a disease or condition, such as an inflammatory disorder.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No.30864-20005.40 DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No.63 / 463,982, filed May 4, 2023, the entire contents of which are hereby incorporated by reference herein. FIELD OF THE INVENTION

[0002] The invention provides diazepino-thieno-quinoxaline compounds, pharmaceutical compositions, their use for inhibiting mitogen-activated protein (MAP) kinase-activated protein kinase 2 (MAPKAPK2, MK2), and their use in the treatment of a disease or condition, such as an inflammatory disorder. BACKGROUND

[0003] Inflammatory disorders impact a substantial number of patients and often involve situations where the patient’s biological response to a stimulus results in the immune system attacking the body’s own cells or tissues. This can lead to abnormal inflammation and result in chronic pain, redness, swelling, stiffness, and / or damage to normal tissues. Inflammatory disorders can be characterized according to whether they are acute or chronic. Common inflammatory disorders affecting a significant number of patients annually include inflammatory bowel disease, asthma, rheumatoid arthritis, ulcerative colitis, and Crohn's disease.

[0004] Common treatments currently available for treating inflammatory disorders include nonsteroidal anti-inflammatory drugs (such as aspirin, ibuprofen, or naproxen), corticosteroids (such as prednisone), and various biologic drugs such as abatacept, adalimumab, certolizumab, etanercept, infliximab, golimumab, rituximab, and tocilizumab. Compounds having inhibitory activity towards mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2 or MK2) have also been reported in literature for use in treating certain inflammatory disorders. See, for example, U.S. Patent Application Publication No.2016 / 0075720 and international patent application publications WO2020 / 236636 and WO 2022 / 020562.

[0005] Mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2 or MK2) has been reported in the literature to mediate multiple p38 MAPK-dependent cellular 1ny-2716015Attorney Docket No.30864-20005.40 responses. See, for example, U.S. Patent Application Publication No.2016 / 0075720. MK2 has also been reported to be an important intracellular regulator of the production of cytokines, such as tumor necrosis factor alpha (TNF-a), interleukin 6 (IL-6) and interferon gamma (IFNg), each of which are involved in several acute and chronic inflammatory diseases. MK2 has also been implicated in heart failure, brain ischemic injury, regulation of stress resistance, and the production of TNF-a. See, e.g., Deak et al., EMBO.17:4426-4441 (1998); Shi et al., Biol. Chem.383:1519-1536 (2002); Staklatvala., Curr. Opin. Pharmacol. 4:372-377 (2004); and Shiroto et al., J. Mol. Cardiol.38:93-97 (2005).

[0006] While existing treatments for inflammatory disorders provide a medical benefit to patients, existing treatments are not effective for a significant percentage of patients and / or have undesirable adverse effects. Thus, new therapies are needed for treating inflammatory disorders. The present invention addresses the foregoing needs and provides other related advantages. SUMMARY

[0007] The invention provides diazepino-thieno-quinoxaline compounds, pharmaceutical compositions, their use for inhibiting MK2, and their use in the treatment of a disease or condition, such as an inflammatory disorder. In particular, one aspect of the invention provides a collection of diazepino-thieno-quinoxaline compounds, such as a compound represented by Formula I:or a pharmaceutically acceptable salt thereof, where the variables are as defined in the detailed description. In one aspect, provided herein are compounds of Formula I’: 2ny-2716015Attorney Docket No.30864-20005.40(I’) or a pharmaceutically acceptable salt thereof, where the variables are as defined in the detailed description.

[0008] Any embodiments provided herein of a compound of Formula I, or a pharmaceutically acceptable salt thereof, or any variation or embodiment thereof, are also embodiments of a compound of formula I’, or a pharmaceutically acceptable salt thereof. Further description of additional collections of diazepino-thieno-quinoxaline compounds are described in the detailed description. The compounds may be part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

[0009] Another aspect of the invention provides a method of treating a disease or condition mediated by MK2 in a subject. The method comprises administering a therapeutically effective amount of a compound described herein, such as a compound of Formula I, I-A, or I-B, to a subject in need thereof to treat the disease or condition, as further described in the detailed description. The method further comprises administering a therapeutically effective amount of a compound described herein, such as a compound of Formula I’, I, I-A, or I-B, to a subject in need thereof to treat the disease or condition, as further described in the detailed description.

[0010] Another aspect of the invention provides a method of inhibiting the activity of a MK2. The method comprises contacting a MK2 with an effective amount of a compound described herein, such as a compound of Formula I, I-A, or I-B, to inhibit the activity of said MK2, as further described in the detailed description. The method further comprises contacting a MK2 with an effective amount of a compound described herein, such as a compound of Formula I’, I, I-A, or I-B, to inhibit the activity of said MK2, as further described in the detailed description.

[0011] Another aspect of the invention provides a method of covalently modifying a MK2. The method comprises contacting a MK2 with an effective amount of a compound described herein, such as a compound of Formula I, I-A, or I-B, to covalently modify the MK2, as 3ny-2716015Attorney Docket No.30864-20005.40 further described in the detailed description. The method further comprises contacting a MK2 with an effective amount of a compound described herein, such as a compound of Formula I’, I, I-A, or I-B, to covalently modify the MK2, as further described in the detailed description. Another aspect of the invention provides a covalently modified MK2 formed by the foregoing method.

[0012] Any embodiments provided herein of a compound of Formula I or I’, or a pharmaceutically acceptable salt thereof, apply where applicable to any other formula detailed herein, the same as if each and every embodiment were specifically and individually listed. Thus, it is understood and described that each embodiment provided herein of a compound of formula I or I’, or a pharmaceutically acceptable salt thereof, such as embodiments related to R1, R2, R3, R4, R5, R6, R7, X, R8, and n apply to formulas I, I’, Ia, Ib, Ic, Id, Ie, If, I-A, I-B, or II, or a pharmaceutically acceptable salt thereof, the same as if each and every embodiment were specifically and individually listed. It is also understood and described that all such embodiments may be used in any of the pharmaceutical compositions, methods, kits, uses, or other aspects detailed herein. DETAILED DESCRIPTION

[0013] The invention provides diazepino-thieno-quinoxaline compounds, pharmaceutical compositions, their use for inhibiting MK2, and their use in the treatment of a disease or condition, such as an inflammatory disorder. The practice of the present invention employs, unless otherwise indicated, conventional techniques of organic chemistry, pharmacology, molecular biology (including recombinant techniques), cell biology, biochemistry, and immunology. Such techniques are explained in the literature, such as in Comprehensive Organic Synthesis (B.M. Trost & I. Fleming, eds., 1991-1992); Handbook of Experimental Immunology (D.M. Weir & C.C. Blackwell, eds.); Current Protocols in Molecular Biology (F.M. Ausubel et al., eds., 1987, and periodic updates); and Current Protocols in Immunology” (J.E. Coligan et al., eds., 1991), each of which is herein incorporated by reference in its entirety.

[0014] Various aspects of the invention are set forth below in sections; however, aspects of the invention described in one particular section are not to be limited to any particular section. Further, when a variable is not accompanied by a definition, the previous definition of the variable controls. 4ny-2716015Attorney Docket No.30864-20005.40 Definitions

[0015] Compounds of the present invention include those described generally herein, and are further illustrated by the classes, subclasses, and species disclosed herein. As used herein, the following definitions shall apply unless otherwise indicated. These definitions apply regardless of whether a term is used by itself or in combination with other terms, unless otherwise indicated. Hence, the definition of “alkyl” applies to “alkyl” as well as the “alkyl” portions of “-O-alkyl” etc. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd. Additionally, general principles of organic chemistry are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito: 1999, and March’s Advanced Organic Chemistry, 5thEd., Ed.: Smith, M.B. and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are hereby incorporated by reference.

[0016] The term “aliphatic” or “aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “cycloaliphatic”), that has a single point of attachment to the rest of the molecule. Unless otherwise specified, aliphatic groups contain 1-6 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1- 5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms. In some embodiments, “cycloaliphatic” refers to a monocyclic C3-C6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.

[0017] As used herein, the term “bicyclic ring” or “bicyclic ring system” refers to any bicyclic ring system, i.e., carbocyclic or heterocyclic, saturated or having one or more units of unsaturation, having one or more atoms in common between the two rings of the ring system. Thus, the term includes any permissible ring fusion, such as ortho-fused or spirocyclic. As used herein, the term “heterobicyclic” is a subset of “bicyclic” that requires that one or more heteroatoms are present in one or both rings of the bicycle. Such heteroatoms may be present 5ny-2716015Attorney Docket No.30864-20005.40 at ring junctions and are optionally substituted, and may be selected from nitrogen (including N-oxides), oxygen, sulfur (including oxidized forms such as sulfones and sulfonates), phosphorus (including oxidized forms such as phosphates), boron, etc. In some embodiments, a bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. As used herein, the term “bridged bicyclic” refers to any bicyclic ring system, i.e., carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge. As defined by IUPAC, a “bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a “bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen). In some embodiments, a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. Such bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bicyclic rings include:6ny-2716015Attorney Docket No.30864-20005.40.

[0019] The term “lower alkyl” refers to a C1-4 straight or branched alkyl group. Exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.

[0020] The term “lower haloalkyl” refers to a C1-4straight or branched alkyl group that is substituted with one or more halogen atoms.

[0021] The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen; or a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR+(as in N-substituted pyrrolidinyl)).

[0022] The term “unsaturated,” as used herein, means that a moiety has one or more units of unsaturation.

[0023] As used herein, the term “bivalent C1-8 (or C1-6) saturated or unsaturated, straight or branched, hydrocarbon chain”, refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.

[0024] The term “alkylene” refers to a bivalent alkyl group. An “alkylene chain” is a polymethylene group, i.e., –(CH2)n–, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.

[0025] The term “-(C0alkylene)-“ refers to a bond. Accordingly, the term “-(C0-3alkylene)-” encompasses a bond (i.e., C0) and a -(C1-3 alkylene)- group.

[0026] The term “alkenylene” refers to a bivalent alkenyl group. A substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group. 7ny-2716015Attorney Docket No.30864-20005.40

[0027] The term “halogen” or “halo” means F, Cl, Br, or I.

[0028] The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments of the present invention, “aryl” refers to an aromatic ring system which includes, but is not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents. Also included within the scope of the term “aryl,” as it is used herein, is a group in which an aromatic ring is fused to one or more non– aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like. The term “phenylene” refers to a multivalent phenyl group having the appropriate number of open valences to account for groups attached to it. For example, “phenylene” is a bivalent phenyl group when it has two groups attached to it (e.g., is a trivalent phenyl group when it has three groups attached to itThe term “arylene” refers to a bivalent aryl group.

[0029] The terms “heteroaryl” and “heteroar–,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 p electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. The term “heteroatom” refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. The terms “heteroaryl” and “heteroar–”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where unless otherwise specified, the radical or point of attachment is on the heteroaromatic ring or on one of the rings to which the heteroaromatic ring is fused. Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H–quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, and tetrahydroisoquinolinyl. A heteroaryl group may be 8ny-2716015Attorney Docket No.30864-20005.40 mono– or bicyclic. The term “heteroaryl” may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted. The term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.

[0030] As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5– to 7–membered monocyclic or 7–10–membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term “nitrogen” includes a substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0–3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4–dihydro–2H–pyrrolyl), NH (as in pyrrolidinyl), or+NR (as in N– substituted pyrrolidinyl).

[0031] A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, 2-oxa-6- azaspiro[3.3]heptane, and quinuclidinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H–indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl. A heterocyclyl group may be mono– or bicyclic. The term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted. The term “oxo-heterocyclyl” refers to a heterocyclyl substituted by an oxo group. The term “heterocyclylene” refers to a multivalent heterocyclyl group having the appropriate number of open valences to account for groups attached to it. For example, “heterocyclylene” is a bivalent heterocyclyl group when it has two groups attached to it; “heterocyclylene” is a trivalent heterocyclyl group when it has three groups attached to it.

[0032] As used herein, the term “partially unsaturated” refers to a ring moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass 9ny-2716015Attorney Docket No.30864-20005.40 rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.

[0033] As described herein, compounds of the invention may contain “optionally substituted” moieties. In general, the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds. The term “stable,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.

[0034] Each optional substituent on a substitutable carbon is a monovalent substituent independently selected from halogen; –(CH2)0–4R°; –(CH2)0–4OR°; -O(CH2)0-4Ro, –O–(CH2)0– 4C(O)OR°; –(CH2)0–4CH(OR°)2; –(CH2)0–4SR°; –(CH2)0–4Ph, which may be substituted with R°; –(CH2)0–4O(CH2)0–1Ph which may be substituted with R°; –CH=CHPh, which may be substituted with R°; –(CH2)0–4O(CH2)0–1-pyridyl which may be substituted with R°; –NO2; – CN; –N3; -(CH2)0–4N(R°)2; –(CH2)0–4N(R°)C(O)R°; –N(R°)C(S)R°; –(CH2)0–4N(R°)C(O)NR°2; -N(R°)C(S)NR°2; –(CH2)0–4N(R°)C(O)OR°; –N(R°)N(R°)C(O)R°; -N(R°)N(R°)C(O)NR°2; -N(R°)N(R°)C(O)OR°; –(CH2)0–4C(O)R°; –C(S)R°; –(CH2)0–4C(O)OR°; –(CH2)0–4C(O)SR°; -(CH2)0–4C(O)OSiR°3; –(CH2)0–4OC(O)R°; –OC(O)(CH2)0–4SR–, SC(S)SR°; –(CH2)0–4SC(O)R°; –(CH2)0–4C(O)NR°2; –C(S)NR°2; –C(S)SR°; –SC(S)SR°, -(CH2)0–4OC(O)NR°2; -C(O)N(OR°)R°; –C(O)C(O)R°; –C(O)CH2C(O)R°; –C(NOR°)R°; -(CH2)0–4SSR°; –(CH2)0–4S(O)2R°; –(CH2)0–4S(O)2OR°; –(CH2)0–4OS(O)2R°; –S(O)2NR°2; –S(O)(NR°)R°; – S(O)2N=C(NR°2)2; -(CH2)0–4S(O)R°; -N(R°)S(O)2NR°2; –N(R°)S(O)2R°; –N(OR°)R°; – C(NH)NR°2; –P(O)2R°; -P(O)R°2; -OP(O)R°2; –OP(O)(OR°)2; SiR°3; –(C1–4 straight or branched alkylene)O–N(R°)2; or –(C1–4 straight or branched alkylene)C(O)O–N(R°)2.

[0035] Each R° is independently hydrogen, C1–6 aliphatic, –CH2Ph, –O(CH2)0–1Ph, -CH2-(5-6 membered heteroaryl ring), or a 5–6–membered saturated, partially unsaturated, or aryl ring 10ny-2716015Attorney Docket No.30864-20005.40 having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 3–12–membered saturated, partially unsaturated, or aryl mono– or bicyclic ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which may be substituted by a divalent substituent on a saturated carbon atom of R° selected from =O and =S; or each R° is optionally substituted with a monovalent substituent independently selected from halogen, –(CH2)0–2Rl, –(haloRl), –(CH2)0–2OH, – (CH2)0–2ORl, –(CH2)0–2CH(ORl)2; -O(haloRl), –CN, –N3, –(CH2)0–2C(O)Rl, –(CH2)0–2C(O)OH, –(CH2)0–2C(O)ORl, –(CH2)0–2SRl, –(CH2)0–2SH, –(CH2)0–2NH2, –(CH2)0–2NHRl, –(CH2)0–2NRl 2, –NO2, –SiRl 3, –OSiRl 3, -C(O)SRl , –(C1–4straight or branched alkylene)C(O)ORl, or –SSRl.

[0036] Each Rlis independently selected from C1–4 aliphatic, –CH2Ph, –O(CH2)0–1Ph, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each Rlis unsubstituted or where preceded by halo is substituted only with one or more halogens; or wherein an optional substituent on a saturated carbon is a divalent substituent independently selected from =O, =S, =NNR*2, =NNHC(O)R*, =NNHC(O)OR*, =NNHS(O)2R*, =NR*,or a divalent substituent bound to vicinal substitutable carbons of an “optionally substituted” group is –O(CR*2)2–3O–, wherein each independent occurrence of R*is selected from hydrogen, C1–6aliphatic or an unsubstituted 5– 6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

[0037] When R*is C1–6aliphatic, R*is optionally substituted with halogen, – Rl, -(haloRl), -OH, –ORl, –O(haloRl), –CN, –C(O)OH, –C(O)ORl, –NH2, –NHRl, –NRl2, or –NO2, wherein each Rlis independently selected from C1–4 aliphatic, –CH2Ph, –O(CH2)0–1Ph, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each Rlis unsubstituted or where preceded by halo is substituted only with one or more halogens.

[0038] An optional substituent on a substitutable nitrogen is independently –R†, –NR†2, – C(O)R†, –C(O)OR†, –C(O)C(O)R†, –C(O)CH2C(O)R†, -S(O)2R†, -S(O)2NR†2, –C(S)NR†2, – C(NH)NR†2, or –N(R†)S(O)2R†; wherein each R†is independently hydrogen, C1–6 aliphatic, unsubstituted –OPh, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, 11ny-2716015Attorney Docket No.30864-20005.40 two independent occurrences of R†, taken together with their intervening atom(s) form an unsubstituted 3–12–membered saturated, partially unsaturated, or aryl mono– or bicyclic ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein when R†is C1–6aliphatic, R†is optionally substituted with halogen, –Rl, -(haloRl), -OH, – ORl, –O(haloRl), –CN, –C(O)OH, –C(O)ORl, –NH2, –NHRl, –NRl2, or –NO2, wherein each Rlis independently selected from C1–4 aliphatic, –CH2Ph, –O(CH2)0–1Ph, or a 5–6– membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and wherein each Rlis unsubstituted or where preceded by halo is substituted only with one or more halogens.

[0039] As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1–19, incorporated herein by reference in its entirety. Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2–hydroxy–ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2– naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3–phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p–toluenesulfonate, undecanoate, valerate salts, and the like.

[0040] Further, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl et al., Camille G. (eds.) Handbook of Pharmaceutical Salts. Properties, 12ny-2716015Attorney Docket No.30864-20005.40 Selection and Use. (2002) Zurich: Wiley-VCH; S. Berge et al., Journal of Pharmaceutical Sciences 1977, 66(1), 1-19; P. Gould, International J. of Pharmaceutics 1986, 33, 201-217; Anderson et al., The Practice of Medicinal Chemistry (1996), Academic Press, New York; and in The Orange Book (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference in their entirety.

[0041] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(C1–4alkyl)4salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.

[0042] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. The invention includes compounds that differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a13C- or14C-enriched carbon are within the scope of this invention. Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.

[0043] Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, such as, for example, by chromatography and / or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixture into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., chiral auxiliary such as a chiral alcohol or Mosher’s acid chloride), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Alternatively, a particular enantiomer of a compound of the present invention may be prepared by asymmetric synthesis. Still further, where the molecule contains a basic functional group (such as amino) or an acidic functional group (such as carboxylic acid) diastereomeric salts 13ny-2716015Attorney Docket No.30864-20005.40 are formed with an appropriate optically-active acid or base, followed by resolution of the diastereomers thus formed by fractional crystallization or chromatographic means known in the art, and subsequent recovery of the pure enantiomers.

[0044] Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. Chiral center(s) in a compound of the present invention can have the S or R configuration as defined by the IUPAC 1974 Recommendations. Further, to the extent a compound described herein may exist as an atropisomer (e.g., substituted biaryls), all forms of such atropisomer are considered part of this invention.

[0045] Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates. It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.

[0046] Unless specified otherwise, the term “about” refers to within ±10% of the stated value. The invention encompasses embodiments where the value is within ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2%, or ±1% of the stated value.

[0047] The terms “a” and “an” as used herein mean “one or more” and include the plural unless the context is inappropriate.

[0048] The term “alkyl” refers to a saturated straight or branched hydrocarbon, such as a straight or branched group of 1-12, 1-10, or 1-6 carbon atoms, referred to herein as C1-C12 alkyl, C1-C10alkyl, and C1-C6alkyl, respectively. Exemplary alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2- methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1- pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4- methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, etc.

[0049] The term “cycloalkyl” refers to a monovalent saturated cyclic, bicyclic, or bridged cyclic (e.g., adamantyl) hydrocarbon group of 3-12, 3-8, 4-8, or 4-6 carbons, referred to herein, e.g., as “C3-C6 cycloalkyl,” derived from a cycloalkane. Exemplary cycloalkyl groups 14ny-2716015Attorney Docket No.30864-20005.40 include cyclohexyl, cyclopentyl, cyclobutyl, and cyclopropyl. The term “cycloalkylene” refers to a bivalent cycloalkyl group.

[0050] The term “haloalkyl” refers to an alkyl group that is substituted with at least one halogen. Exemplary haloalkyl groups include -CH2F, -CHF2, -CF3, -CH2CF3, -CF2CF3, and the like. The term “haloalkylene” refers to a bivalent haloalkyl group.

[0051] The term “haloheteroaryl” refers to a heteroaryl group that is substituted with at least one chloro group. In certaine embodiments, the haloheteroaryl is a heteroaryl group that is substituted with one chloro group.

[0052] The terms “alkenyl” and “alkynyl” are art-recognized and refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double or triple bond, respectively.

[0053] The terms “alkoxyl” or “alkoxy” are art-recognized and refer to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like. The term “haloalkoxyl” refers to an alkoxyl group that is substituted with at least one halogen. Exemplary haloalkoxyl groups include -OCH2F, -OCHF2, -OCF3, -OCH2CF3, -OCF2CF3, and the like. The term “hydroxyalkoxyl” refers to an alkoxyl group that is substituted with at least one hydroxyl. Exemplary hydroxyalkoxyl groups include -OCH2CH2OH, -OCH2C(H)(OH)CH2CH2OH, and the like. The term “alkoxylene” refers to a bivalent alkoxyl group.

[0054] The term “oxo” is art-recognized and refers to a “=O” substituent. For example, a cyclopentane substituted with an oxo group is cyclopentanone.

[0055] The symbol “ ” indicates a point of attachment.

[0056] When any substituent or variable occurs more than one time in any constituent or the compound of the invention, its definition on each occurrence is independent of its definition at every other occurrence, unless otherwise indicated.

[0057] One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. “Solvate” means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example 15ny-2716015Attorney Docket No.30864-20005.40 when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanolates, methanolates, and the like. “Hydrate” is a solvate wherein the solvent molecule is H2O.

[0058] As used herein, the terms “subject” and “patient” are used interchangeably and refer to organisms to be treated by the methods of the present invention. Such organisms preferably include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines, and the like), and, most preferably, include humans.

[0059] As used herein, the term “compound” refers to a quantity of molecules that is sufficient to be weighed, tested for its structural identity, and to have a demonstrable use (e.g., a quantity that can be shown to be active in an assay, an in vitro test, or in vivo test, or a quantity that can be administered to a patient and provide a therapeutic benefit).

[0060] The term “IC50” is art-recognized and refers to the concentration of a compound that is required to achieve 50% inhibition of the target.

[0061] As used herein, the term “effective amount” refers to the amount of a compound sufficient to effect beneficial or desired results (e.g., a therapeutic, ameliorative, inhibitory, or preventative result). An effective amount can be administered in one or more administrations, applications, or dosages and is not intended to be limited to a particular formulation or administration route.

[0062] As used herein, the term “treating” includes any effect, e.g., lessening, reducing, modulating, ameliorating or eliminating, that results in the improvement of the condition, disease, disorder, and the like, or ameliorating a symptom thereof.

[0063] As used herein, the term “pharmaceutical composition” refers to the combination of an active agent with a carrier, inert or active, making the composition especially suitable for diagnostic or therapeutic use in vivo or ex vivo.

[0064] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutical carriers, such as a phosphate-buffered saline solution, water, emulsions (e.g., such as oil / water or water / oil emulsions), and various types of wetting agents. The compositions also can include stabilizers and preservatives. For examples of carriers, stabilizers and adjuvants, see e.g., Martin, Remington’s Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA

[1975] , herein incorporated by reference in its entirety. 16ny-2716015Attorney Docket No.30864-20005.40

[0065] Throughout the description, where compositions are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is contemplated that, additionally, there are compositions of the present invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the present invention that consist essentially of, or consist of, the recited processing steps.

[0066] As a general matter, compositions specifying a percentage are by weight unless otherwise specified. I. Diazepino-thieno-quinoxaline Compounds

[0067] The invention provides diazepino-thieno-quinoxaline compounds. The compounds may be used in the pharmaceutical compositions and therapeutic methods described herein. Exemplary compounds are described in the following sections, along with exemplary procedures for making the compounds.

[0068] One aspect of the invention provides a compound represented by Formula I’:or a pharmaceutically acceptable salt thereof, wherein: R1and R2are independently hydrogen or C1-4 alkyl; or R1and R2are taken together with the carbon atom to which they are attached to form a 3-7 membered saturated carbocyclic ring or a 3-7 membered heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of R6; R3and R4are independently hydrogen or C1-4alkyl; R5is -O-(9-11 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7; R6is C1-4alkyl or C1-4haloalkyl; 17ny-2716015Attorney Docket No.30864-20005.40 R7is C1-4alkyl, C1-4deuteroalkyl, C1-4haloalkyl, -(C1-3alkylene)-C1-4alkoxy, or oxo; or two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring; X is -N(R8)-, -O-, or -CH2-; R8is hydrogen or C1-4alkyl; and n is 0, 1, 2, or 3.

[0069] One aspect of the invention provides a compound represented by Formula I:or a pharmaceutically acceptable salt thereof, wherein: R1and R2are independently hydrogen or C1-4 alkyl; or R1and R2are taken together with the carbon atom to which they are attached to form a 3-7 membered saturated carbocyclic ring or a 3-7 membered heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of R6; R3and R4are independently hydrogen or C1-4 alkyl; R5is -O-(9-11 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7; R6is C1-4alkyl or C1-4haloalkyl; R7is C1-4alkyl, C1-4deuteroalkyl, C1-4haloalkyl, -(C1-3alkylene)-C1-4alkoxy, or oxo; or two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring; X is -N(R8)-, -O-, or -CH2-; R8is hydrogen or C1-4 alkyl; and n is 0, 1, or 2.

[0070] The definitions of variables in Formula I above encompass multiple chemical groups. The application contemplates embodiments where, for example, (i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, (ii) 18ny-2716015Attorney Docket No.30864-20005.40 the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and (iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).

[0071] In certain embodiments, the compound is a compound of Formula I.

[0072] As defined generally above, R1and R2are independently hydrogen or C1-4alkyl; or R1and R2are taken together with the carbon atom to which they are attached to form a 3-7 membered saturated carbocyclic ring or a 3-7 membered heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of R6. In certain embodiments, R1is C1-4 alkyl. In certain embodiments, R1is methyl. In certain embodiments, R2is hydrogen. In certain embodiments, R1is methyl and R2is hydrogen. In certain embodiments, R1is hydrogen. In certain embodiments, R2is C1-4 alkyl. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 3 membered saturated carbocyclic ring substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 3 membered saturated carbocyclic ring substituted with 0 occurrences of methyl. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 3 membered saturated carbocyclic ring substituted with 1 occurrence of methyl. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 4 membered saturated carbocyclic ring or a 4 membered heterocyclic ring containing 1 nitrogen atom, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 4 membered saturated carbocyclic ring, wherein the carbocyclic ring is substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 4 membered heterocyclic ring containing 1 nitrogen atom, wherein the heterocyclic ring is substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 6 membered saturated carbocyclic ring or a 6 membered heterocyclic ring containing 1 nitrogen atom, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 6 membered saturated carbocyclic ring, wherein the carbocyclic ring is substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2, taken together with the carbon 19ny-2716015Attorney Docket No.30864-20005.40 atom to which they are attached, form a 6 membered heterocyclic ring containing 1 nitrogen atom, wherein the heterocyclic ring is substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a ring selected from, wherein * represents the carbon atom. In certain embodiments, R1is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R2is selected from the groups depicted in the compounds in Table 1, below.

[0073] As defined generally above, R3and R4are independently hydrogen or C1-4alkyl. In certain embodiments, each of R3and R4is hydrogen. In certain embodiments, R3is hydrogen. In certain embodiments, R4is hydrogen. In certain embodiments, R3is C1-4 alkyl. In certain embodiments, R4is C1-4 alkyl. In certain embodiments, R3is methyl. In certain embodiments, R4is methyl. In certain embodiments, R3is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R4is selected from the groups depicted in the compounds in Table 1, below.

[0074] As defined generally above, R5is -O-(9-11 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(9 membered bicyclic heteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(9 membered bicyclic heteroaryl containing 1 heteroatom selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(9 membered bicyclic heteroaryl containing 2 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(9 membered bicyclic heteroaryl containing 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(10 membered bicyclic heteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(10 membered bicyclic heteroaryl containing 1 heteroatom selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(10 membered bicyclic heteroaryl containing 2 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted 20ny-2716015Attorney Docket No.30864-20005.40 with n occurrences of R7). In certain embodiments, R5is -O-(10 membered bicyclic heteroaryl containing 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(11 membered bicyclic heteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(11 membered bicyclic heteroaryl containing 1 heteroatom selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(11 membered bicyclic heteroaryl containing 2 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(11 membered bicyclic heteroaryl containing 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7).

[0075] In certain embodiments,A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclyl is substituted with n occurrence of R7. In certain embodiments,wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclyl is substituted with n occurrences of R7. In certain embodiments,wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclyl is substituted with n occurrences of R7. In certain embodiments,, wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclyl is 21ny-2716015Attorney Docket No.30864-20005.40 substituted with n occurrences of R7. In certain embodiments,wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclyl is unsubstituted. In certain embodiments,wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclyl is substituted with 1 occurrence of R7. In certain embodiments,wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclyl is substituted with 2 occurrences of R7.22ny-2716015Attorney Docket No.30864-20005.40 embodiments,certain embodiments,certain embodiments,. In certain embodiments,certain embodiments, R5iscertain embodiments,certain embodiments,certain embodiments,certain embodiments,certain embodiments,In certain embodiments,certain embodiments, R5is. In certain embodiments, R5is selected from the groups depicted in the compounds in Table 1, below. 23ny-2716015Attorney Docket No.30864-20005.40

[0077] As defined generally above, R6is C1-4alkyl or C1-4haloalkyl. In certain embodiments, R6is methyl. In certain embodiments, R6is C2 alkyl. In certain embodiments, R6is C3 alkyl. In certain embodiments, R6is C4 alkyl. In certain embodiments, R6is C1-4 haloalkyl. In certain embodiments, R6is C1haloalkyl. In certain embodiments, R6is C2haloalkyl. In certain embodiments, R6is C3haloalkyl. In certain embodiments, R6is C4haloalkyl. In certain embodiments, R6is selected from the groups depicted in the compounds in Table 1, below.

[0078] As defined generally above, R7is C1-4alkyl, C1-4deuteroalkyl, C1-4haloalkyl, or oxo; or two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring. In certain embodiments, R7is methyl, - CHF2, -CH2CHF2, or oxo. In certain embodiments, n is 2, the two R7groups are attached to the same carbon atom, and the two R7groups are taken together with the carbon atom to which they are attached to form a cyclopropyl ring. In certain embodiments, R7is C1-4 alkyl. In certain embodiments, R7is C2alkyl. In certain embodiments, R7is C3alkyl. In certain embodiments, R7is C4alkyl. In certain embodiments, R7is C1-4deuteroalkyl. In certain embodiments, R7is C1 deuteroalkyl. In certain embodiments, R7is C2 deuteroalkyl. In certain embodiments, R7is C3deuteroalkyl. In certain embodiments, R7is C4deuteroalkyl. In certain embodiments, R7is -CD3. In certain embodiments, R7is C1-4haloalkyl. In certain embodiments, R7is C1 haloalkyl. In certain embodiments, R7is C2 haloalkyl. In certain embodiments, R7is C3 haloalkyl. In certain embodiments, R7is C4 haloalkyl. In certain embodiments, R7is oxo. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 4 membered saturated carbocyclic ring. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 5 membered saturated carbocyclic ring. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 6 membered saturated carbocyclic ring. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 7 membered saturated carbocyclic ring. In certain embodiments, R7is selected from the groups depicted in the compounds in Table 1, below. 24ny-2716015Attorney Docket No.30864-20005.40

[0079] As defined generally above, X is -N(R8)-, -O-, or -CH2-. In certain embodiments, X is -N(R8)-. In certain embodiments, X is -O-. In certain embodiments, X is -CH2-. In certain embodiments, X is selected from the groups depicted in the compounds in Table 1, below.

[0080] As defined generally above, R8is hydrogen or C1-4alkyl. In certain embodiments, R8is hydrogen. In certain embodiments, R8is C1-4alkyl. In certain embodiments, R8is C1alkyl. In certain embodiments, R8is C2 alkyl. In certain embodiments, R8is C3 alkyl. In certain embodiments, R8is C4alkyl. In certain embodiments, R8is selected from the groups depicted in the compounds in Table 1, below.

[0081] As defined generally above, n is 0, 1, or 2. In certain embodiments, n is 0, 1, 2, or 3. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2. In certain embodiments, n is 3.

[0082] The description above describes multiple embodiments relating to compounds of Formula I. The patent application specifically contemplates all combinations of the embodiments.

[0083] In certain embodiments, the compound of Formula I is further defined by Formula Ia:Ia or a pharmaceutically acceptable salt thereof. In certain embodiments, the definition of variable R5is one of the embodiments described above in connection with Formula I. In certain embodiments, the compound of Formula I’ is further defined by Formula Ia, or a pharmaceutically acceptable salt thereof.

[0084] In certain embodiments, the compound of Formula I is further defined by Formula Ib:25ny-2716015Attorney Docket No.30864-20005.40 Ib or a pharmaceutically acceptable salt thereof. In certain embodiments, the definition of variable R5is one of the embodiments described above in connection with Formula I. In certain embodiments, the compound of Formula I’ is further defined by Formula Ib, or a pharmaceutically acceptable salt thereof.

[0085] In certain embodiments, the compound of Formula I is further defined by Formula Ic:Ic or a pharmaceutically acceptable salt thereof. In certain embodiments, the definition of variable R5is one of the embodiments described above in connection with Formula I. In certain embodiments, the compound of Formula I’ is further defined by Formula Ic, or a pharmaceutically acceptable salt thereof.

[0086] In certain embodiments, the compound of Formula I is further defined by Formula Id:or a pharmaceutically acceptable salt thereof. In certain embodiments, the definition of variable R5is one of the embodiments described above in connection with Formula I. In certain embodiments, the compound of Formula I’ is further defined by Formula Id, or a pharmaceutically acceptable salt thereof. 26ny-2716015Attorney Docket No.30864-20005.40

[0087] In certain embodiments, the compound of Formula I is further defined by Formula Ie:or a pharmaceutically acceptable salt thereof, wherein q is 0, 1, or 2. In certain embodiments, the definition of variables R5and R6is one of the embodiments described above in connection with Formula I. In certain embodiments, the compound of Formula I’ is further defined by Formula Ie, or a pharmaceutically acceptable salt thereof.

[0088] In certain embodiments, the compound of Formula I is further defined by Formula If:If or a pharmaceutically acceptable salt thereof, wherein q is 0, 1, or 2. In certain embodiments, the definition of variables R5and R20is one of the embodiments described above in connection with Formula I. In certain embodiments, the compound of Formula I’ is further defined by Formula If, or a pharmaceutically acceptable salt thereof.

[0089] Another aspect of the invention provides a compound represented by Formula I-A:27ny-2716015Attorney Docket No.30864-20005.40 or a pharmaceutically acceptable salt thereof, wherein: R1and R2are independently hydrogen or C1-4 alkyl; or R1and R2are taken together with the carbon atom to which they are attached to form a 3-7 membered saturated carbocyclic ring or a 3-7 membered heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of R6; R3and R4are independently hydrogen or C1-4alkyl; R5is -O-(9-11 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7; R6is C1-4alkyl; R7is C1-4 alkyl, C1-4 deuteroalkyl, C1-4 haloalkyl, -(C1-3 alkylene)-C1-4 alkoxy, or oxo; or two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring; and n is 0, 1, or 2.

[0090] The definitions of variables in Formula I-A above encompass multiple chemical groups. The application contemplates embodiments where, for example, (i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, (ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and (iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).

[0091] In certain embodiments, the compound is a compound of Formula I-A.

[0092] As defined generally above, R1and R2are independently hydrogen or C1-4 alkyl; or R1and R2are taken together with the carbon atom to which they are attached to form a 3-7 membered saturated carbocyclic ring or a 3-7 membered heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of R6. In certain embodiments, R1is C1-4 alkyl. In certain embodiments, R1is methyl. In certain embodiments, R2is hydrogen. In certain embodiments, R1is methyl, and R2is hydrogen. In certain embodiments, R1is hydrogen. In certain embodiments, R2is C1-4 alkyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 3 membered saturated carbocyclic ring substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 3 membered saturated carbocyclic ring 28ny-2716015Attorney Docket No.30864-20005.40 substituted with 0 occurrences of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 3 membered saturated carbocyclic ring substituted with 1 occurrence of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 4 membered saturated carbocyclic ring or a 4 membered heterocyclic ring containing 1 nitrogen atom, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 4 membered saturated carbocyclic ring, wherein the carbocyclic ring is substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 4 membered heterocyclic ring containing 1 nitrogen atom, wherein the heterocyclic ring is substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 6 membered saturated carbocyclic ring or a 6 membered heterocyclic ring containing 1 nitrogen atom, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 6 membered saturated carbocyclic ring, wherein the carbocyclic ring is substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 6 membered heterocyclic ring containing 1 nitrogen atom, wherein the heterocyclic ring is substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a ring selected from , ,,, wherein * represents the carbon atom. In certain embodiments, R1is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R2is selected from the groups depicted in the compounds in Table 1, below.

[0093] As defined generally above, R3and R4are independently hydrogen or C1-4 alkyl. In certain embodiments, each of R3and R4is hydrogen. In certain embodiments, R3is hydrogen. In certain embodiments, R4is hydrogen. In certain embodiments, R3is C1-4alkyl. In certain embodiments, R4is C1-4 alkyl. In certain embodiments, R3is methyl. In certain embodiments, R4is methyl. In certain embodiments, R3is selected from the groups depicted 29ny-2716015Attorney Docket No.30864-20005.40 in the compounds in Table 1, below. In certain embodiments, R4is selected from the groups depicted in the compounds in Table 1, below.

[0094] As defined generally above, R5is -O-(9-11 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(9 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(9 membered bicyclic chloroheteroaryl containing 1 heteroatom selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(9 membered bicyclic chloroheteroaryl containing 2 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(9 membered bicyclic chloroheteroaryl containing 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(10 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(10 membered bicyclic chloroheteroaryl containing 1 heteroatom selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(10 membered bicyclic chloroheteroaryl containing 2 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(10 membered bicyclic chloroheteroaryl containing 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(11 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(11 membered bicyclic chloroheteroaryl containing 1 heteroatom selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(11 membered bicyclic chloroheteroaryl containing 2 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(11 membered bicyclic chloroheteroaryl containing 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). 30ny-2716015Attorney Docket No.30864-20005.40

[0095] In certain embodiments,, wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclic ring is substituted with n occurrence of R7. In certain embodiments,wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclic ring is substituted with n occurrences of R7. In certain embodiments, R5is, wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclic ring is substituted with n occurrences of R7. In certain embodiments,, wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclic ring is substituted with n occurrences of R7. In certain embodiments,wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclic ring is unsubstituted. In certain embodiments,wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclic ring is substituted with 1 occurrence of R7. In certain embodiments, 31ny-2716015Attorney Docket No.30864-20005.40wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclic ring is substituted with 2 occurrences of R7.certain embodiments,certain embodiments,32ny-2716015Attorney Docket No.30864-20005.40 . In certain embodiments,certain embodiments, R5iscertain embodiments,embodiments,certain embodiments,embodiments,In certain embodiments,certain embodiments, R5is. In certain embodiments, R5is selected from the groups depicted in the compounds in Table 1, below.

[0097] As defined generally above, R6is C1-4 alkyl. In certain embodiments, R6is methyl. In certain embodiments, R6is C2 alkyl. In certain embodiments, R6is C3 alkyl. In certain embodiments, R6is C4alkyl. In certain embodiments, R6is selected from the groups depicted in the compounds in Table 1, below.

[0098] As defined generally above, R7is C1-4 alkyl, C1-4 deuteroalkyl, C1-4 haloalkyl, or oxo; or two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring. In certain embodiments, R7is methyl, - 33ny-2716015Attorney Docket No.30864-20005.40 CHF2, -CH2CHF2, or oxo. In certain embodiments, n is 2, the two R7groups are attached to the same carbon atom, and the two R7groups are taken together with the carbon atom to which they are attached to form a cyclopropyl ring. In certain embodiments, R7is C1-4 alkyl. In certain embodiments, R7is C2alkyl. In certain embodiments, R7is C3alkyl. In certain embodiments, R7is C4alkyl. In certain embodiments, R7is C1-4deuteroalkyl. In certain embodiments, R7is C1 deuteroalkyl. In certain embodiments, R7is C2 deuteroalkyl. In certain embodiments, R7is C3deuteroalkyl. In certain embodiments, R7is C4deuteroalkyl. In certain embodiments, R7is -CD3. In certain embodiments, R7is C1-4haloalkyl. In certain embodiments, R7is C1 haloalkyl. In certain embodiments, R7is C2 haloalkyl. In certain embodiments, R7is C3 haloalkyl. In certain embodiments, R7is C4 haloalkyl. In certain embodiments, R7is oxo. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 4 membered saturated carbocyclic ring. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 5 membered saturated carbocyclic ring. In certain embodiments, two R7groups attached to the same carbon atom are together with the carbon atom to form a 6 membered saturated carbocyclic ring. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 7 membered saturated carbocyclic ring. In certain embodiments, R7is selected from the groups depicted in the compounds in Table 1, below.

[0099] As defined generally above, n is 0, 1, or 2. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2.

[0100] The description above describes multiple embodiments relating to compounds of Formula I-A. The patent application specifically contemplates all combinations of the embodiments.

[0101] Another aspect of the invention provides a compound represented by Formula I-B:34ny-2716015Attorney Docket No.30864-20005.40 (I-B) or a pharmaceutically acceptable salt thereof, wherein: R1and R2are independently hydrogen or C1-4 alkyl; or R1and R2are taken together with the carbon atom to which they are attached to form a 3-7 membered saturated carbocyclic ring or a 3-7 membered heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of R6;, wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclic ring is substituted with n occurrence of R7. R6is C1-4 alkyl; R7is C1-4alkyl, C1-4deuteroalkyl, C1-4haloalkyl, -(C1-3alkylene)-C1-4alkoxy, or oxo; or two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring; and n is 0, 1, or 2.

[0102] The definitions of variables in Formula I-B above encompass multiple chemical groups. The application contemplates embodiments where, for example, (i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, (ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and (iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).

[0103] In certain embodiments, the compound is a compound of Formula I-B.

[0104] As defined generally above, R1and R2are independently hydrogen or C1-4 alkyl; or R1and R2are taken together with the carbon atom to which they are attached to form a 3-7 membered saturated carbocyclic ring or a 3-7 membered heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of R6. In certain embodiments, R1is C1-4 alkyl. In certain embodiments, R1is methyl. In certain embodiments, R2is hydrogen. In certain embodiments, R1is methyl, and R2is hydrogen. In certain embodiments, R1is hydrogen. In certain embodiments, R2is 35ny-2716015Attorney Docket No.30864-20005.40 C1-4alkyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 3 membered saturated carbocyclic ring substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 3 membered saturated carbocyclic ring substituted with 0 occurrences of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 3 membered saturated carbocyclic ring substituted with 1 occurrence of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 4 membered saturated carbocyclic ring or a 4 membered heterocyclic ring containing 1 nitrogen atom, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 4 membered saturated carbocyclic ring, wherein the carbocyclic ring is substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 4 membered heterocyclic ring containing 1 nitrogen atom, wherein the heterocyclic ring is substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 6 membered saturated carbocyclic ring or a 6 membered heterocyclic ring containing 1 nitrogen atom, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 6 membered saturated carbocyclic ring, wherein the carbocyclic ring is substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a 6 membered heterocyclic ring containing 1 nitrogen atom, wherein the heterocyclic ring is substituted with 0 or 1 occurrences of methyl. In certain embodiments, R1and R2are taken together with the carbon atom to which they are attached to form a ring selected from , ,,, wherein * represents the carbon atom. In certain embodiments, R1is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R2is selected from the groups depicted in the compounds in Table 1, below.

[0105] As defined generally above, R5is -O-(9-11 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the 36ny-2716015Attorney Docket No.30864-20005.40 heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(9 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(9 membered bicyclic chloroheteroaryl containing 1 heteroatom selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(9 membered bicyclic chloroheteroaryl containing 2 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(9 membered bicyclic chloroheteroaryl containing 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(10 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(10 membered bicyclic chloroheteroaryl containing 1 heteroatom selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(10 membered bicyclic chloroheteroaryl containing 2 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(10 membered bicyclic chloroheteroaryl containing 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(11 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(11 membered bicyclic chloroheteroaryl containing 1 heteroatom selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(11 membered bicyclic chloroheteroaryl containing 2 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7). In certain embodiments, R5is -O-(11 membered bicyclic chloroheteroaryl containing 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7).

[0106] In certain embodiments,, wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, 37ny-2716015Attorney Docket No.30864-20005.40 nitrogen, and sulfur, and wherein the heterocyclic ring is substituted with n occurrence of R7. In certain embodiments,wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclic ring is substituted with n occurrences of R7. In certain embodiments, R5is, wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclyl is substituted with n occurrences of R7. In certain embodiments,, wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclic ring is substituted with n occurrences of R7. In certain embodiments,wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclic ring is unsubstituted. In certain embodiments,wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclic ring is substituted with 1 occurrence of R7. In certain embodiments,wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclic ring is substituted with 2 occurrences of R7. 38ny-2716015Attorney Docket No.30864-20005.40

[0107] In certain embodiments, R5is selected fromcertain embodiments,certain embodiments,. In certain embodiments,certain embodiments, R5iscertain embodiments, 39ny-2716015Attorney Docket No.30864-20005.40embodiments,certain embodiments,embodiments,In certain embodiments,certain embodiments, R5is. In certain embodiments, R5is selected from the groups depicted in the compounds in Table 1, below.

[0108] As defined generally above, R6is C1-4 alkyl. In certain embodiments, R6is methyl. In certain embodiments, R6is C2 alkyl. In certain embodiments, R6is C3 alkyl. In certain embodiments, R6is C4alkyl. In certain embodiments, R6is selected from the groups depicted in the compounds in Table 1, below.

[0109] As defined generally above, R7is C1-4 alkyl, C1-4 deuteroalkyl, C1-4 haloalkyl, or oxo; or two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring. In certain embodiments, R7is methyl, - CHF2, -CH2CHF2, or oxo. In certain embodiments, n is 2, the two R7groups are attached to the same carbon atom, and the two R7groups are taken together with the carbon atom to which they are attached to form a cyclopropyl ring. In certain embodiments, R7is C1-4alkyl. In certain embodiments, R7is C2 alkyl. In certain embodiments, R7is C3 alkyl. In certain embodiments, R7is C4 alkyl. In certain embodiments, R7is C1-4 deuteroalkyl. In certain embodiments, R7is C1deuteroalkyl. In certain embodiments, R7is C2deuteroalkyl. In certain embodiments, R7is C3deuteroalkyl. In certain embodiments, R7is C4deuteroalkyl. 40ny-2716015Attorney Docket No.30864-20005.40 In certain embodiments, R7is -CD3. In certain embodiments, R7is C1-4haloalkyl. In certain embodiments, R7is C1 haloalkyl. In certain embodiments, R7is C2 haloalkyl. In certain embodiments, R7is C3 haloalkyl. In certain embodiments, R7is C4 haloalkyl. In certain embodiments, R7is oxo. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 4 membered saturated carbocyclic ring. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 5 membered saturated carbocyclic ring. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 6 membered saturated carbocyclic ring. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 7 membered saturated carbocyclic ring. In certain embodiments, R7is selected from the groups depicted in the compounds in Table 1, below.

[0110] As defined generally above, n is 0, 1, or 2. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2.

[0111] The description above describes multiple embodiments relating to compounds of Formula I-B. The patent application specifically contemplates all combinations of the embodiments.

[0112] Another aspect of the invention provides a compound represented by Formula II:or a pharmaceutically acceptable salt thereof, wherein: R1and R3are independently hydrogen, C1-4 alkyl, or C3-4 cycloalkyl; R2is C1-4alkyl, C1-4hydroxyalkyl, -C(O)N(R6)(R7), or hydrogen; or, alternatively, R1and R2, taken together with the carbon atom to which they are attached, form a 3-7 membered saturated carbocyclic ring or a 3-7 membered saturated heterocyclic ring containing 1 or 2 41ny-2716015Attorney Docket No.30864-20005.40 nitrogen atoms, wherein the carbocyclylic ring and the heterocyclylic ring are substituted with 1 or 2 occurrences of R20; R4is hydrogen, C1-4 alkyl, or -C(O)N(R9)(R10); or R4and R3are taken together to form oxo; Y is -O- or -N(R8)-; R5Ais a 9-11 membered bicyclic haloheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the haloheteroaryl is substituted with n occurrences of R7); R6is C1-4 alkyl or C1-4 haloalkyl; R7is C1-4 alkyl, C1-4 deuteroalkyl, C1-4 haloalkyl, -(C1-3 alkylene)-C1-4 alkoxy, or oxo; or two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring; X is -N(R8)-, -O-, or -CH2-; R8is hydrogen or C1-4alkyl; R9and R10are independently hydrogen, C1-6alkyl, -(C1-6alkylene)-(C3-7cycloalkyl), or C3-7 cycloalkyl; or R9and R10when bonded to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 3-7 membered heterocyclic ring containing 1 nitrogen atom; and n is 0, 1, or 2.

[0113] The definitions of variables in Formula II above encompass multiple chemical groups. The application contemplates embodiments where, for example, (i) the definition of a variable is a single chemical group selected from those chemical groups set forth above, (ii) the definition of a variable is a collection of two or more of the chemical groups selected from those set forth above, and (iii) the compound is defined by a combination of variables in which the variables are defined by (i) or (ii).

[0114] In certain embodiments, the compound is a compound of Formula II.

[0115] As defined generally above, R1and R3are independently hydrogen, C1-4 alkyl, or C3-4 cycloalkyl. In certain embodiments, R1and R3are hydrogen. In certain embodiments, R1is hydrogen. In certain embodiments, R1is C1-4 alkyl. In certain embodiments, R1is C1 alkyl. In certain embodiments, R1is C2 alkyl. In certain embodiments, R1is C3 alkyl. In certain embodiments, R1is C4alkyl. In certain embodiments, R1is C3-4cycloalkyl. In certain embodiments, R1is C3 cycloalkyl. In certain embodiments, R1is C4 cycloalkyl. In certain embodiments, R3is hydrogen. In certain embodiments, R3is C1-4 alkyl. In certain 42ny-2716015Attorney Docket No.30864-20005.40 embodiments, R3is C1alkyl. In certain embodiments, R3is C2alkyl. In certain embodiments, R3is C3 alkyl. In certain embodiments, R3is C4 alkyl. In certain embodiments, R3is C3-4 cycloalkyl. In certain embodiments, R3is C3 cycloalkyl. In certain embodiments, R3is C4cycloalkyl. In certain embodiments, R1is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R3is selected from the groups depicted in the compounds in Table 1, below.

[0116] As defined generally above, R2is C1-4alkyl, C1-4hydroxyalkyl, -C(O)N(R6)(R7), or hydrogen; or, alternatively, R1and R2, taken together with the carbon atom to which they are attached, form a 3-7 membered saturated carbocyclic ring or a 3-7 membered saturated heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the carbocyclic ring and the heterocyclic ring are substituted with 1 or 2 occurrences of R20. In certain embodiments, R2is C1-4 alkyl. In certain embodiments, R2is -CH3. In certain embodiments, R2is C1-4 hydroxyalkyl. In certain embodiments, R2is -C(O)N(R6)(R7). In certain embodiments, R2is hydrogen. In certain embodiments, R2is C2alkyl. In certain embodiments, R2is C3alkyl. In certain embodiments, R2is C4alkyl. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 3-7 membered saturated carbocyclic ring, wherein the carbocyclic ring is substituted with 1 or 2 occurrences of R20. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 3 membered saturated carbocyclic ring, wherein the carbocyclic ring is substituted with 1 or 2 occurrences of R20. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 4 membered saturated carbocyclic ring, wherein the carbocyclyic ring is substituted with 1 or 2 occurrences of R20. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 5 membered saturated carbocyclic ring, wherein the carbocyclic ring is substituted with 1 or 2 occurrences of R20. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 6 membered saturated carbocyclic ring, wherein the carbocyclic ring is substituted with 1 or 2 occurrences of R20. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 7 membered saturated carbocyclic ring, wherein the carbocyclic ring is substituted with 1 or 2 occurrences of R20. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 3-7 membered saturated heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the heterocyclic ring is substituted with 1 or 2 occurrences of R20. In certain embodiments, R1and R2, taken together with the carbon atom 43ny-2716015Attorney Docket No.30864-20005.40 to which they are attached, form a 3 membered saturated heterocyclic ring containing 1 nitrogen atom, wherein the heterocyclic ring is substituted with 1 or 2 occurrences of R20. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 4 membered saturated heterocyclic ring containing 1 nitrogen atom, wherein the heterocyclic ring is substituted with 1 or 2 occurrences of R20. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 5 membered satured heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the heterocyclic ring is substituted with 1 or 2 occurrences of R20. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 6 membered saturated heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the heterocyclic ring is substituted with 1 or 2 occurrences of R20. In certain embodiments, R1and R2, taken together with the carbon atom to which they are attached, form a 7 membered satured heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the heterocyclic ring is substituted with 1 or 2 occurrences of R20. In certain embodiments, R2is selected from the groups depicted in the compounds in Table 1, below.

[0117] As defined generally above, R4is hydrogen, C1-4 alkyl, or -C(O)N(R6)(R7); or R4and R3are taken together to form oxo. In certain embodiments, R4is hydrogen. In certain embodiments, R4is -C(O)N(R6)(R7). In certain embodiments, R4and R3are taken together to form oxo. In certain embodiments, R4is C1-4 alkyl. In certain embodiments, R4is selected from the groups depicted in the compounds in Table 1, below.

[0118] As defined generally above, Y is -O- or -N(R8)-. In certain embodiments, Y is -O-. In certain embodiments, Y is -N(R8)-. In certain embodiments, Y is selected from the groups depicted in the compounds in Table 1, below.

[0119] As defined generally above, R5Ais a 9-11 membered bicyclic haloheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the haloheteroaryl is substituted with n occurrences of R7. In certain embodiments, R5Ais a 9-11 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the chloroheteroaryl is substituted with n occurrences of R7. In certain embodiments, R5Ais a 9-11 membered bicyclic fluoroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the fluoroheteroaryl is substituted with n occurrences of R7. 44ny-2716015Attorney Docket No.30864-20005.40

[0120] In certain embodiments, R5Ais a 9 membered bicyclic haloheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the haloheteroaryl is substituted with n occurrences of R7. In certain embodiments, R5Ais a 9 membered bicyclic haloheteroaryl containing 1 heteroatom selected from nitrogen, oxygen, and sulfur, wherein the haloheteroaryl is substituted with n occurrences of R7. In certain embodiments, R5Ais a 9 membered bicyclic haloheteroaryl containing 2 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the haloheteroaryl is substituted with n occurrences of R7. In certain embodiments, R5Ais a 9 membered bicyclic haloheteroaryl containing 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the haloheteroaryl is substituted with n occurrences of R7. In certain embodiments, R5Ais a 10 membered bicyclic haloheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the haloheteroaryl is substituted with n occurrences of R7. In certain embodiments, R5Ais a 10 membered bicyclic haloheteroaryl containing 1 heteroatom selected from nitrogen, oxygen, and sulfur, wherein the haloheteroaryl is substituted with n occurrences of R7. In certain embodiments, R5Ais a 10 membered bicyclic haloheteroaryl containing 2 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the haloheteroaryl is substituted with n occurrences of R7. In certain embodiments, R5Ais a 10 membered bicyclic haloheteroaryl containing 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the haloheteroaryl is substituted with n occurrences of R7. In certain embodiments, R5Ais an 11 membered bicyclic haloheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the haloheteroaryl is substituted with n occurrences of R7. In certain embodiments, R5Ais an 11 membered bicyclic haloheteroaryl containing 1 heteroatom selected from nitrogen, oxygen, and sulfur, wherein the haloheteroaryl is substituted with n occurrences of R7. In certain embodiments, R5Ais an 11 membered bicyclic haloheteroaryl containing 2 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the haloheteroaryl is substituted with n occurrences of R7. In certain embodiments, R5Ais an 11 membered bicyclic haloheteroaryl containing 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the haloheteroaryl is substituted with n occurrences of R7. 45ny-2716015Attorney Docket No.30864-20005.40

[0121] In certain embodiments,,wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclyl is substituted with n occurrence of R7. In certain embodiments, R5Ais, wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclyl is substituted with n occurrences of R7. In certain embodiments,, wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclyl is substituted with n occurrences of R7. In certain embodiments, R5Ais, wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclyl is substituted with n occurrences of R7. In certain embodiments,, wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclyl is unsubstituted. In certain embodiments,wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclyl is substituted with 1 occurrence of R7. In 46ny-2716015Attorney Docket No.30864-20005.40 certain embodiments,, wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclyl is substituted with 2 occurrences of R7.

[0122] In certain embodiments,wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclyl is substituted with n occurrences of R7. In certain embodiments, R5Ais, wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclyl is substituted with n occurrences of R7. In certain embodiments,, wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclyl is substituted with n occurrences of R7. In certain embodiments,wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclyl is unsubstituted. In certain embodiments,wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclyl is substituted with 1 occurrence of R7. In certain embodiments, R5Ais 47ny-2716015Attorney Docket No.30864-20005.40, wherein A is a 5-7 membered heterocyclyl containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclyl is substituted with 2 occurrences of R7.In certain embodiments,certain embodiments, R5Ais 48ny-2716015Attorney Docket No.30864-20005.40certain embodiments,embodiments,certain embodiments,certain embodiments,certain embodiments,In certain embodiments,certain embodiments, R5Ais49ny-2716015Attorney Docket No.30864-20005.40In certain embodiments,certain embodiments, R5Aiscertain embodiments,embodiments,certain embodiments,certain embodiments,certain embodiments,50ny-2716015Attorney Docket No.30864-20005.40 In certain embodiments,certain embodiments, R5Aiscertain embodiments,certain embodiments, R5Ais selected from the groups depicted in the compounds in Table 1, below.

[0125] As defined generally above, R6is C1-4alkyl or C1-4haloalkyl. In certain embodiments, R6is methyl. In certain embodiments, R6is C2alkyl. In certain embodiments, R6is C3 alkyl. In certain embodiments, R6is C4 alkyl. In certain embodiments, R6is C1-4 haloalkyl. In certain embodiments, R6is C1 haloalkyl. In certain embodiments, R6is C2 haloalkyl. In certain embodiments, R6is C3haloalkyl. In certain embodiments, R6is C4haloalkyl. In certain embodiments, R6is selected from the groups depicted in the compounds in Table 1, below.

[0126] As defined generally above, R7is C1-4alkyl, C1-4deuteroalkyl, C1-4haloalkyl, or oxo; or two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring. In certain embodiments, R7is methyl, - CHF2, -CH2CHF2, or oxo. In certain embodiments, n is 2, the two R7groups are attached to the same carbon atom, and the two R7groups are taken together with the carbon atom to which they are attached to form a cyclopropyl ring. In certain embodiments, R7is C1-4 alkyl. In certain embodiments, R7is C2 alkyl. In certain embodiments, R7is C3 alkyl. In certain embodiments, R7is C4alkyl. In certain embodiments, R7is C1-4deuteroalkyl. In certain embodiments, R7is C1 deuteroalkyl. In certain embodiments, R7is C2 deuteroalkyl. In certain embodiments, R7is C3 deuteroalkyl. In certain embodiments, R7is C4 deuteroalkyl. In certain embodiments, R7is -CD3. In certain embodiments, R7is C1-4haloalkyl. In certain embodiments, R7is C1haloalkyl. In certain embodiments, R7is C2haloalkyl. In certain embodiments, R7is C3 haloalkyl. In certain embodiments, R7is C4 haloalkyl. In certain embodiments, R7is oxo. In certain embodiments, two R7groups attached to the same carbon 51ny-2716015Attorney Docket No.30864-20005.40 atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 4 membered saturated carbocyclic ring. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 5 membered saturated carbocyclic ring. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 6 membered saturated carbocyclic ring. In certain embodiments, two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 7 membered saturated carbocyclic ring. In certain embodiments, R7is selected from the groups depicted in the compounds in Table 1, below.

[0127] As defined generally above, X is -N(R8)-, -O-, or -CH2-. In certain embodiments, X is -N(R8)-. In certain embodiments, X is -O-. In certain embodiments, X is -CH2-. In certain embodiments, X is selected from the groups depicted in the compounds in Table 1, below.

[0128] As defined generally above, R8is hydrogen or C1-4alkyl. In certain embodiments, R8is hydrogen. In certain embodiments, R8is C1-4alkyl. In certain embodiments, R8is C1alkyl. In certain embodiments, R8is C2 alkyl. In certain embodiments, R8is C3 alkyl. In certain embodiments, R8is C4alkyl. In certain embodiments, R8is selected from the groups depicted in the compounds in Table 1, below.

[0129] As defined generally above, R9and R10are independently hydrogen, C1-6 alkyl, -(C1-6 alkylene)-(C3-7 cycloalkyl), or C3-7 cycloalkyl; or R9and R10when bonded to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 3-7 membered heterocyclic ring containing 1 nitrogen atom. In certain embodiments, R9and R10are independently hydrogen or C1-6 alkyl. In certain embodiments, R9is hydrogen. In certain embodiments, R9is C1-6alkyl. In certain embodiments, R9is –(C1-6alkylene)-(C3-7cycloalkyl), In certain embodiments, R9is C3-7cycloalkyl. In certain embodiments, R10is hydrogen. In certain embodiments, R10is C1-6 alkyl. In certain embodiments, R10is –(C1-6 alkylene)-(C3-7 cycloalkyl), In certain embodiments, R10is C3-7 cycloalkyl. In certain embodiments, R9and R10when bonded to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 3-7 membered heterocyclic ring containing 1 nitrogen atom. In certain embodiments, R9and R10when bonded to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 3 membered heterocyclic ring containing 1 nitrogen atom. In certain embodiments, R9and R10when bonded to the same nitrogen atom are taken together with the nitrogen atom to 52ny-2716015Attorney Docket No.30864-20005.40 which they are attached to form a 4 membered heterocyclic ring containing 1 nitrogen atom. In certain embodiments, R9and R10when bonded to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 5 membered heterocyclic ring containing 1 nitrogen atom. In certain embodiments, R9and R10when bonded to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 6 membered heterocyclic ring containing 1 nitrogen atom. In certain embodiments, R9and R10when bonded to the same nitrogen atom are taken together with the nitrogen atom to which they are attached to form a 7 membered heterocyclic ring containing 1 nitrogen atom. In certain embodiments, R9is selected from the groups depicted in the compounds in Table 1, below. In certain embodiments, R10is selected from the groups depicted in the compounds in Table 1, below.

[0130] As defined generally above, n is 0, 1, or 2. In certain embodiments, n is 0. In certain embodiments, n is 1. In certain embodiments, n is 2.

[0131] The description above describes multiple embodiments relating to compounds of Formula II. The patent application specifically contemplates all combinations of the embodiments.

[0132] Another aspect of the invention provides a compound in Table 1 below, or a pharmaceutically acceptable salt thereof. In certain embodiments, the compound is a compound in Table 1. In certain embodiments, the compound is selected from compounds I- 1 to I-32 in Table 1. TABLE 1.53 ny-2716015Attorney Docket No.30864-20005.4054 ny-2716015Attorney Docket No.30864-20005.4055 ny-2716015Attorney Docket No.30864-20005.4056 ny-2716015Attorney Docket No.30864-20005.4057 ny-2716015Attorney Docket No.30864-20005.4058 ny-2716015Attorney Docket No.30864-20005.4059 ny-2716015Attorney Docket No.30864-20005.40

[0133] Another aspect of the invention provides a compound selected from the group consisting of: (R)-3-((2-chloro-7-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (15R)-5-({2-chloro-7-methyl-5H,6H,7H,8H,9H-pyrimido[4,5-d]azepin-4-yl}oxy)-15- methyl-11-thia-3,6,14,17-tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)- hexaen-13-one; 2-chloro-4-{[(15R)-15-methyl-13-oxo-11-thia-3,6,14,17- tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-5-yl]oxy}-5H,7H-6λ⁶- thieno[3,4-d]pyrimidine-6,6-dione; (R)-3-((2-chloro-5,5-dioxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (R)-3-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (R)-3-((2-chloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 2-chloro-4-{[(15R)-15-methyl-13-oxo-11-thia-3,6,14,17- tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-5-yl]oxy}-5H,7H,8H- 6λ⁶-thiopyrano[4,3-d]pyrimidine-6,6-dione; (R)-3-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (R)-3-((2-chloro-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 60 ny-2716015Attorney Docket No.30864-20005.40 (R)-3-((2-chloro-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12- tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (R)-3-((2-chloro-7,7-dimethyl-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (R)-3-((2-chloro-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3’-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclobutane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[azetidine-3,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-methyl- 11’,12’-dihydrospiro[azetidine-3,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)- one; 3’-((2’-chloro-5’,8’-dihydro-6’H-spiro[cyclopropane-1,7’-pyrido[4,3-d]pyrimidin]-4’- yl)oxy)-11’,12’-dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2- f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-6-(difluoromethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 11’,12’-dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]- 8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclobutane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[azetidine-3,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-methyl- 11’,12’-dihydrospiro[azetidine-3,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)- one; 3’-((2’-chloro-6’-methyl-5’,8’-dihydro-6’H-spiro[cyclopropane-1,7’-pyrido[4,3- d]pyrimidin]-4’-yl)oxy)-11’,12’-dihydrospiro[cyclopropane-1,10’- [1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 61 ny-2716015Attorney Docket No.30864-20005.40 3’-((2-chloro-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 11’,12’-dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]- 8’(9’H)-one; 3’-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinolin]-8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinolin]-8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; (R)-3-((2-chloro-7-methyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (R)-3-((2-chloro-6-(methyl-d3)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (R)-3-((2-chloro-6-methyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (R)-3-((2-chloro-6-(methyl-d3)-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4- yl)oxy)-10-methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8- one; (R)-3-((2-chloro-6-methyl-7-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10,10-dimethyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10,10- dimethyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10,10-dimethyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-(2-methoxyethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 10,10-dimethyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin-8-one; 62 ny-2716015Attorney Docket No.30864-20005.40 3'-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11',12'- dihydrospiro[cyclopropane-1,10'-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin]-8'(9'H)-one; and 3'-((2-chloro-6-(2-methoxyethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 11',12'-dihydrospiro[cyclopropane-1,10'-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin]- 8'(9'H)-one; or a pharmaceutically acceptable salt thereof.

[0134] Another aspect of the invention provides a compound selected from the group consisting of: 3-((2-chloro-7-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 5-({2-chloro-7-methyl-5H,6H,7H,8H,9H-pyrimido[4,5-d]azepin-4-yl}oxy)-15-methyl- 11-thia-3,6,14,17-tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-13- one; 2-chloro-4-{[15-methyl-13-oxo-11-thia-3,6,14,17- tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-5-yl]oxy}-5H,7H-6λ⁶- thieno[3,4-d]pyrimidine-6,6-dione; 3-((2-chloro-5,5-dioxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12- tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 2-chloro-4-{[15-methyl-13-oxo-11-thia-3,6,14,17- tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-5-yl]oxy}-5H,7H,8H- 6λ⁶-thiopyrano[4,3-d]pyrimidine-6,6-dione; 3-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12- tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12- tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 63 ny-2716015Attorney Docket No.30864-20005.40 3-((2-chloro-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12- tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-7,7-dimethyl-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3’-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclobutane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[azetidine-3,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-methyl- 11’,12’-dihydrospiro[azetidine-3,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)- one; 3’-((2’-chloro-5’,8’-dihydro-6’H-spiro[cyclopropane-1,7’-pyrido[4,3-d]pyrimidin]-4’- yl)oxy)-11’,12’-dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2- f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-6-(difluoromethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 11’,12’-dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]- 8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclobutane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[azetidine-3,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-methyl- 11’,12’-dihydrospiro[azetidine-3,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)- one; 3’-((2’-chloro-6’-methyl-5’,8’-dihydro-6’H-spiro[cyclopropane-1,7’-pyrido[4,3- d]pyrimidin]-4’-yl)oxy)-11’,12’-dihydrospiro[cyclopropane-1,10’- [1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 64 ny-2716015Attorney Docket No.30864-20005.40 3’-((2-chloro-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 11’,12’-dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]- 8’(9’H)-one; 3’-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinolin]-8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinolin]-8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3-((2-chloro-7-methyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-(methyl-d3)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-methyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-(methyl-d3)-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-methyl-7-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10,10-dimethyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10,10- dimethyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10,10-dimethyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-(2-methoxyethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 10,10-dimethyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin-8-one; 65 ny-2716015Attorney Docket No.30864-20005.40 3'-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11',12'- dihydrospiro[cyclopropane-1,10'-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin]-8'(9'H)-one; and 3'-((2-chloro-6-(2-methoxyethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 11',12'-dihydrospiro[cyclopropane-1,10'-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin]- 8'(9'H)-one; or a pharmaceutically acceptable salt thereof.

[0135] Another aspect of the invention provides a compound selected from the group consisting of: (R)-3-((2-chloro-7-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (15R)-5-({2-chloro-7-methyl-5H,6H,7H,8H,9H-pyrimido[4,5-d]azepin-4-yl}oxy)-15- methyl-11-thia-3,6,14,17-tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)- hexaen-13-one; 2-chloro-4-{[(15R)-15-methyl-13-oxo-11-thia-3,6,14,17- tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-5-yl]oxy}-5H,7H-6λ⁶- thieno[3,4-d]pyrimidine-6,6-dione; (R)-3-((2-chloro-5,5-dioxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (R)-3-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (R)-3-((2-chloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 2-chloro-4-{[(15R)-15-methyl-13-oxo-11-thia-3,6,14,17- tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-5-yl]oxy}-5H,7H,8H- 6λ⁶-thiopyrano[4,3-d]pyrimidine-6,6-dione; (R)-3-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (R)-3-((2-chloro-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 66 ny-2716015Attorney Docket No.30864-20005.40 (R)-3-((2-chloro-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12- tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (R)-3-((2-chloro-7,7-dimethyl-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (R)-3-((2-chloro-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3’-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclobutane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[azetidine-3,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-methyl- 11’,12’-dihydrospiro[azetidine-3,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)- one; 3’-((2-chloro-6-(difluoromethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 11’,12’-dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]- 8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclobutane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[azetidine-3,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-methyl- 11’,12’-dihydrospiro[azetidine-3,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)- one; 3’-((2-chloro-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 11’,12’-dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]- 8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 67 ny-2716015Attorney Docket No.30864-20005.40 (R)-3-((2-chloro-7-methyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (R)-3-((2-chloro-6-(methyl-d3)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (R)-3-((2-chloro-6-methyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; (R)-3-((2-chloro-6-(methyl-d3)-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4- yl)oxy)-10-methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8- one; (R)-3-((2-chloro-6-methyl-7-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10,10-dimethyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10,10- dimethyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10,10-dimethyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-(2-methoxyethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 10,10-dimethyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin-8-one; 3'-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11',12'- dihydrospiro[cyclopropane-1,10'-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin]-8'(9'H)-one; and 3'-((2-chloro-6-(2-methoxyethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 11',12'-dihydrospiro[cyclopropane-1,10'-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin]- 8'(9'H)-one; or a pharmaceutically acceptable salt thereof.

[0136] Another aspect of the invention provides a compound selected from the group consisting of: 3-((2-chloro-7-methyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 68 ny-2716015Attorney Docket No.30864-20005.40 (5-({2-chloro-7-methyl-5H,6H,7H,8H,9H-pyrimido[4,5-d]azepin-4-yl}oxy)-15-methyl- 11-thia-3,6,14,17-tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-13- one; 2-chloro-4-{[15-methyl-13-oxo-11-thia-3,6,14,17- tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-5-yl]oxy}-5H,7H-6λ⁶- thieno[3,4-d]pyrimidine-6,6-dione; 3-((2-chloro-5,5-dioxido-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12- tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 2-chloro-4-{[15-methyl-13-oxo-11-thia-3,6,14,17- tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-5-yl]oxy}-5H,7H,8H- 6λ⁶-thiopyrano[4,3-d]pyrimidine-6,6-dione; 3-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12- tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12- tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12- tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-7,7-dimethyl-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3’-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclobutane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[azetidine-3,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 69 ny-2716015Attorney Docket No.30864-20005.40 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-methyl- 11’,12’-dihydrospiro[azetidine-3,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)- one; 3’-((2-chloro-6-(difluoromethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 11’,12’-dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]- 8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclobutane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[azetidine-3,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-1-methyl- 11’,12’-dihydrospiro[azetidine-3,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)- one; 3’-((2-chloro-6-(2,2-difluoroethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 11’,12’-dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]- 8’(9’H)-one; 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3’-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)-one; 3-((2-chloro-7-methyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-(methyl-d3)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-methyl-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-(methyl-d3)-5-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-methyl-7-oxo-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one; 70 ny-2716015Attorney Docket No.30864-20005.40 3-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10,10-dimethyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10,10- dimethyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-10,10-dimethyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin-8-one; 3-((2-chloro-6-(2-methoxyethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 10,10-dimethyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin-8-one; 3'-((2-chloro-6-ethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)-11',12'- dihydrospiro[cyclopropane-1,10'-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin]-8'(9'H)-one; and 3'-((2-chloro-6-(2-methoxyethyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 11',12'-dihydrospiro[cyclopropane-1,10'-[1,4]diazepino[5',6':4,5]thieno[3,2-f]quinoxalin]- 8'(9'H)-one; or a pharmaceutically acceptable salt thereof.

[0137] Methods for preparing compounds described herein are illustrated in the following synthetic schemes. The schemes are provided for the purpose of illustrating the invention, and are not intended to limit the scope or spirit of the invention. Starting materials shown in the schemes can be obtained from commercial sources or can be prepared based on procedures described in the literature. Additional strategies for preparing starting materials and other compounds are described in, for example, international patent application publication WO2016 / 044463 A1, the entirety of which is hereby incorporated by reference.

[0138] In the schemes, it is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule should be compatible with the reagents and reactions proposed. Substituents not compatible with the reaction conditions will be apparent to one skilled in the art, and alternate methods are therefore indicated (for example, use of protecting groups or alternative reactions). Protecting group chemistry and strategy is well known in the art, for example, as described in detail in Protecting Groups in Organic Synthesis, 3rdEdition, T. W. Greene and P. G. M. Wuts, John Wiley & Sons, 1999 and Greene’s Protective Groups in Organic Synthesis, 5thEd., (Peter G. M. Wuts, John Wiley & Sons: 2014), the entire contents of both of which are hereby incorporated by reference. 71 ny-2716015Attorney Docket No.30864-20005.40

[0139] The synthetic route illustrated in Scheme 1 is a general method for preparing diazepino-thieno-quinoxaline compounds. In Scheme 1, Ar is a 9-11 membered bicyclic chloroheteroaryl, and LG represents a leaving group suitable for nucleophilic aromatic substitution. SCHEME 1.

[0140] The modular synthetic routes illustrated in Scheme 1 can also be readily modified by one of skill in the art to provide additional diazepino-thieno-quinoxalines and related compounds by conducting functional group transformations on the intermediate and final compounds. Such functional group transformations are well known in the art, as described in, for example, Comprehensive Organic Synthesis (B.M. Trost & I. Fleming, eds., 1991- 1992); Organic Synthesis, 3rdEd. (Michael B. Smith, Wavefunction, Inc., Irvine: 2010); Modern Methods of Organic Synthesis, 4thEd. (William Carruthers and Iain Coldham, Cambridge University Press, Cambridge: 2004); March’s Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 8thEd., (Michael B. Smith, John Wiley & Sons, New York: 2020); and Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 3rdEd. (Richard C. Larock, ed., John Wiley & Sons, New York: 2018), each of which is herein incorporated by reference in its entirety. 72ny-2716015Attorney Docket No.30864-20005.40 II. Therapeutic Applications of Diazepino-thieno-quinoxaline Compounds

[0141] The diazepino-thieno-quinoxaline compounds described herein, such as a compound of Formula I, I-A, I-B, II, or other compounds in Section I, provide therapeutic benefits to subjects suffering from inflammatory disorders (e.g., autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplasias, cardiovascular or cerebrovascular disorders, and myeloid cell-driven hyper-inflammatory response in COVID-19 infections) and other diseases or conditions.

[0142] Accordingly, one aspect of the invention provides a method for treating a disease or condition mediated by MK2. The method comprises administering a therapeutically effective amount of a compound described herein, such as a compound of Formula I, I-A, I-B, II, or other compounds in Section I, to a subject in need thereof to treat the disease or condition. In certain embodiments, the compound is a compound of Formula I, I-A, I-B, II, or other compounds in Section I, defined by one of the embodiments described above. In another aspect, the method further comprises administering a therapeutically effective amount of a compound described herein, such as a compound of Formula I’, I, I-A, I-B, II, or other compounds in Section I, to a subject in need thereof to treat the disease or condition. In certain embodiments, the compound is a compound of Formula I’, I, I-A, I-B, II, or other compounds in Section I, defined by one of the embodiments described above. Further description of exemplary diseases or conditions mediated by MK2 is provided herein below.

[0143] Another aspect of the invention provides a method of inhibiting the activity of a MK2. The method comprises contacting a MK2 with an effective amount of a diazepino-thieno- quinoxaline compound or related compound described herein, such as a compound of Formula I, I-A, I-B, II, or other compounds in Section I, to inhibit the activity of said MK2. In certain embodiments, the compound is a compound of Formula I, I-A, I-B, II, or other compounds in Section I, defined by one of the embodiments described above. In another aspect, the method further comprises contacting a MK2 with an effective amount of a diazepino-thieno-quinoxaline compound or related compound described herein, such as a compound of Formula I’, I, I-A, I-B, II, or other compounds in Section I, to inhibit the activity of said MK2. In certain embodiments, the compound is a compound of Formula I’, I, I-A, I-B, II, or other compounds in Section I, defined by one of the embodiments described above. 73ny-2716015Attorney Docket No.30864-20005.40

[0144] Another aspect of the invention provides a method of covalently modifying a MK2. The method comprises contacting a MK2 with an effective amount of a compound described herein, such as a compound of Formula I, I-A, I-B, II, or other compounds in Section I, to covalently modify the MK2. In certain embodiments, the compound is a compound of Formula I, I-A, I-B, II, or other compounds in Section I, defined by one of the embodiments described above. In certain embodiments, the MK2 is in a subject and the method comprises administered to the subject an effective amount of a compound described herein, such as a compound of Formula I, I-A, I-B, II, or other compounds in Section I. In another aspect, the method further comprises contacting a MK2 with an effective amount of a compound described herein, such as a compound of Formula I’, I, I-A, I-B, II, or other compounds in Section I, to covalently modify the MK2. In certain embodiments, the compound is a compound of Formula I’, I, I-A, I-B, II, or other compounds in Section I, defined by one of the embodiments described above. In certain embodiments, the MK2 is in a subject and the method comprises administered to the subject an effective amount of a compound described herein, such as a compound of Formula I’, I, I-A, I-B, II, or other compounds in Section I. In certain embodiments, the subject is suffering from a treating a disease or condition mediated by MK2.

[0145] Another aspect of the invention provides a covalently modified MK2 formed by the foregoing method. In certain embodiments, the MK2 is in a subject and the method comprises administered to the subject an effective amount of a compound described herein, such as a compound of Formula I, I-A, I-B, II, or other compounds in Section I. In certain embodiments, the MK2 is in a subject and the method comprises administered to the subject an effective amount of a compound described herein, such as a compound of Formula I’, I, I- A, I-B, II, or other compounds in Section I. Exemplary Diseases or Conditions Mediated by MK2

[0146] In one embodiment, the disease or condition mediated by MK2 is an inflammatory disorder, such as an autoimmune disorder, chronic inflammatory disorder, acute inflammatory disorder, auto-inflammatory disorder, fibrotic disorder, metabolic disorder, neoplasia, cardiovascular or cerebrovascular disorder, or myeloid cell-driven hyper- inflammatory response in COVID-19 infection.

[0147] In one embodiment, the disease or condition mediated by MK2 is ankylosing spondylitis, rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft- versus-host disease, Crohn’s disease, inflammatory bowel disease, multiple sclerosis, 74ny-2716015Attorney Docket No.30864-20005.40 systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren’s syndrome, scleroderma, ulcerative colitis, asthma, uveitis, psoriatic arthritis, hidradenitis suppurativa, cryopyrin-associated periodic syndromes, or juvenile idiopathic arthritis. In one embodiment, the disease or condition mediated by MK2 is ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn’s disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren’s syndrome, scleroderma, ulcerative colitis, or asthma. In one embodiment, the disease or condition mediated by MK2 is rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, hidradenitis suppurativa, cryopyrin-associated periodic syndromes, or juvenile idiopathic arthritis. In one embodiment, the disease or condition mediated by MK2 is cancer. In one embodiment, the disease or condition mediated by MK2 is a cancer selected from pancreatic cancer, colorectal cancer, multiple myeloma, lung cancer, gastric cancer, breast cancer, nasopharyngeal cancer, skin cancer, bladder cancer, prostate cancer, head and neck cancer, or glioblastoma. In one embodiment, the disease or condition mediated by MK2 is pancreatic cancer.

[0148] In certain embodiments, said disease or condition mediated by MK2 is an acute inflammatory disorder. In certain embodiments, said disease or condition mediated by MK2 is an auto-inflammatory disorder. In certain embodiments, said disease or condition mediated by MK2 is a fibrotic disorder. In certain embodiments, said disease or condition mediated by MK2 is a metabolic disorder. In certain embodiments, said disease or condition mediated by MK2 is a neoplasia. In certain embodiments, said disease or condition mediated by MK2 is a cardiovascular or cerebrovascular disorder. In certain embodiments, said disease or condition mediated by MK2 is a myeloid cell-driven hyper-inflammatory response in COVID-19 infections.

[0149] In certain embodiments, said disease or condition mediated by MK2 is an autoimmune disorder. In certain embodiments, said disease or condition mediated by MK2 is a chronic inflammatory disorder. In certain embodiments, said disease or condition mediated by MK2 is an acute inflammatory disorder. In certain embodiments, said disease or condition mediated by MK2 is an auto-inflammatory disorder. In certain embodiments, said disease or condition mediated by MK2 is a combination of one, two, or all three of a chronic inflammatory disorder, an acute inflammatory disorder, and an auto-inflammatory disorder. 75ny-2716015Attorney Docket No.30864-20005.40

[0150] In certain embodiments, said disease or condition mediated by MK2 is an inflammatory bowel disease (e.g., ulcerative colitis or Crohn’s disease). In certain embodiments, said disease or condition mediated by MK2 is multiple sclerosis. In certain embodiments, said disease or condition mediated by MK2 is psoriasis. In certain embodiments, said disease or condition mediated by MK2 is arthritis. In certain embodiments, said disease or condition mediated by MK2 is rheumatoid arthritis. In certain embodiments, said disease or condition mediated by MK2 is osteoarthritis. In certain embodiments, said disease or condition mediated by MK2 is juvenile arthritis. In certain embodiments, said disease or condition mediated by MK2 is psoriatic arthritis. In certain embodiments, said disease or condition mediated by MK2 is reactive arthritis. In certain embodiments, said disease or condition mediated by MK2 is ankylosing spondylitis. In certain embodiments, said disease or condition mediated by MK2 is cryopyrin-associated periodic syndromes. In certain embodiments, said disease or condition mediated by MK2 is Muckle-Wells syndrome. In certain embodiments, said disease or condition mediated by MK2 is familial cold auto-inflammatory syndrome. In certain embodiments, said disease or condition mediated by MK2 is neonatal-onset multisystem inflammatory disease. In certain embodiments, said disease or condition mediated by MK2 is TNF receptor-associated periodic syndrome. In certain embodiments, said disease or condition mediated by MK2 is acute and chronic pancreatitis. In certain embodiments, said disease or condition mediated by MK2 is atherosclerosis. In certain embodiments, said disease or condition mediated by MK2 is gout. In certain embodiments, said disease or condition mediated by MK2 is a fibrotic disorder (e.g., hepatic fibrosis or idiopathic pulmonary fibrosis). In certain embodiments, said disease or condition mediated by MK2 is nephropathy. In certain embodiments, said disease or condition mediated by MK2 is sarcoidosis. In certain embodiments, said disease or condition mediated by MK2 is scleroderma. In certain embodiments, said disease or condition mediated by MK2 is anaphylaxis. In certain embodiments, said disease or condition mediated by MK2 is diabetes (e.g., diabetes mellitus type 1 or diabetes mellitus type 2). In certain embodiments, said disease or condition mediated by MK2 is diabetic retinopathy. In certain embodiments, said disease or condition mediated by MK2 is Still’s disease. In certain embodiments, said disease or condition mediated by MK2 is vasculitis. In certain embodiments, said disease or condition mediated by MK2 is sarcoidosis. In certain embodiments, said disease or condition mediated by MK2 is pulmonary inflammation. In certain embodiments, said disease or condition mediated by MK2 is acute respiratory distress syndrome. In certain embodiments, said disease or 76ny-2716015Attorney Docket No.30864-20005.40 condition mediated by MK2 is wet and dry age-related macular degeneration. In certain embodiments, said disease or condition mediated by MK2 is autoimmune hemolytic syndromes. In certain embodiments, said disease or condition mediated by MK2 is autoimmune and inflammatory hepatitis. In certain embodiments, said disease or condition mediated by MK2 is autoimmune neuropathy. In certain embodiments, said disease or condition mediated by MK2 is autoimmune ovarian failure. In certain embodiments, said disease or condition mediated by MK2 is autoimmune orchitis. In certain embodiments, said disease or condition mediated by MK2 is autoimmune thrombocytopenia. In certain embodiments, said disease or condition mediated by MK2 is silicone implant-associated autoimmune disease. In certain embodiments, said disease or condition mediated by MK2 is Sjogren’s syndrome. In certain embodiments, said disease or condition mediated by MK2 is familial Mediterranean fever. In certain embodiments, said disease or condition mediated by MK2 is systemic lupus erythematosus. In certain embodiments, said disease or condition mediated by MK2 is vasculitis syndromes (e.g., t. emporal, Takayasu’s and giant cell arteritis, Behcet’s disease or Wegener’s granulomatosis). In certain embodiments, said disease or condition mediated by MK2 is vitiligo. In certain embodiments, said disease or condition mediated by MK2 is secondary hematologic manifestation of autoimmune diseases (e.g., anemias). In certain embodiments, said disease or condition mediated by MK2 is drug- induced autoimmunity. In certain embodiments, said disease or condition mediated by MK2 is Hashimoto’s thyroiditis. In certain embodiments, said disease or condition mediated by MK2 is hypophysitis. In certain embodiments, said disease or condition mediated by MK2 is idiopathic thrombocytic pupura. In certain embodiments, said disease or condition mediated by MK2 is metal-induced autoimmunity. In certain embodiments, said disease or condition mediated by MK2 is myasthenia gravis. In certain embodiments, said disease or condition mediated by MK2 is pemphigus. In certain embodiments, said disease or condition mediated by MK2 is autoimmune deafness (e.g., Meniere’s disease). In certain embodiments, said disease or condition mediated by MK2 is Goodpasture’s syndrome. In certain embodiments, said disease or condition mediated by MK2 is Graves’ disease. In certain embodiments, said disease or condition mediated by MK2 is an HW-related autoimmune syndromes. In certain embodiments, said disease or condition mediated by MK2 is Gullain-Barre disease. In certain embodiments, said disease or condition mediated by MK2 is Addison’s disease. In certain embodiments, said disease or condition mediated by MK2 is anti-phospholipid syndrome. In certain embodiments, said disease or condition mediated by MK2 is asthma. In certain embodiments, said disease or condition mediated by MK2 is atopic dermatitis. In 77ny-2716015Attorney Docket No.30864-20005.40 certain embodiments, said disease or condition mediated by MK2 is Celiac disease. In certain embodiments, said disease or condition mediated by MK2 is Cushing’s syndrome. In certain embodiments, said disease or condition mediated by MK2 is dermatomyositis. In certain embodiments, said disease or condition mediated by MK2 is idiopathic adrenal atrophy. In certain embodiments, said disease or condition mediated by MK2 is idiopathic thrombocytopenia. In certain embodiments, said disease or condition mediated by MK2 is Kawasaki syndrome. In certain embodiments, said disease or condition mediated by MK2 is Lambert-Eaton Syndrome. In certain embodiments, said disease or condition mediated by MK2 is pernicious anemia. In certain embodiments, said disease or condition mediated by MK2 is pollinosis. In certain embodiments, said disease or condition mediated by MK2 is polyarteritis nodosa. In certain embodiments, said disease or condition mediated by MK2 is primary biliary cirrhosis. In certain embodiments, said disease or condition mediated by MK2 is primary sclerosing cholangitis. In certain embodiments, said disease or condition mediated by MK2 is Raynaud’s disease. In certain embodiments, said disease or condition mediated by MK2 is Raynaud’s phenomenon. In certain embodiments, said disease or condition mediated by MK2 is Reiter’s Syndrome. In certain embodiments, said disease or condition mediated by MK2 is relapsing polychondritis. In certain embodiments, said disease or condition mediated by MK2 is Schmidt’s syndrome. In certain embodiments, said disease or condition mediated by MK2 is thyrotoxidosis. In certain embodiments, said disease or condition mediated by MK2 is sepsis. In certain embodiments, said disease or condition mediated by MK2 is septic shock. In certain embodiments, said disease or condition mediated by MK2 is endotoxic shock. In certain embodiments, said disease or condition mediated by MK2 is exotoxin-induced toxic shock. In certain embodiments, said disease or condition mediated by MK2 is gram negative sepsis. In certain embodiments, said disease or condition mediated by MK2 is toxic shock syndrome. In certain embodiments, said disease or condition mediated by MK2 is glomerulonephritis. In certain embodiments, said disease or condition mediated by MK2 is peritonitis. In certain embodiments, said disease or condition mediated by MK2 is interstitial cystitis. In certain embodiments, said disease or condition mediated by MK2 is hyperoxia-induced inflammations. In certain embodiments, said disease or condition mediated by MK2 is chronic obstructive pulmonary disease (COPD). In certain embodiments, said disease or condition mediated by MK2 is vasculitis. In certain embodiments, said disease or condition mediated by MK2 is graft vs. host reaction (e.g., graft vs. host disease). In certain embodiments, said disease or condition mediated by MK2 is allograft rejections (e.g., acute allograft rejection or chronic allograft rejection). In 78ny-2716015Attorney Docket No.30864-20005.40 certain embodiments, said disease or condition mediated by MK2 is early transplantation rejection (e.g., acute allograft rejection). In certain embodiments, said disease or condition mediated by MK2 is reperfusion injury. In certain embodiments, said disease or condition mediated by MK2 is pain (e.g., acute pain, chronic pain, neuropathic pain, or fibromyalgia). In certain embodiments, said disease or condition mediated by MK2 is a chronic infection. In certain embodiments, said disease or condition mediated by MK2 is meningitis. In certain embodiments, said disease or condition mediated by MK2 is encephalitis. In certain embodiments, said disease or condition mediated by MK2 is myocarditis. In certain embodiments, said disease or condition mediated by MK2 is gingivitis. In certain embodiments, said disease or condition mediated by MK2 is post-surgical trauma. In certain embodiments, said disease or condition mediated by MK2 is tissue injury. In certain embodiments, said disease or condition mediated by MK2 is traumatic brain injury. In certain embodiments, said disease or condition mediated by MK2 is enterocolitis. In certain embodiments, said disease or condition mediated by MK2 is sinusitis. In certain embodiments, said disease or condition mediated by MK2 is uveitis. In certain embodiments, said disease or condition mediated by MK2 is ocular inflammation. In certain embodiments, said disease or condition mediated by MK2 is optic neuritis. In certain embodiments, said disease or condition mediated by MK2 is gastric ulcers. In certain embodiments, said disease or condition mediated by MK2 is esophagitis. In certain embodiments, said disease or condition mediated by MK2 is peritonitis. In certain embodiments, said disease or condition mediated by MK2 is periodontitis. In certain embodiments, said disease or condition mediated by MK2 is dermatomyositis. In certain embodiments, said disease or condition mediated by MK2 is gastritis. In certain embodiments, said disease or condition mediated by MK2 is myositis. In certain embodiments, said disease or condition mediated by MK2 is polymyalgia. In certain embodiments, said disease or condition mediated by MK2 is pneumonia. In certain embodiments, said disease or condition mediated by MK2 is bronchitis.

[0151] In certain embodiments, the disorder or condition mediated by MK2 is a fibrotic disorder. In certain embodiments, said disease or condition mediated by MK2 is systemic sclerosis / scleroderma. In certain embodiments, said disease or condition mediated by MK2 is lupus nephritis. In certain embodiments, said disease or condition mediated by MK2 is connective tissue disease. In certain embodiments, said disease or condition mediated by MK2 is wound healing. In certain embodiments, said disease or condition mediated by MK2 79ny-2716015Attorney Docket No.30864-20005.40 is surgical scarring. In certain embodiments, said disease or condition mediated by MK2 is spinal cord injury. In certain embodiments, said disease or condition mediated by MK2 is CNS scarring. In certain embodiments, said disease or condition mediated by MK2 is acute lung injury. In certain embodiments, said disease or condition mediated by MK2 is pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis or cystic fibrosis). In certain embodiments, said disease or condition mediated by MK2 is chronic obstructive pulmonary disease. In certain embodiments, said disease or condition mediated by MK2 is adult respiratory distress syndrome. In certain embodiments, said disease or condition mediated by MK2 is acute lung injury. In certain embodiments, said disease or condition mediated by MK2 is drug- induced lung injury. In certain embodiments, said disease or condition mediated by MK2 is glomerulonephritis. In certain embodiments, said disease or condition mediated by MK2 is chronic kidney disease (e.g., diabetic nephropathy). In certain embodiments, said disease or condition mediated by MK2 is hypertension-induced nephropathy. In certain embodiments, said disease or condition mediated by MK2 is alimentary track or gastrointestinal fibrosis. In certain embodiments, said disease or condition mediated by MK2 is renal fibrosis. In certain embodiments, said disease or condition mediated by MK2 is hepatic or biliary fibrosis. In certain embodiments, said disease or condition mediated by MK2 is liver fibrosis (e.g., nonalcoholic steatohepatitis, hepatitis C, or hepatocellular carcinoma). In certain embodiments, said disease or condition mediated by MK2 is cirrhosis (e.g., primary biliary cirrhosis or cirrhosis due to fatty liver disease, such as alcoholic and nonalcoholic steatosis). In certain embodiments, said disease or condition mediated by MK2 is radiation-induced fibrosis (e.g., head and neck, gastrointestinal or pulmonary). In certain embodiments, said disease or condition mediated by MK2 is primary sclerosing cholangitis. In certain embodiments, said disease or condition mediated by MK2 is restenosis. In certain embodiments, said disease or condition mediated by MK2 is cardiac fibrosis (e.g., endomyocardial fibrosis or atrial fibrosis). In certain embodiments, said disease or condition mediated by MK2 is opthalmic scarring. In certain embodiments, said disease or condition mediated by MK2 is fibrosclerosis. In certain embodiments, said disease or condition mediated by MK2 is a fibrotic cancer. In certain embodiments, said disease or condition mediated by MK2 is fibroids. In certain embodiments, said disease or condition mediated by MK2 is fibroma. In certain embodiments, said disease or condition mediated by MK2 is a fibroadenoma. In certain embodiments, said disease or condition mediated by MK2 is a fibrosarcoma. In certain embodiments, said disease or condition mediated by MK2 is transplant arteriopathy. In 80ny-2716015Attorney Docket No.30864-20005.40 certain embodiments, said disease or condition mediated by MK2 is keloid. In certain embodiments, said disease or condition mediated by MK2 is mediastinal fibrosis. In certain embodiments, said disease or condition mediated by MK2 is myelofibrosis. In certain embodiments, said disease or condition mediated by MK2 is retroperitoneal fibrosis. In certain embodiments, said disease or condition mediated by MK2 is progressive massive fibrosis. In certain embodiments, said disease or condition mediated by MK2 is nephrogenic systemic fibrosis.

[0152] In certain embodiments, said disease or condition mediated by MK2 is a metabolic disorders. In certain embodiments, said disease or condition mediated by MK2 is obesity. In certain embodiments, said disease or condition mediated by MK2 is steroid-resistance. In certain embodiments, said disease or condition mediated by MK2 is glucose intolerance. In certain embodiments, said disease or condition mediated by MK2 is metabolic syndrome.

[0153] In certain embodiments, said disease or condition mediated by MK2 is a neoplasia. In certain embodiments, said disease or condition mediated by MK2 is a cancer. In certain embodiments, said disease or condition mediated by MK2 is an angiogenesis disorder. In certain embodiments, said disease or condition mediated by MK2 is a multiple myeloma. In certain embodiments, said disease or condition mediated by MK2 is a leukemia (e.g., acute lymphocytic leukemia, acute and chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphoblastic leukemia, chronic myelomonocytic leukemia, or promyelocytic leukemia).

[0154] In certain embodiments, said disease or condition mediated by MK2 is a lymphoma (e.g., B-cell lymphoma, T-cell lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma, hairy cell lymphoma, Burkitt’s lymphoma, mast cell tumors, Hodgkin’s disease or non-Hodgkin’s disease). In certain embodiments, said disease or condition mediated by MK2 is myelodysplastic syndrome. In certain embodiments, said disease or condition mediated by MK2 is fibrosarcoma. In certain embodiments, said disease or condition mediated by MK2 is rhabdomyosarcoma. In certain embodiments, said disease or condition mediated by MK2 is astrocytoma. In certain embodiments, said disease or condition mediated by MK2 is neuroblastoma. In certain embodiments, said disease or condition mediated by MK2 is glioma and schwannomas. In certain embodiments, said disease or condition mediated by MK2 is melanoma. In certain embodiments, said disease or condition mediated by MK2 is seminoma. In certain embodiments, said disease or condition mediated by MK2 is teratocarcinoma. In certain embodiments, said disease or condition mediated by 81ny-2716015Attorney Docket No.30864-20005.40 MK2 is osteosarcoma. In certain embodiments, said disease or condition mediated by MK2 is xenoderma pigmentosum. In certain embodiments, said disease or condition mediated by MK2 is keratoctanthoma. In certain embodiments, said disease or condition mediated by MK2 is thyroid follicular cancer. In certain embodiments, said disease or condition mediated by MK2 is Kaposi’s sarcoma. In certain embodiments, said disease or condition mediated by MK2 is melanoma. In certain embodiments, said disease or condition mediated by MK2 is teratoma. In certain embodiments, said disease or condition mediated by MK2 is rhabdomyosarcoma. In certain embodiments, said disease or condition mediated by MK2 is a metastatic and bone disorder. In certain embodiments, said disease or condition mediated by MK2 is cancer of the bone. In certain embodiments, said disease or condition mediated by MK2 is cancer of the mouth / pharynx. In certain embodiments, said disease or condition mediated by MK2 is cancer of the esophagus. In certain embodiments, said disease or condition mediated by MK2 is cancer of the larynx. In certain embodiments, said disease or condition mediated by MK2 is cancer of the stomach. In certain embodiments, said disease or condition mediated by MK2 is cancer of the intestine. In certain embodiments, said disease or condition mediated by MK2 is cancer of the colon. In certain embodiments, said disease or condition mediated by MK2 is cancer of the rectum. In certain embodiments, said disease or condition mediated by MK2 is cancer of the lung (e.g., non-small cell lung cancer or small cell lung cancer). In certain embodiments, said disease or condition mediated by MK2 is cancer of the liver. In certain embodiments, said disease or condition mediated by MK2 is cancer of the pancreas. In certain embodiments, said disease or condition mediated by MK2 is cancer of the nerve. In certain embodiments, said disease or condition mediated by MK2 is cancer of the brain (e.g., glioma or glioblastoma multiforme). In certain embodiments, said disease or condition mediated by MK2 is cancer of the head and neck. In certain embodiments, said disease or condition mediated by MK2 is cancer of the throat. In certain embodiments, said disease or condition mediated by MK2 is cancer of the ovary. In certain embodiments, said disease or condition mediated by MK2 is cancer of the uterus. In certain embodiments, said disease or condition mediated by MK2 is cancer of the prostate. In certain embodiments, said disease or condition mediated by MK2 is cancer of the testis. In certain embodiments, said disease or condition mediated by MK2 is cancer of the bladder. In certain embodiments, said disease or condition mediated by MK2 is cancer of the kidney. In certain embodiments, said disease or condition mediated by MK2 is cancer of the breast. In certain embodiments, said disease or condition mediated by MK2 is cancer of the gall bladder. In certain embodiments, said disease or condition mediated by MK2 is cancer of the 82ny-2716015Attorney Docket No.30864-20005.40 cervix. In certain embodiments, said disease or condition mediated by MK2 is cancer of the thyroid. In certain embodiments, said disease or condition mediated by MK2 is cancer of the prostate. In certain embodiments, said disease or condition mediated by MK2 is cancer of the skin (e.g., skin squamous cell carcinoma). In certain embodiments, said disease or condition mediated by MK2 is a solid tumor. In certain embodiments, said disease or condition mediated by MK2 is gastric cancer. In certain embodiments, said disease or condition mediated by MK2 is hepatocellular carcinoma. In certain embodiments, said disease or condition mediated by MK2 is a peripheral nerve sheath tumor. In certain embodiments, said disease or condition mediated by MK2 is pulmonary arterial hypertension.

[0155] In certain embodiments, said disease or condition mediated by MK2 is a cardiovascular or cerebrovascular disorder. In certain embodiments, said disease or condition mediated by MK2 is atherosclerosis. In certain embodiments, said disease or condition mediated by MK2 is restenosis of an atherosclerotic coronary artery. In certain embodiments, said disease or condition mediated by MK2 is acute coronary syndrome. In certain embodiments, said disease or condition mediated by MK2 is myocardial infarction. In certain embodiments, said disease or condition mediated by MK2 is cardiac-allograft vasculopathy. In certain embodiments, said disease or condition mediated by MK2 is stroke. In certain embodiments, said disease or condition mediated by MK2 is a central nervous system disorder with an inflammatory or apoptotic component. In certain embodiments, said disease or condition mediated by MK2 is Alzheimer’s disease. In certain embodiments, said disease or condition mediated by MK2 is Parkinson’s disease. In certain embodiments, said disease or condition mediated by MK2 is Huntington’s disease. In certain embodiments, said disease or condition mediated by MK2 is amyotrophic lateral sclerosis. In certain embodiments, said disease or condition mediated by MK2 is spinal cord injury. In certain embodiments, said disease or condition mediated by MK2 is neuronal ischemia. In certain embodiments, said disease or condition mediated by MK2 is peripheral neuropathy.

[0156] In certain embodiments, said disease or condition mediated by MK2 is a disease or disorder associated with a coronavirus (e.g., SARS-CoV-2). In certain embodiments, said coronavirus is SARS-CoV-2. In certain embodiments, the disease or disorder associated with SARS-CoV-2 is COVID-19.

[0157] In certain embodiments, the disease or condition mediated by MK2 is a rheumatic disease. In certain embodiments, the disease or condition mediated by MK2 is an inflammatory arthropathy. In certain embodiments, the disease or condition mediated by 83ny-2716015Attorney Docket No.30864-20005.40 MK2 is rheumatoid arthritis, juvenile arthritis, Still’s disease, juvenile rheumatoid arthritis, systemic onset rheumatoid arthritis, pauciarticular rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular rheumatoid arthritis, enteropathic arthritis, juvenile Reiter’s Syndrome, ankylosing spondylitis, juvenile ankylosing spondylitis, SEA Syndrome, reactive arthritis (reactive arthropathy), psoriatic arthropathy, juvenile enteropathic arthritis, polymyalgia rheumatica, enteropathic spondylitis, juvenile Idiopathic Arthritis (JIA), juvenile psoriatic arthritis, juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, giant cell arteritis, secondary osteoarthritis from an inflammatory disease.

[0158] In certain embodiments, the disease or condition mediated by MK2 is a connective tissue disease. In certain embodiments, the disease or condition mediated by MK2 is lupus, systemic lupus erythematosus, juvenile systemic lupus erythematosus, nephritis, Sjögren’s syndrome, scleroderma (systemic sclerosis), Raynaud’s phenomenonjuvenile scleroderma, polymyositis, dermatomyositis, polymyositis-dermatomyositis, polymyalgia rheumatica, a mixed connective tissue disease, sarcoidosis, fibromyalgia, vasculitis microscopic polyangiitis, vasculitis, eosinophilic granulomatosis with polyangiitis (formerly known as Churg-Strauss Syndrome), granulomatosis with polyangiitis (formerly known as Wegener’s granulomatosis), polyarteritis nodosa, Henoch-Schönlein purpura, idiopathic thrombocytopenic thrombotic purpura, juvenile vasculitis, polyarteritis nodossa (also known as panarteritis nodosa, periarteritis nodosa Kussmaul disease, Kussmaul-Maier disease or PAN), serum sickness, myasthenia gravis, Takayasu’s arteritis, Behçet’s syndrome, Kawasaki’s disease (mucocutaneous lymph node syndrome), Buerger’s disease (thromboangiitis obliterans), Vogt–Koyanagi–Harada syndrome, Addison’s disease, Hashimoto’s thyroiditis, primary biliary sclerosis, autoimmune hepatitis, chronic aggressive hepatitis, nonalcoholic hepatic steatosis, sclerosing cholangitis, membranous glomerulopathy, polymyositis, myositis, atherosclerosis, autoimmune hemolytic anemia, autoimmune orchitis, Goodpasture’s disease,

[0159] In certain embodiments, the disease or condition mediated by MK2 is a neurodegenerative disease or neuroinflammatory disease. In certain embodiments, the disease or condition mediated by MK2 is multiple sclerosis, amyotropic lateral sclerosis, Guillain-Barre disease, autoimmune encephalomyelitis, Alzheimer’s disease, major depressive disorder, traumatic brain injury, epilepsy, Parkinson’s disease, or bipolar disorder. 84ny-2716015Attorney Docket No.30864-20005.40

[0160] In certain embodiments, the disease or condition mediated by MK2 is an inflammatory bowel disease. In certain embodiments, the disease or condition mediated by MK2 is Crohn’s disease, ulcerative colitis, Celiac Sprue, Celiac disease, proctitis, eosinophilic gastroenteritis, autoimmune atrophic gastritis of pernicious anemia, or mastocytosis.

[0161] In certain embodiments, the disease or condition mediated by MK2 is a skin autoimmune disorder. In certain embodiments, the disease or condition mediated by MK2 is psoriasis. In certain embodiments, the disease or condition mediated by MK2 is plaque psoriasis, Guttate psoriasis, psoriatic epidermal hyperplasia, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, atopic dermatitis, eczema dermatitis, dermatitis, pruritus, epidermal hyperplasia, juvenile dermatomyositis, dermatomyositis, or hidradenitis suppurativa.

[0162] In certain embodiments, the disease or condition mediated by MK2 is an autoimmune disease of the eye. In certain embodiments, the disease or condition mediated by MK2 is Graves’ disease, noninfectious uveitis, dry eye syndrome, sympathetic ophthalmia, Cogan’s syndrome, keratoconjunctivitis, vernal conjunctivitis, uveitis (e.g., uveitis associated with Behcet’s disease and lens-induced uveitis), keratitis, herpetic keratitis, conical keratitis, corneal epithelial dystrophy, keratoleukoma, ocular premphigus, Mooren’s ulcer, scleritis, keratoconjunctivitis sicca (dry eye), phlyctenule, iridocyclitis, sarcoidosis, endocrine ophthalmopathy, sympathetic ophthalmitis, allergic conjunctivitis, or ocular neovascularization

[0163] In certain embodiments, the disease or condition mediated by MK2 is an ocular manifestation of an autoimmune disease.

[0164] In certain embodiments, the disease or condition mediated by MK2 is a respiratory disease. In certain embodiments, the disease or condition mediated by MK2 is asthma, chronic obstructive pulmonary disease, or acute respiratory disease.

[0165] In certain embodiments, the disease or condition mediated by MK2 is diabetes. In certain embodiments, the disease or condition mediated by MK2 is Type I diabetes mellitus, Type II diabetes mellitus, or juvenile onset diabetes

[0166] In certain embodiments, the subject is a human. In certain embodiments, the subject is an adult human. In certain embodiments, the subject is a pediatric human. In certain embodiments, the subject is a geriatric human. 85ny-2716015Attorney Docket No.30864-20005.40

[0167] Another aspect of the invention provides for the use of a compound described herein (such as a compound of Formula I, I-A, I-B, II, or other compounds in Section I) in the manufacture of a medicament. In certain embodiments, the medicament is for treating a disease or condition described herein, such as an inflammatory disorder.

[0168] Another aspect of the invention provides for the use of a compound described herein (such as a compound of Formula I’, I, I-A, I-B, II, or other compounds in Section I) in the manufacture of a medicament. In certain embodiments, the medicament is for treating a disease or condition described herein, such as an inflammatory disorder.

[0169] Another aspect of the invention provides for the use of a compound described herein (such as a compound of Formula I, I-A, I-B, II, or other compounds in Section I) for treating a disease or condition, such as a disease or condition described herein (e.g., an inflammatory disorder).

[0170] Another aspect of the invention provides for the use of a compound described herein (such as a compound of Formula I’, I, I-A, I-B, II, or other compounds in Section I) for treating a disease or condition, such as a disease or condition described herein (e.g., an inflammatory disorder). III. Combination Therapy

[0171] Another aspect of the invention provides for combination therapy. Diazepino-thieno- quinoxaline compounds described herein (e.g., a compound of Formula I, I-A, I-B, II, or other compounds in Section I) or their pharmaceutically acceptable salts may be used in combination with additional therapeutic agents to treat diseases or conditions, such as an inflammatory disorder.

[0172] Another aspect of the invention provides for combination therapy. Diazepino-thieno- quinoxaline compounds described herein (e.g., a compound of Formula I', I, I-A, I-B, II, or other compounds in Section I) or their pharmaceutically acceptable salts may be used in combination with additional therapeutic agents to treat diseases or conditions, such as an inflammatory disorder.

[0173] Accordingly, in some embodiments, the present invention provides a method of treating a disclosed disease or condition comprising administering to a patient in need thereof an effective amount of a compound disclosed herein and co-administering simultaneously or sequentially an effective amount of one or more additional therapeutic agents, such as those described herein. In some embodiments, the method includes co-administering one 86ny-2716015Attorney Docket No.30864-20005.40 additional therapeutic agent. In some embodiments, the method includes co-administering two additional therapeutic agents.

[0174] One or more other therapeutic agents may be administered separately from a compound or composition of the invention, as part of a multiple dosage regimen. Alternatively, one or more other therapeutic agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as a multiple dosage regime, one or more other therapeutic agent and a compound or composition of the invention may be administered simultaneously, sequentially or within a period of time from one another.

[0175] In certain embodiments, the compounds of the disclosure can be administered with one or more of a second therapeutic agent, sequentially or concurrently, either by the same route or by different routes of administration. When administered sequentially, the time between administrations is selected to benefit, among others, the therapeutic efficacy and / or safety of the combination treatment. In certain embodiments, the compound of the disclosure can be administered first followed by a second therapeutic agent, or alternatively, the second therapeutic agent administered first followed by the compound of the disclosure. In certain embodiments, the compound of the disclosure can be administered for the same duration as the second therapeutic agent, or alternatively, for a longer or shorter duration as the second therapeutic compound.

[0176] When administered concurrently, the compounds of the disclosure can be administered separately at the same time as the second therapeutic agent, by the same or different routes, or administered in a single composition by the same route. In certain embodiments, the compound of the disclosure is prepared as a first pharmaceutical composition, and the second therapeutic agent prepared as a second pharmaceutical composition, where the first pharmaceutical composition and the second pharmaceutical composition are administered simultaneously, sequentially, or separately. In certain embodiments, the amount and frequency of administration of the second therapeutic agent can used standard dosages and standard administration frequencies used for the particular therapeutic agent. See, e.g., Physicians’ Desk Reference, 70thEd., PDR Network, 2015; incorporated herein by reference.

[0177] In certain embodiments, the additional therapeutic agent is a leukotriene inhibitor, non-steroidal anti-inflammatory drug (NSAID), steroid, tyrosine kinase inhibitor, receptor 87ny-2716015Attorney Docket No.30864-20005.40 kinase inhibitor, modulator of nuclear receptor family of transcription factor, HSP90 inhibitor, adenosine receptor (A2A) agonist, disease modifying antirheumatic drugs (DMARDS), phosphodiesterase (PDE) inhibitor, neutrophil elastase inhibitor, modulator of Axl kinase, an anti-cancer agent, anti-allergic agent, anti-nausea agent (or anti-emetic), pain reliever, cytoprotective agent, or a combination thereof. In certain embodiments, the additional therapeutic agent is an anti-cancer agent, an analgesic, an anti-inflammatory agent, or a combination thereof.

[0178] In certain embodiments, the second therapeutic agent is a leukotriene inhibitor. Exemplary leukotriene inhibitors are montelukast, zafirlukast, pranlukast, zileuton, or combinations thereof.

[0179] In certain embodiments, the second therapeutic agent is a an NSAID. Exemplary NSAIDs are acetylsalicylic acid, diflunisal, salsalate, ibuprofen, dexibuprofen, naioxen, fenoprofen, ketoprofen, dexketoprofen, flurbiprofen, oxaprozin, loxoprofen, indomethacin, tolmetin, sulindac, etodolac, ketorolac, diclofenac, aceclofenac, nabumetone, piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam, phenylbutazone, mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, celecoxib, or combinations thereof.

[0180] In certain embodiments, the second therapeutic agent is a steroid. Exemplary steroids are prednisone, prednisolone, methylprednisone, triacmcinolone, betamethasone, dexamethasone, and prodrugs thereof.

[0181] In certain embodiments, the second therapeutic agent is a tyrosine kinase inhibitor. Exemplary tyrosine kinase inhibitors are JAK, Syk, JNK / SAPK, MAPK, PI-3K, and / or Ripk2. In certain embodiments, the tyrosine kinase inhibitor is ruxolitinib, tofacitinib, oclactinib, filgotinib, ganotinib, lestaurtinib, momelotinib, pacritinib, upadacitinib, peficitinib, fedratinib, bentamapimod, D-JNKI-1 (XG-102, AM-111), ponatinib, WEHI-345, OD36, GSK583, idelalisib, copanlisib, taselisib, duvelisib, alpelisib, umbralisib, dactolisib, CUDC-907, entospletinib, fostamatinib, or combinations thereof.

[0182] In certain embodiments, the second therapeutic agent is a receptor kinase inhibitor, including among others, an inhibitor of EGFR or HER2. Exemplary receptor kinase inhibitors are gefitinib, erlotinib, neratinib, lapatinib, cetuximab, panitumumab, vandetanib, necitumumab, osimertinib, trastuzumab, neratinib, lapatinib, pertuzumab, or combinations thereof. 88ny-2716015Attorney Docket No.30864-20005.40

[0183] In certain embodiments, the second therapeutic agent is a modulator of nuclear receptor family of transcription factors, including, among others, an inhibitor of PPAR, RXR, FXR, or LXR. In certain embodiments, the inhibitor is pioglitazone, bexarotene, obeticholic acid, ursodeoxycholic acid, fexaramine, hypocholamide, or combinations thereof.

[0184] In certain embodiments, the second therapeutic agent is an HSP90 inhibitor. Exemplary HSP90 inhibitors are ganetespib, 17-AAG (17-allylaminogeldanamycin, NSC330507), 17-DMAG (17-dimethylaminoethylamino-17-demethoxy-geldanamycin, NSC707545), IPI-504, CNF1010, CNF2024, CNF1010, or combinations thereof.

[0185] In certain embodiments, the second therapeutic agent is an adenosine receptor 2A (A2A) agonist. Exemplary adenosine receptor agonists are those disclosed in U.S. Pat. No. 9,067,963, which is incorporated herein by reference. In certain embodiments, the adenosine receptor agonist is LNC-3050, LNC-3015, LNC-3047, LNC-3052, or combinations thereof.

[0186] In certain embodiments, the second therapeutic agent is selected from disease modifying antirheumatic drugs (DMARDS). Exemplary DMARDS are tocilizumab, certolizumab, etanercept, adalimumab, anakinra, abatacept, infliximab, rituximab, golimumab, uteskinumab, or combinations thereof.

[0187] In certain embodiments, the second therapeutic agent is a phosphodiesterase (PDE) inhibitor. Exemplary phosphodiesterase inhibitors are apremilast, crisaborole, piclimilast, drotaverine, ibudulast, roflumilast, sildenafil, tadalafil, vardenafil, or combinations thereof.

[0188] In certain embodiments, the second therapeutic agent is a neutrophil elastase inhibitor. Examples of neutrophil elastase inhibitors considered for use in combination therapies of the invention include but are not limited to sivelestat.

[0189] In certain embodiments, the second therapeutic agent is a modulator of Axl kinase. Exemplary modulators of Axl kinase are bemcentinib (BGB324 or R428), TP-0903, LY2801653, amuvatinib (MP-470), bosutinib (SKI-606), MGCD 265, ASP2215, cabozantinib (XL184), foretinib (GSK1363089 / XL880), and SGI-7079. In certain embodiments, the modulator of Axl kinase is a monoclonal antibody targeting AXL (e.g., YW327.6S2) or an AXL decoy receptor (e.g., GL2I.T), or glesatinib, merestinib, or a dual Flt3-Axl inhibitor such as gilteritinib.

[0190] In certain embodiments, the additional therapeutic agent is an anti-cancer agent or chemo-therapeutic agent. Examples of anti-cancer agents considered for use in combination therapies of the invention include but are not limited erlotinib, bortezomib, fulvestrant, 89ny-2716015Attorney Docket No.30864-20005.40 sunitib, imatinib mesylate, letrozole, finasunate, platins such as oxaliplatin, carboplatin, and cisplatin, finasunate, fluorouracil, rapamycin, leucovorin, lapatinib, lonafamib, sorafenib, gefitinib, camptothecin, topotecan, bryostatin, adezelesin, anthracyclin, carzelesin, bizelesin, dolastatin, auristatins, duocarmycin, eleutherobin, taxols such as paclitaxel or docetaxel, cyclophosphamide, doxorubicin, vincristine, prednisone or prednisolone, other alkylating agents such as mechlorethamine, chlorambucil, and ifosfamide, antimetabolites such as azathioprine or mercaptopurine, other microtubule inhibitors (vinca alkaloids like vincristine, vinblastine, vinorelbine, and vindesine, as well as taxanes), podophyllotoxins (etoposide, teniposide, etoposide phosphate, and epipodophyllotoxins), topoisomerase inhibitors, other cytotoxins such as actinomycin, daunorubicin, valrubicin, idarubicin, edrecolomab, epirubicin, bleomycin, plicamycin, mitomycin, as well as other anticancer antibodies (cetuximab, bevacizumab, ibritumomab, abagovomab, adecatumumab, afutuzumab, alacizumab, alemtuzumab, anatumomab, apolizumab, bavituximab, belimumab, bivatuzumab mertansine, blinatumomab, brentuximab vedotin, cantuzumab mertansine, catumazomab, cetuximab, citatuzumab bogatox, cixutumumab, clivatuzumab tetraxetan, conatumumab, dacetuzumab, daclizumab, detumomab, ecromeximab, edrecolomab, elotuzumab, epratuzumab, ertumaxomab, etaracizumab, farletuzumab, figitumumab, fresolimumab, galiximab, gembatumumab vedotin, gemtuzumab, ibritumomab tiuxetan, inotuzumab ozogamicin, intetumumab, ipilimumab, iratumumab, labetuzumab, lexatumumab, lintuzumab, lucatumumab, lumilisimab, mapatumumab, matuzumab, milatuzumab, mitumomab, nacolomab tafenatox, naptumomab estafenatox, necitumumab, nimotuzumab, ofatumumab, olaratumab, oportuzumab monatox, oregovomab, panitumumab, pemtumomab, pertuzumab, pintumomab, pritumumab, ramucirumab, rilotumumab, robatumumab, rituximab, sibrotuzumab, tacatuzumab tetraxetan, taplitumomab paptox, tenatumomab, ticilimumab, tigatuzumab, tositumomab or131I-tositumomab, trastuzumab, tremelimumab, tuocotuzumab celmoleukin, veltuzumab, visilizumab, volocixumab, votumumab, zalutumumab, zanolimumab, IGN-101, MDX-010, ABX-EGR, EMD72000, ior-t1, MDX- 220, MRA, H-11 scFv, huJ591, TriGem, TriAb, R3, MT-201, G-250, ACA-125, Onyvax- 105, CD:-960,Cea-Vac, BrevaRex AR54, IMC-1C11, GlioMab-H, ING-1, anti-LCG Mabs, MT-103, KSB-303, Therex, KW2871, anti-HMI.24, Anti-PTHrP, 2C4 antibody, SGN-30, TRAIL-RI Mab, Prostate Cancer antibody, H22xKi-r, ABX-Mai, Imuteran, Monopharm-C), and antibody-drug conjugates comprising any of the above agents (especially auristatins MMAE and MMAF, maytansinoids like DM-1, calicheamycins, or various cytotoxins). 90ny-2716015Attorney Docket No.30864-20005.40

[0191] In certain embodiments, the additional therapeutic agent is selected from anastrozole (ARIMIDEX®), bicalutamide (CASODEX®), bleomycin sulfate (BLENOXANE®), busulfan (MYLERAN®), busulfan injection (BUSULFEX®), capecitabine (XELODA®), N4-pentoxycarbonyl-5-deoxy-5-fluorocytidine, carboplatin (PARAPLATIN®), carmustine (BiCNU®), chlorambucil (LEUKERAN®), cisplatin (PLATINOL®), cladribine (LEUSTATIN®), cyclophosphamide (CYTOXAN® or NEOSAR®), cytarabine, cytosine arabinoside (CYTOSAR-U®), cytarabine liposome injection (DEPOCYT®), dacarbazine (DTIC-Dome®), dactinomycin (actinomycin D, COSMEGAN®), daunorubicin hydrochloride (CERUBIDINE®), daunorubicin citrate liposome injection (DAUNOXOME®), dexamethasone, docetaxel (TAXOTERE®), doxorubicin hydrochloride (ADRIAMYCIN®, RUBEX®), etoposide (VEPESID®), fludarabine phosphate (FLUDARA®), 5-fluorouracil (ADRUCIL®, EFUDEX®), flutamide (EULEXIN®), tezacitibine, gemcitabine (difluorodeoxycitidine), hydroxyurea (HYDREA®), idarubicin (IDAMYCIN®), ifosfamide (IFEX®), irinotecan (CAMPTOSAR®), L-asparaginase (ELSPAR®), leucovorin calcium, melphalan (ALKERAN®), 6-mercaptopurine (PURINETHOL®), methotrexate (FOLEX®), mitoxantrone (NOVANTRONE®), gemtuzumab ozogamicin (MYLOTARGTM), paclitaxel (TAXOL®), nab-paclitaxel (ABRAXANE®), phoenix (Yttrium90 / MX-DTPA), pentostatin, polifeprosan 20 with carmustine implant (GLIADEL®), tamoxifen citrate (NOLVADEX®), teniposide (VUMON®), 6-thioguanine, thiotepa, tirapazamine (TIRAZONE®), topotecan hydrochloride for injection (HYCAMPTIN®), vinblastine (VELBAN®), vincristine (ONCOVIN®), and vinorelbine (NAVELBINE®).

[0192] In certain embodiments, the additional therapeutic agent is capable of inhibiting BRAF, MEK, CDK4 / 6, SHP-2, HDAC, EGFR, MET, mTOR, PI3K or AKT, or a combination thereof. In a particular embodiment, the compounds of the present invention are combined with another therapeutic agent selected from vemurafinib, debrafinib, LGX818, trametinib, MEK162, LEE011, PD-0332991, panobinostat, verinostat, romidepsin, cetuximab, gefitinib, erlotinib, lapatinib, panitumumab, vandetanib, INC280, everolimus, simolimus, BMK120, BYL719 or CLR457, or a combination thereof.

[0193] In certain embodiments, the additional therapeutic agent is selected based on the disease or condition that is being treated. For example, in the treatment of melanoma, the additional therapeutic agent is selected from aldesleukin (e.g., PROLEUKIN®), dabrafenib (e.g., TAFINLAR®), dacarbazine, recombinant interferon alfa-2b (e.g., INTRON® A), 91ny-2716015Attorney Docket No.30864-20005.40 ipilimumab, trametinib (e.g., MEKINIST®), peginterferon alfa-2b (e.g., PEGINTRON®, SYLATRONTM), vemurafenib (e.g., ZELBORAF®)), and ipilimumab (e.g., YERVOY®).

[0194] For the treatment of ovarian cancer, the additional therapeutic agent is selected from doxorubicin hydrochloride (Adriamycin®), carboplatin (PARAPLATIN®), cyclophosphamide (CYTOXAN®, NEOSAR®), cisplatin (PLATINOL®, PLATINOL- AQ®), doxorubicin hydrochloride liposome (DOXIL®, DOX-SL®, EVACET®, LIPODOX®), gemcitabine hydrochloride (GEMZAR®), topotecan hydrochloride (HYCAMTIN®), and paclitaxel (TAXOL®).

[0195] For the treatment of thyroid cancer, the additional therapeutic agent is selected from doxorubicin hydrochloride (Adriamycin®), cabozantinib-S-malate (COMETRIQ®), and vandetanib (CAPRELSA®).

[0196] For the treatment of colon cancer, the additional therapeutic agent is selected from fluorouracil (e.g., ADRUCIL®, EFUDEX®, FLUOROPLEX®), bevacizumab (AVASTIN®), irinotecan hydrochloride (CAMPTOSTAR®), capecitabine (XELODA®), cetuximab (ERBITUX®), oxaliplatin (ELOXATIN®), leucovorin calcium (WELLCOVORIN®), regorafenib (STIVARGA®), panitumumab (VECTIBIX®), and ziv- aflibercept (ZALTRAP®).

[0197] For the treatment of lung cancer, the additional therapeutic agent is selected from methotrexate, methotrexate LPF (e.g., FOLEX®, FOLEX PFS®, Abitrexate®, MEXATE®, MEXATE-AQ®), paclitaxel (TAXOL®), paclitaxel albumin-stabilized nanoparticle formulation (ABRAXANE®), afatinib dimaleate (GILOTRIF®), pemetrexed disodium (ALIMTA®), bevacizumab (AVASTIN®), carboplatin (PARAPLATIN®), cisplatin (PLATINOL®, PLATINOL-AQ®), crizotinib (XALKORI®), erlotinib hydrochloride (TARCEVA®), gefitinib (IRESSA®), and gemcitabine hydrochloride (GEMZAR®).

[0198] For the treatment of pancreatic cancer, the other therapeutic agent may be selected from fluorouracil (ADRUCIL®), EFUDEX®, FLUOROPLEX®), erlotinib hydrochloride (TARCEVA®), gemcitabine hydrochloride (GEMZAR®), and mitomycin or mitomycin C (MITOZYTREXTM, MUTAMYCIN®).

[0199] For the treatment of cervical cancer, the additional therapeutic agent is selected from bleomycin (BLENOXANE®), cisplatin (PLATINOL®, PLATINOL-AQ®) and topotecan hydrochloride (HYCAMTIN®). 92ny-2716015Attorney Docket No.30864-20005.40

[0200] For the treatment of head and neck cancer, the additional therapeutic agent is selected from methotrexate, methotrexate LPF (e.g., FOLEX®, FOLEX PFS®, Abitrexate®, MEXATE®, MEXATE-AQ®), fluorouracil (ADRUCIL®, EFUDEX®, FLUOROPLEX®), bleomycin (BLENOXANE®), cetuximab (ERBITUX®), cisplatin (PLATINOL®, PLATINOL-AQ®) and docetaxel (TAXOTERE®).

[0201] For the treatment of leukemia, including chronic myelomonocytic leukemia (CMML), the additional therapeutic agent is selected from bosutinib (BOSULIF®), cyclophosphamide (CYTOXAN®, NEOSAR®), cytarabine (CYTOSAR-U®, TARABINE PFS®), dasatinib (SPRYCEL®), imatinib mesylate (GLEEVEC®), ponatinib (ICLUSIG®), nilotinib (TASIGNA®) and omacetaxine mepesuccinate (SYNRIBO®).

[0202] In some instances, patients may experience allergic reactions to the compounds of the present invention and / or other anti-cancer agent(s) during or after administration. Therefore, anti-allergic agents may be administered to minimize the risk of an allergic reaction. Suitable anti-allergic agents include corticosteroids, such as dexamethasone (e.g., DECADRON®), beclomethasone (e.g., BECLOVENT®), hydrocortisone (also known as cortisone, hydrocortisone sodium succinate, hydrocortisone sodium phosphate; e.g., ALA-CORT®, hydrocortisone phosphate, Solu-CORTEF®, HYDROCORT Acetate® and LANACORT®), prednisolone (e.g., DELTA-Cortel®, ORAPRED®, PEDIAPRED® and PRELONE®), prednisone (e.g., DELTASONE®, LIQUID RED®, METICORTEN® and ORASONE®), methylprednisolone (also known as 6-methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate; e.g., DURALONE®, MEDRALONE®, MEDROL®, M-PREDNISOL® and SOLU-MEDROL®); antihistamines, such as diphenhydramine (e.g., BENADRYL®), hydroxyzine, and cyproheptadine; and bronchodilators, such as the beta- adrenergic receptor agonists, albuterol (e.g., PROVENTIL®), and terbutaline (BRETHINE®).

[0203] In other instances, patients may experience nausea during and after administration of the compound of the present invention and / or other anti-cancer agent(s). Therefore, anti- emetics may be administered in preventing nausea (upper stomach) and vomiting. Suitable anti-emetics include aprepitant (EMEND®), ondansetron (ZOFRAN®), granisetron HCl (KYTRIL®), lorazepam (ATIVAN®. Dexamethasone (DECADRON®), prochlorperazine (COMPAZINE®), casopitant (REZONIC® and Zunrisa®), and combinations thereof. 93ny-2716015Attorney Docket No.30864-20005.40

[0204] In yet other instances, medication to alleviate the pain experienced during the treatment period is prescribed to make the patient more comfortable. Common over-the- counter analgesics, such TYLENOL®, are often used. Opioid analgesic drugs such as hydrocodone / paracetamol or hydrocodone / acetaminophen (e.g., VICODIN®), morphine (e.g., ASTRAMORPH® or AVINZA®), oxycodone (e.g., OXYCONTIN® or PERCOCET®), oxymorphone hydrochloride (OPANA®), and fentanyl (e.g., DURAGESIC®) are also useful for moderate or severe pain.

[0205] Furthermore, cytoprotective agents (such as neuroprotectants, free-radical scavengers, cardioprotectors, anthracycline extravasation neutralizers, nutrients and the like) may be used as an adjunct therapy to protect normal cells from treatment toxicity and to limit organ toxicities. Suitable cytoprotective agents include amifostine (ETHYOL®), glutamine, dimesna (TAVOCEPT®), mesna (MESNEX®), dexrazoxane (ZINECARD® or TOTECT®), xaliproden (XAPRILA®), and leucovorin (also known as calcium leucovorin, citrovorum factor and folinic acid).

[0206] In yet another aspect, a compound of the present invention may be used in combination with known therapeutic processes, for example, with the administration of hormones or in radiation therapy. In certain instances, a compound of the present invention may be used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.

[0207] The doses and dosage regimen of the active ingredients used in the combination therapy may be determined by an attending clinician. In certain embodiments, the compound described herein (e.g., a compound of Formula I, I-A, I-B, II, or other compounds in Section I) and the additional therapeutic agent(s) are administered in doses commonly employed when such agents are used as monotherapy for treating the disease or condition. In other embodiments, the compound described herein (e.g., a compound of Formula I, I-A, I-B, II, or other compounds in Section I) and the additional therapeutic agent(s) are administered in doses lower than the doses commonly employed when such agents are used as monotherapy for treating the disease or condition. In certain embodiments, the compound described herein (e.g., a compound of Formula I, I-A, I-B, II, or other compounds in Section I) and the additional therapeutic agent(s) are present in the same composition, which is suitable for oral administration. In certain embodiments, the compound described herein (e.g., a compound of Formula I’, I, I-A, I-B, II, or other compounds in Section I) and the additional therapeutic agent(s) are administered in doses commonly employed when such agents are used as 94ny-2716015Attorney Docket No.30864-20005.40 monotherapy for treating the disease or condition. In other embodiments, the compound described herein (e.g., a compound of Formula I’, I, I-A, I-B, II, or other compounds in Section I) and the additional therapeutic agent(s) are administered in doses lower than the doses commonly employed when such agents are used as monotherapy for treating the disease or condition. In certain embodiments, the compound described herein (e.g., a compound of Formula I’, I, I-A, I-B, II, or other compounds in Section I) and the additional therapeutic agent(s) are present in the same composition, which is suitable for oral administration.

[0208] In certain embodiments, the compound described herein (e.g., a compound of Formula I, I-A, I-B, II, or other compounds in Section I) and the additional therapeutic agent(s) may act additively or synergistically. A synergistic combination may allow the use of lower dosages of one or more agents and / or less frequent administration of one or more agents of a combination therapy. A lower dosage or less frequent administration of one or more agents may lower toxicity of the therapy without reducing the efficacy of the therapy. In certain embodiments, the compound described herein (e.g., a compound of Formula I’, I, I-A, I-B, II, or other compounds in Section I) and the additional therapeutic agent(s) may act additively or synergistically. A synergistic combination may allow the use of lower dosages of one or more agents and / or less frequent administration of one or more agents of a combination therapy. A lower dosage or less frequent administration of one or more agents may lower toxicity of the therapy without reducing the efficacy of the therapy.

[0209] Another aspect of this invention is a kit comprising a therapeutically effective amount of a compound described herein (e.g., a compound of Formula I, I-A, I-B, II, or other compounds in Section I), a pharmaceutically acceptable carrier, vehicle or diluent, and optionally at least one additional therapeutic agent listed above. In certain embodiments, the kit further comprises instructions, such as instructions for treating a disease described herein.

[0210] Another aspect of this invention is a kit comprising a therapeutically effective amount of a compound described herein (e.g., a compound of Formula I’, I, I-A, I-B, II, or other compounds in Section I), a pharmaceutically acceptable carrier, vehicle or diluent, and optionally at least one additional therapeutic agent listed above. In certain embodiments, the kit further comprises instructions, such as instructions for treating a disease described herein. 95ny-2716015Attorney Docket No.30864-20005.40 IV. Pharmaceutical Compositions and Dosing Considerations

[0211] As indicated above, the invention provides pharmaceutical compositions, which comprise a therapeutically-effective amount of one or more of the compounds described above, formulated together with one or more pharmaceutically acceptable carriers (additives) and / or diluents. The pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; (3) topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a pessary, cream or foam; (5) sublingually; (6) ocularly; (7) transdermally; or (8) nasally. In certain embodiments, the invention provides a pharmaceutical composition comprising a compound described herein (e.g., a compound of Formula I, I-A, I-B, II, or other compounds in Section I, ) and a pharmaceutically acceptable carrier. In certain embodiments, the invention provides a pharmaceutical composition comprising a compound described herein (e.g., a compound of Formula I’, I, I-A, I-B, II, or other compounds in Section I, ) and a pharmaceutically acceptable carrier.

[0212] The phrase “therapeutically effective amount” as used herein means that amount of a compound, material, or composition comprising a compound of the present invention which is effective for producing some desired therapeutic effect in at least a sub-population of cells in an animal at a reasonable benefit / risk ratio applicable to any medical treatment.

[0213] The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0214] Wetting agents, emulsifiers and lubricants, such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions. Examples of pharmaceutically-acceptable antioxidants include: (1) water 96ny-2716015Attorney Docket No.30864-20005.40 soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and the like; (2) oil-soluble antioxidants, such as ascorbyl palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and the like; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and the like.

[0215] Formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and / or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will vary depending upon the host being treated, the particular mode of administration. The amount of active ingredient which can be combined with a carrier material to produce a single dosage form will generally be that amount of the compound which produces a therapeutic effect. Generally, out of one hundred percent, this amount will range from about 0.1 percent to about ninety-nine percent of active ingredient, preferably from about 5 percent to about 70 percent, most preferably from about 10 percent to about 30 percent.

[0216] In certain embodiments, a formulation of the present invention comprises an excipient selected from the group consisting of cyclodextrins, celluloses, liposomes, micelle forming agents, e.g., bile acids, and polymeric carriers, e.g., polyesters and polyanhydrides; and a compound of the present invention. In certain embodiments, an aforementioned formulation renders orally bioavailable a compound of the present invention.

[0217] Methods of preparing these formulations or compositions include the step of bringing into association a compound of the present invention with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a compound of the present invention with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product.

[0218] Formulations of the invention suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored basis, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin, or sucrose and acacia) and / or as 97ny-2716015Attorney Docket No.30864-20005.40 mouth washes and the like, each containing a predetermined amount of a compound of the present invention as an active ingredient. A compound of the present invention may also be administered as a bolus, electuary or paste.

[0219] In solid dosage forms of the invention for oral administration (e.g., capsules, tablets, pills, dragees, powders, granules, trouches and the like), the active ingredient is mixed with one or more pharmaceutically-acceptable carriers, such as sodium citrate or dicalcium phosphate, and / or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and / or acacia; (3) humectants, such as glycerol; (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds and surfactants, such as poloxamer and sodium lauryl sulfate; (7) wetting agents, such as, for example, cetyl alcohol, glycerol monostearate, and non-ionic surfactants; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, zinc stearate, sodium stearate, stearic acid, and mixtures thereof; (10) coloring agents; and (11) controlled release agents such as crospovidone or ethyl cellulose. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-shelled gelatin capsules using such excipients as lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like.

[0220] A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared using binder (for example, gelatin or hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (for example, sodium starch glycolate or cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

[0221] The tablets, and other solid dosage forms of the pharmaceutical compositions of the present invention, such as dragees, capsules, pills and granules, may optionally be scored or prepared with coatings and shells, such as enteric coatings and other coatings well known in the pharmaceutical-formulating art. They may also be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl 98ny-2716015Attorney Docket No.30864-20005.40 cellulose in varying proportions to provide the desired release profile, other polymer matrices, liposomes and / or microspheres. They may be formulated for rapid release, e.g., freeze-dried. They may be sterilized by, for example, filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use. These compositions may also optionally contain opacifying agents and may be of a composition that they release the active ingredient(s) only, or preferentially, in a certain portion of the gastrointestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. The active ingredient can also be in micro-encapsulated form, if appropriate, with one or more of the above-described excipients.

[0222] Liquid dosage forms for oral administration of the compounds of the invention include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active ingredient, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubilizing agents and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.

[0223] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.

[0224] Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, and mixtures thereof.

[0225] Formulations of the pharmaceutical compositions of the invention for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more compounds of the invention with one or more suitable nonirritating excipients or carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a 99ny-2716015Attorney Docket No.30864-20005.40 salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the rectum or vaginal cavity and release the active compound.

[0226] Formulations of the present invention which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.

[0227] Dosage forms for the topical or transdermal administration of a compound of this invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active compound may be mixed under sterile conditions with a pharmaceutically-acceptable carrier, and with any preservatives, buffers, or propellants which may be required.

[0228] The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.

[0229] Powders and sprays can contain, in addition to a compound of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants, such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons, such as butane and propane.

[0230] Transdermal patches have the added advantage of providing controlled delivery of a compound of the present invention to the body. Such dosage forms can be made by dissolving or dispersing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate of such flux can be controlled by either providing a rate controlling membrane or dispersing the compound in a polymer matrix or gel.

[0231] Ophthalmic formulations, eye ointments, powders, solutions and the like, are also contemplated as being within the scope of this invention.

[0232] Pharmaceutical compositions of this invention suitable for parenteral administration comprise one or more compounds of the invention in combination with one or more pharmaceutically-acceptable sterile isotonic aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, or sterile powders which may be reconstituted into sterile injectable solutions or dispersions just prior to use, which may contain sugars, alcohols, 100ny-2716015Attorney Docket No.30864-20005.40 antioxidants, buffers, bacteriostats, solutes which render the formulation isotonic with the blood of the intended recipient or suspending or thickening agents.

[0233] Examples of suitable aqueous and nonaqueous carriers which may be employed in the pharmaceutical compositions of the invention include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils, such as olive oil, and injectable organic esters, such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials, such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.

[0234] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms upon the subject compounds may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like into the compositions. In addition, prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.

[0235] In some cases, in order to prolong the effect of a drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material having poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally-administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.

[0236] Injectable depot forms are made by forming microencapsule matrices of the subject compounds in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of drug to polymer, and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissue.

[0237] When the compounds of the present invention are administered as pharmaceuticals, to humans and animals, they can be given per se or as a pharmaceutical composition containing, 101ny-2716015Attorney Docket No.30864-20005.40 for example, 0.1 to 99% (more preferably, 10 to 30%) of active ingredient in combination with a pharmaceutically acceptable carrier.

[0238] The preparations of the present invention may be given orally, parenterally, topically, or rectally. They are of course given in forms suitable for each administration route. For example, they are administered in tablets or capsule form, by injection, inhalation, eye lotion, ointment, suppository, etc. administration by injection, infusion or inhalation; topical by lotion or ointment; and rectal by suppositories. Oral administrations are preferred.

[0239] The phrases “parenteral administration” and “administered parenterally” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrasternal injection and infusion.

[0240] The phrases “systemic administration,” “administered systemically,” “peripheral administration” and “administered peripherally” as used herein mean the administration of a compound, drug or other material other than directly into the central nervous system, such that it enters the patient’s system and, thus, is subject to metabolism and other like processes, for example, subcutaneous administration.

[0241] These compounds may be administered to humans and other animals for therapy by any suitable route of administration, including orally, nasally, as by, for example, a spray, rectally, intravaginally, parenterally, intracisternally and topically, as by powders, ointments or drops, including buccally and sublingually.

[0242] Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and / or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically-acceptable dosage forms by conventional methods known to those of skill in the art.

[0243] Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

[0244] The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide 102ny-2716015Attorney Docket No.30864-20005.40 thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and / or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

[0245] A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.

[0246] In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Preferably, the compounds are administered at about 0.01 mg / kg to about 200 mg / kg, more preferably at about 0.1 mg / kg to about 100 mg / kg, even more preferably at about 0.5 mg / kg to about 50 mg / kg. When the compounds described herein are co-administered with another agent (e.g., as sensitizing agents), the effective amount may be less than when the agent is used alone.

[0247] If desired, the effective daily dose of the active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. Preferred dosing is one administration per day.

[0248] The invention further provides a unit dosage form (such as a tablet or capsule) comprising a diazepino-thieno-quinoxaline compound or related compound described herein in a therapeutically effective amount for the treatment of a disease or condition described herein. IV. Medical Kits

[0249] Another aspect of the invention provides a medical kit comprising, for example, (i) a compound described herein, and (ii) instructions for use according to a method described herein. Enumerated Embodiments 103ny-2716015Attorney Docket No.30864-20005.40

[0250] The following enumerated embodimetns are representative of some aspects of the invention.

[0251] Enumerated Embodiment 1. A compound represented by Formula I:pharmaceutically acceptable salt thereof, wherein: R1and R2are independently hydrogen or C1-4 alkyl; or R1and R2are taken together with the carbon atom to which they are attached to form a 3-7 membered saturated carbocyclic ring or a 3-7 membered heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of R6; R3and R4are independently hydrogen or C1-4 alkyl; R5is -O-(9-11 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7); R6is C1-4alkyl or C1-4haloalkyl; R7is C1-4alkyl, C1-4deuteroalkyl, C1-4haloalkyl, -(C1-3alkylene)-C1-4alkoxy, or oxo; or two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring; X is -N(R8)-, -O-, or -CH2-; R8is hydrogen or C1-4 alkyl; and n is 0, 1, or 2.

[0252] Enumerated Embodiment 2. The compound of Enumerated Embodiment 1, wherein the compound is a compound of Formula I.

[0253] Enumerated Embodiment 3. The compound of Enumerated Embodiments 1 or 2, wherein X is -N(R8)-.

[0254] Enumerated Embodiment 4. The compound of any one of Enumerated Embodiments 1-3, wherein R8is hydrogen. 104ny-2716015Attorney Docket No.30864-20005.40

[0255] Enumerated Embodiment 5. The compound of any one of Enumerated Embodiments 1-3, wherein R8is methyl.

[0256] Enumerated Embodiment 6. The compound of Enumerated Embodiments 1 or 2, wherein X is -O-.

[0257] Enumerated Embodiment 7. The compound of Enumerated Embodiments 1 or 2, wherein X is -CH2-.

[0258] Enumerated Embodiment 8. The compound of Enumerated Embodiment 1, wherein the compound is a compound of Formula Ia:pharmaceutically acceptable salt thereof.

[0259] Enumerated Embodiment 9. The compound of Enumerated Embodiment 1, wherein the compound is a compound of Formula Ib:pharmaceutically acceptable salt thereof.

[0260] Enumerated Embodiment 10. The compound of Enumerated Embodiment 1, wherein the compound is a compound of formulapharmaceutically acceptable salt thereof. 105ny-2716015Attorney Docket No.30864-20005.40

[0261] Enumerated Embodiment 11. The compound of Enumerated Embodiment 1, whereinpharmaceutically acceptable salt thereof.

[0262] Enumerated Embodiment 12. The compound of Enumerated Embodiment 1, wherein the compound is a compound of formula Ie:pharmaceutically acceptable salt thereof.

[0263] Enumerated Embodiment 13. The compound of Enumerated Embodiment 1, whereinpharmaceutically acceptable salt thereof.

[0264] Enumerated Embodiment 14. The compound of Enumerated Embodiment 1, wherein the compound is a compound of Formula I-A:pharmaceutically acceptable salt thereof, wherein: R1and R2are independently hydrogen or C1-4 alkyl; or R1and R2are taken together with the carbon atom to which they are attached to form a 3-7 membered saturated carbocyclic ring or 106ny-2716015Attorney Docket No.30864-20005.40 a 3-7 membered heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of R6; R3and R4are independently hydrogen or C1-4 alkyl; R5is -O-(9-11 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7); R6is C1-4alkyl; R7is C1-4alkyl, C1-4deuteroalkyl, C1-4haloalkyl, -(C1-3alkylene)-C1-4alkoxy, or oxo; or two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring; and n is 0, 1, or 2.

[0265] Enumerated Embodiment 15. The compound of Enumerated Embodiment 14, wherein the compound is a compound of Formula I-A.

[0266] Enumerated Embodiment 16. The compound of any one of Enumerated Embodiments 1-7, 14, or 15, wherein each of R3and R4is hydrogen.

[0267] Enumerated Embodiment 17. The compound of Enumerated Embodiment 1, wherein the compound is a compound of Formulapharmaceutically acceptable salt thereof, wherein: R1and R2are independently hydrogen or C1-4 alkyl; or R1and R2are taken together with the carbon atom to which they are attached to form a 3-7 membered saturated carbocyclic ring or a 3-7 membered heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of R6; 107ny-2716015Attorney Docket No.30864-20005.40heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclic ring is substituted with n occurrence of R7. R6is C1-4 alkyl; R7is C1-4alkyl, C1-4deuteroalkyl, C1-4haloalkyl, -(C1-3alkylene)-C1-4alkoxy, or oxo; or two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring; and n is 0, 1, or 2.

[0268] Enumerated Embodiment 18. The compound of Enumerated Embodiment 17, wherein the compound is a compound of Formula I-B.

[0269] Enumerated Embodiment 19. The compound of any one of Enumerated Embodiments 1-7 or 14-18, wherein R1is C1-4alkyl.

[0270] Enumerated Embodiment 20. The compound of any one of Enumerated Embodiments 1-7 or 14-18, wherein R1is methyl.

[0271] Enumerated Embodiment 21. The compound of any one of Enumerated Embodiments 1-7 or 14-20, wherein R2is hydrogen.

[0272] Enumerated Embodiment 22. The compound of any one of Enumerated Embodiments 1-7 or 14-18, wherien R1is methyl, and R2is hydrogen.

[0273] Enumerated Embodiment 23. The compound of any one of Enumerated Embodiments 1-7 or 14-18, wherein R1and R2are taken together with the carbon atom to which they are attached to form a 3 membered saturated carbocyclic ring substituted with 0 or 1 occurrences of methyl.

[0274] Enumerated Embodiment 24. The compound of any one of Enumerated Embodiments 1-7 or 14-18, wherein R1and R2are taken together with the carbon atom to which they are attached to form a 4 membered saturated carbocyclic ring or a 4 membered heterocyclic ring containing 1 nitrogen atom, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of methyl. 108ny-2716015Attorney Docket No.30864-20005.40

[0275] Enumerated Embodiment 25. The compound of any one of Enumerated Embodiments 1-7 or 14-18, wherein R1and R2are taken together with the carbon atom to which they are attached to form a 6 membered saturated carbocyclic ring or a 6 membered heterocyclic ring containing 1 nitrogen atom, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of methyl.

[0276] Enumerated Embodiment 26. The compound of any one of Enumerated Embodiments 1-7 or 14-18, wherein R1and R2are taken together with the carbon atom to which they are attached to form a ring selected from , , , , and, wherein * represents the carbon atom.

[0277] Enumerated Embodiment 27. The compound of any one of Enumerated Embodiments 1-26, whereinwherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclic ring is substituted with n occurrences of R7.

[0278] Enumerated Embodiment 28. The compound of any one of Enumerated Embodiments 1-26, wherein, wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclic ring is substituted with n occurrences of R7.

[0279] Enumerated Embodiment 29. The compound of any one of Enumerated Embodiments 1-26, wherein, wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclic ring is substituted with n occurrences of R7. 109ny-2716015Attorney Docket No.30864-20005.40

[0280] Enumerated Embodiment 30. The compound of any one of Enumerated Embodiments 1-26, whereinwherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclic ring is unsubstituted.

[0281] Enumerated Embodiment 31. The compound of any one of Enumerated Embodiments 1-26, whereinwherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclic ring is substituted with 1 occurrence of R7.

[0282] Enumerated Embodiment 32. The compound of any one of Enumerated Embodiments 1-26, whereinwherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclic ring is substituted with 2 occurrences of R7.

[0283] Enumerated Embodiment 33. The compound of any one of Enumerated Embodiments 1-32, wherein R7is methyl, -CHF2, -CH2CHF2, or oxo.

[0284] Enumerated Embodiment 34. The compound of any one of Enumerated Embodiments 1-32, wherein n is 2, the two R7groups are attached to the same carbon atom, and the two R7groups are taken together with the carbon atom to which they are attached to form a cyclopropyl ring.

[0285] Enumerated Embodiment 35. The compound of any one of Enumerated Embodiments 1-32, wherein n is 0.

[0286] Enumerated Embodiment 36. The compound of any one of Enumerated Embodiments 1-33, wherein n is 1.

[0287] Enumerated Embodiment 37. The compound of any one of Enumerated Embodiments 1-33, wherein n is 2. 110ny-2716015Attorney Docket No.30864-20005.40

[0288] Enumerated Embodiment 38. The compound of any one of Enumerated ,

[0289] Enumerated Embodiment 39. The compound of any one of Enumerated Embodiments 1-26, wherein R5is selected from.

[0290] Enumerated Embodiment 40. A compound in Table 1 herein, or a pharmaceutically acceptable salt thereof.

[0291] Enumerated Embodiment 41. A pharmaceutical composition comprising a compound of any one of Enumerated Embodiments 1-40 and a pharmaceutically acceptable carrier.

[0292] Enumerated Embodiment 42. A method for treating a disease or condition mediated by MK2, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of Enumerated Embodiments 1-40 to treat the disease or condition. 111ny-2716015Attorney Docket No.30864-20005.40

[0293] Enumerated Embodiment 43. The method of Enumerated Embodiment 42, wherein said disease or condition mediated by MK2 is an inflammatory disorder.

[0294] Enumerated Embodiment 44. The method of Enumerated Embodiment 42, wherein said disease or condition mediated by MK2 is ankylosing spondylitis, rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn’s disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren’s syndrome, scleroderma, ulcerative colitis, asthma, uveitis, psoriatic arthritis, hidradenitis suppurativa, cryopyrin-associated periodic syndromes, or juvenile idiopathic arthritis.

[0295] Enumerated Embodiment 45. The method of Enumerated Embodiment 42, wherein said disease or condition mediated by MK2 is ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn’s disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren’s syndrome, scleroderma, ulcerative colitis, or asthma.

[0296] Enumerated Embodiment 46. The method of Enumerated Embodiment 42, wherein said disease or condition mediated by MK2 is rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, hidradenitis suppurativa, cryopyrin-associated periodic syndromes, or juvenile idiopathic arthritis.

[0297] Enumerated Embodiment 47. The method of Enumerated Embodiment 42, wherein said disease or condition mediated by MK2 is cancer.

[0298] Enumerated Embodiment 48. The method of Enumerated Embodiment 42, wherein said disease or condition mediated by MK2 is a cancer selected from pancreatic cancer, colorectal cancer, multiple myeloma, lung cancer, gastric cancer, breast cancer, nasopharyngeal cancer, skin cancer, bladder cancer, prostate cancer, head and neck cancer, or glioblastoma.

[0299] Enumerated Embodiment 49. The method of Enumerated Embodiment 42, wherein said disease or condition mediated by MK2 is pancreatic cancer.

[0300] Enumerated Embodiment 50. The method of any one of Enumerated Embodiments 42-49, wherein the subject is a human. 112ny-2716015Attorney Docket No.30864-20005.40

[0301] Enumerated Embodiment 51. A method of inhibiting the activity of a MK2, comprising contacting a MK2 with an effective amount of a compound of any one of Enumerated Embodiments 1-40 to inhibit the activity of said MK2.

[0302] Enumerated Embodiment 52. A method of covalently modifying a MK2, comprising contacting a MK2 with an effective amount of a compound of any one of Enumerated Embodiments 1-40 to covalently modify the MK2.

[0303] Enumerated Embodiment 53. A covalently modified MK2 formed by the method of Enumerated Embodiment 52. EXAMPLES

[0304] The invention now being generally described, will be more readily understood by reference to the following examples, which are included merely for purposes of illustrating certain aspects and embodiments of the present invention, and are not intended to limit the invention. EXAMPLE 1 – Synthesis of (R)-3-((2-chloro-5,5-dioxido-6,7-dihydrothieno[3,2-d] pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5] thieno[3,2-f]quinoxalin-8-one (I-4)

[0305] Step 1. Preparation of 2,4-dichloro-6,7-dihydrothieno[3, 2-d]pyrimidine 5,5- dioxide. To a solution of 2,4-dichloro-5H,6H-thieno[2,3-d]pyrimidine (0.5 g, 2.41 mmol) in dichloromethane (10 mL) at 0 ℃ was added 3-chlorobenzene-1-carboperoxoic acid (5.77 g, 10 eq, 24.1 mmol). The reaction mixture was stirred at 25 ℃ for 1 hour. TLC (eluted with petroleum ether / ethyl acetate = 1 / 1, Rf = 0.35) showed the starting material was consumed and the desired product was formed. One additional reaction was set up as described above. 113ny-2716015Attorney Docket No.30864-20005.40 Both reaction mixtures were combined, quenched with sodium sulfite aqueous solution (20 mL), and extracted with dichloromethane (3 × 10 mL). The combined organic phase was washed with brine (20 mL), dried over magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give a residue, which was purified via silica gel chromatography eluting with 25-30% ethyl acetate in petroleum. Pure fractions were combined and concentrated to afford 0.3 g (25.98%) of 2, 4-dichloro-6, 7-dihydrothieno [3,2- d] pyrimidine 5,5-dioxide as a white solid.1H NMR (400 MHz, CDCl3) δ 3.75 – 3.65 (m, 2H), 3.57 – 3.48 (m, 2H).

[0306] Step 2. Preparation of (R)-3-((2-chloro-5,5-dioxido-6,7-dihydrothieno[3,2-d] pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno [3,2-f]quinoxalin-8-one. To a solution of 2, 4-dichloro-6,7-dihydrothieno [3,2-d]pyrimidine 5,5-dioxide (5 mg, 20.9 µmol) in acetonitrile (1.25 mL) at 0 ℃ was added (R)-3-hydroxy-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino [5’,6’:4,5] thieno [3,2-f] quinoxalin-8-one (3.14 mg, 0.5 eq, 10.5 µmol) and dipotassium carbonate (5.78 mg, 2 eq, 41.8 µmol). The reaction mixture was stirred at 0 ℃ for 0.5 hour. LCMS showed the starting material was consumed and the desired product was detected. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue, which was purified by prep-HPLC to afford 2 mg (19.01%) of (R)-3-((2-chloro-5,5-dioxido-6,7-dihydrothieno[3,2- d] pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12-tetrahydro-8H- [1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one as a yellow solid. LCMS (ESI+): Rt = 01.475 min, m / z 503.0 (M+H)+.1H NMR (400 MHz, DMSO-d6) δ 9.16 (s, 1H), 9.09 (s, 1H), 8.83 (s, 1H), 8.75 (s, 1H), 8.40 (d, J = 8.9 Hz, 1H), 8.37 (s, 1H), 7.99 (d, J = 9.0 Hz, 1H), 7.77 (br d, J = 1.6 Hz, 2H), 7.32 (br s, 2H), 4.79 (s, 2H), 4.72 (s, 1H), 3.19 (s, 3H), 3.13 (s, 1H). EXAMPLE 2 – Synthesis of (R)-3-((2-chloro-5-oxo-5,6,7,8-tetrahydropyrido [4,3-d] pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5] thieno[3,2-f]quinoxalin-8-one (I-12)114ny-2716015Attorney Docket No.30864-20005.40

[0307] To a solution of (R)-3-hydroxy-10-methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino [5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one (20.67 mg, 1 eq, 68.7 µmol) in dimethyl sulfoxide (0.5 mL) was added 2,4-dichloro-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one (15 mg, 1 eq, 68.7 µmol) and cesium carbonate (44.7 mg, 2 eq, 137.4 µmol) at 25 ℃. The reaction mixture was stirred at 25 ℃ for 1 hour. LCMS showed the material peak was consumed and the desired peak was detected. The mixture was diluted with water (5 mL) and extracted with ethyl acetate (3 × 3 mL). The organic phase was combined, washed with brine (5 mL), and dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep- HPLC to afford 3 mg (9.05%) of (R)-3-((2-chloro-5-oxo-5,6,7,8-tetrahydropyrido [4,3- d]pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12-tetrahydro-8H- [1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one as a yellow solid. LCMS (ESI+): Rt = 0.538 min, m / z 482.0 (M+H)+.1H NMR (400 MHz, DMSO-d6) 9.10 (s, 1H) 8.81 (br t, J = 3.63 Hz, 1H) 8.61 (br s, 1H) 8.36 (d, J = 9.01 Hz, 1H) 7.99 (br d, J = 4.38 Hz, 1H) 7.97 (d, J = 8.88 Hz, 1H) 3.66 – 3.69 (m, 1H) 3.54 (m, 2H) 3.52 – 3.54 (m, 2H) 3.07 (t, J = 6.63 Hz, 2H) 1.22 (d, J = 6.63 Hz, 3H). EXAMPLE 3 – Synthesis of (R)-3-((2-chloro-7,7-dimethyl-5,7-dihydrofuro[3,4- d]pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12-tetrahydro-8H- [1,4]diazepino[5’,6’:4,5]thieno[3,2-f] quinoxalin-8-one (I-11)

[0308] To a solution of (R)-3-hydroxy-10-methyl-9,10,11,12-tetrahydro-8H[1,4]diazepino [5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one (5.00 mg, 1 eq, 0.02 mmol) in dimethyl sulfoxide (0.30 mL) was added 2,4-dichloro-7,7-dimethyl-5,7-dihydrofuro[3,4-d]pyrimidine (3.65 mg, 1 eq, 0.02 mmol) and cesium carbonate (10.80 mg, 2 eq, 0.03 mmol) at 25 ℃. The reaction mixture was heated to 60 ℃ and stirred at 60 ℃ for 1 hour. LCMS showed the starting material was consumed completely and the desired product was detected. Seven additional reactions were set up as described above. After cooling to 25 ℃, all eight reaction mixtures were combined and filtered. The filtrate was concentrated under reduced pressure to give a 115ny-2716015Attorney Docket No.30864-20005.40 residue, which was purified by prep-HPLC (formic acid conditions) to afford 15.1 mg (25.50%) of (R)-3-((2-chloro-7,7-dimethyl-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)oxy)-10- methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one as a yellow solid. LCMS (ESI+): Rt = 0.750 min, m / z 482.9 (M+H)+.1H NMR (400 MHz, DMSO-d6) 9.11 (s, 1H), 8.83 – 8.77 (m, 1H), 8.35 (d, J = 8.8 Hz, 1H), 8.03 – 7.99 (m, 1H), 7.96 (d, J = 8.8 Hz, 1H), 5.09 (s, 2H), 3.71 – 3.65 (m, 1H), 3.63 – 3.58 (m, 2H), 1.48 (s, 6H), 1.21 (d, J = 6.8 Hz, 3H). EXAMPLE 4 – Synthesis of (R)-3-((2-chloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4- yl)oxy)-10-methyl-9, 10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f] quinoxalin-8-one (I-6)

[0309] Step 1. Preparation of tert-butyl (R)-2-chloro-4-((10-methyl-8-oxo-9,10,11,12- tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-3-yl)oxy)-5,7-dihydro- 6H-pyrrolo[3,4-d]pyrimidine-6-carboxylate. To a solution of tert-butyl 2,4-dichloro-5,7- dihydro-6H-pyrrolo[3,4-d]pyrimidine-6- carboxylate (50 mg, 1 eq, 172 µmol) in dimethyl sulfoxide (1 mL) was added (R)-3-hydroxy- 10-methyl-9,10,11,12-tetrahydro-8H- [1,4]diazepino[5’,6’:4,5] thieno[3,2-f]quinoxalin-8-one (51.8 mg, 1 eq, 172 µmol) and cesium carbonate (112 mg, 2 eq, 345 µmol) at 25 ℃. The reaction mixture was stirred at 25 ℃ for 0.5 hour. LCMS showed the starting material peak was consumed and the desired peak was detected. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (3 × 5 mL). The organic phase was combined, washed with brine (10 mL), and dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC to afford 9 116ny-2716015Attorney Docket No.30864-20005.40 mg (9.43%) of tert-butyl (R)-2-chloro-4-((10-methyl-8-oxo-9,10,11,12-tetrahydro-8H- [1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-3-yl)oxy)-5,7-dihydro-6H-pyrrolo[3,4- d]pyrimidine-6-carboxylate as an orange solid. LCMS (ESI+): Rt = 0.540 min, m / z 554.1 (M+H)+.

[0310] Step 2. Preparation of (R)-3-((2-chloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin- 4-yl)oxy)-10-methyl-9, 10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f] quinoxalin-8-one. To a solution of (R)-3-hydroxy-10-methyl-9,10,11,12-tetrahydro-8H- [1,4]diazepino[5’,6’:4,5] thieno[3,2-f]quinoxalin-8-one (9 mg, 1 eq, 16.24 µmol) in dichloromethane (1 mL) was added trifluoroacetic acid (0.1 mL) at 25 ℃. The reaction mixture was stirred at 25 ℃ for 1 hour. LCMS showed the starting material peak was consumed and the desired peak was detected. The mixture was concentrated under reduced pressure to obtain a residue. The residue was purified by prep-HPLC to afford 6 mg (81.37%) of (R)-3-((2-chloro-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidin-4-yl)oxy)-10-methyl- 9, 10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one as an orange solid. LCMS (ESI+): Rt = 0.335 min, m / z 454.0 (M+H)+.1H NMR (400 MHz,DMSO-d6) 9.83 (br s, 2H), 9.10 (s, 1H), 8.89 – 8.68 (m, 1H), 8.38 (d, J = 8.9 Hz, 1H), 8.02 (br d, J = 4.4 Hz, 1H), 7.94 (d, J = 8.9 Hz, 1H), 4.69 (br d, J = 5.5 Hz, 2H), 3.73 – 3.64 (m, 1H), 3.61 (br s, 2H), 1.22 (d, J = 6.6 Hz, 3H). EXAMPLE 5 – Synthesis of 2-chloro-4-{[(15R)-15-methyl-13-oxo-11-thia-3,6,14,17- tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-5-yl]oxy}- 5H,7H-6λ⁶-thieno[3,4-d]pyrimidine-6,6-dione (I-3)117ny-2716015Attorney Docket No.30864-20005.40

[0311] Step 1. Preparation of 2,4-dichloro-5H,7H-6λ⁶-thieno[3,4-d]pyrimidine-6,6-dione. To a solution of 2,4-dichloro-5H,7H-thieno[3,4-d]pyrimidine (0.1 g, 1 eq, 483 µmol) in dichloromethane (2 mL) was added 3-chlorobenzene-1-carboperoxoic acid (208 mg, 2.5 eq 1.21 mmol, 85% purity) at 25 ℃. The reaction mixture was stirred at 25 ℃ for 1 hour. LCMS showed the starting material peak was consumed and the desired peak was detected. Two additional reactions were set up as described above. All three reaction mixtures were combined. The mixture was quenched with saturated sodium sulfite solution (10 mL) and extracted with ethyl acetate (3 × 3 mL). The organic phase was washed with brine (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give a residue, which was purified by prep-HPLC to afford 90 mg (25.98%) of 2,4-dichloro-5H,7H-6λ⁶-thieno[3,4-d]pyrimidine-6,6-dione as a white solid. LCMS: Rt= 1.451 min, 97.53% purity, m / z = 238.9 (M+H)+

[0312] Step 2. Preparation of 2-chloro-4-{[(15R)-15-methyl-13-oxo-11-thia-3,6,14,17- tetraazatetracyclo [8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-5-yl]oxy}- 5H,7H-6λ⁶-thieno[3,4-d]pyrimidine-6,6-dione. To a solution of 2,4-dichloro-5H,7H-6λ⁶- thieno[3,4-d]pyrimidine-6,6-dione (23.9 mg, 3 eq, 99.9 µmol) and (15R)-5-hydroxy-15- methyl-11-thia-3,6,14,17-tetraazatetracyclo [8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)- hexaen-13-one (10 mg, 33.3 µmol) in dimethylsulfoxide (0.5 mL) was added cesium carbonate (21.7 mg, 2 eq, 66.6 µmol) at 25 ℃. The reaction mixture was heated to 60 ℃ and stirred at 60 ℃ for 1 hour. LCMS showed the starting material peak was consumed and the desired peak was detected. One additional vial was set up as described above. After cooling to 25 ℃, both reaction mixtures were combined. The mixture was filtered, and the filtrate was purified by prep-HPLC to obtain 1.1 mg (2.63%) of 2-chloro-4-{[(15R)-15-methyl-13- oxo-11-thia-3,6,14,17-tetraazatetracyclo [8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)- hexaen-5-yl]oxy}-5H,7H-6λ⁶-thieno[3,4-d]pyrimidine-6,6-dione as an orange solid. LCMS (ESI+): Rt = 1.557 min, m / z 503.0 (M+H)+.1H NMR (400 MHz, DMSO-d6) 9.14 (s, 1H), 8.80 (br s, 1H), 8.37 (d, J = 9.0 Hz, 1H), 8.01 (br d, J = 4.0 Hz, 1H), 7.96 (d, J = 9.0 Hz, 1H), 4.88 (s, 2H), 4.78 (s, 2H), 3.71 – 3.65 (m, 1H), 3.61 (br s, 2H), 1.23 (br s, 3H). 118ny-2716015Attorney Docket No.30864-20005.40 EXAMPLE 6 – Synthesis of (15R)-5-({2-chloro-7-methyl-5H,6H,7H,8H,9H- pyrimido[4,5-d]azepin-4-yl}oxy)-15-methyl-11-thia-3,6,14,17- tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-13-one (I-2)

[0313] Step 1. Preparation of tert-butyl 2-chloro-4-{[(15R)-15-methyl-13-oxo-11-thia- 3,6,14,17-tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-5- yl]oxy}-5H,6H,7H,8H,9H-pyrimido[4,5-d]azepine-7-carboxylate. To a solution of tert- butyl 2,4-dichloro-5H,6H,7H,8H,9H-pyrimido[4,5-d]azepine-7-carboxylate (39.7 mg, 1 eq, 125 µmol) in dimethyl sulfoxide (2 mL) at room temperature was added dipotassium carbonate (34.5 mg, 2 eq, 250 µmol) and (15R)-5-hydroxy-15-methyl-11-thia- 3,6,14,17- tetraazatetracyclo [8.8.0.0²,⁷.0¹²,¹⁸] octadeca-1(10),2(7),3,5,8,12(18)-hexaen-13-one (30 mg, 0.8 eq, 99.9 µmol). The reaction mixture was heated to 60 ℃ and stirred at 60 ℃ for 1 hour. LCMS analysis showed the starting material was consumed completely and the desired product was detected. The reaction mixture was quenched with water (10 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic phase was washed with brine (20 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to give 72.7 mg (93.3%) of tert-butyl 2-chloro-4-{[(15R)-15-methyl-13- oxo-11-thia-3,6,14,17-tetra-azatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸] octadeca-1(10),2(7),3,5,8,12(18)- hexaen-5-yl]oxy}-5H,6H, 7H,8H,9H-pyrimido[4,5-d]azepine-7-carboxylate as a yellow solid, which was used directly in the next step without purification. LCMS: Rt = 0.518 min, m / z = 582.3 (M+H)+.

[0314] Step 2. Preparation of (15R)-5-({2-chloro-5H,6H,7H,8H,9H-pyrimido[4,5- d]azepin-4-yl}oxy)-15-methyl-11-thia-3,6,14,17- 119ny-2716015Attorney Docket No.30864-20005.40 tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7), 3,5,8,12(18)-hexaen-13-one. tert- Butyl-2-chloro-4-{[(15R)-15-methyl-13-oxo-11-thia-3,6,14,17- tetraazatetracyclo[8.8.0.0², ⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-5-yl]oxy}-5H,6H,7H,8H,9H-pyrimido[4,5- d]azepine-7-carboxylate (60 mg, 1 eq, 103 µmol) was added to a mixture of dichloromethane (2 mL) and trifluoroacetic acid (0.4 mL) at room temperature. The reaction mixture was stirred at 25 ℃ for 1 hour. LCMS analysis showed the starting material was consumed completely and the desired product was detected. The mixture was dried over anhydrous sodium sulfate under reduced pressure to give 73 mg (89.63%) of (15R)-5-({2-chloro- 5H,6H,7H,8H,9H-pyrimido[4,5-d]azepin-4-yl}oxy)-15- methyl-11-thia-3,6,14,17-tetra- azatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-13-one as a yellow oil, which was used directly in the next step without purification. LCMS: Rt = 0.401 min, m / z = 482.1 (M+H)+.

[0315] Step 3. Preparation of (15R)-5-({2-chloro-7-methyl-5H,6H,7H,8H,9H- pyrimido[4,5-d]azepin-4-yl}oxy) -15-methyl-11-thia-3,6,14,17- tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-13-one. To a solution of (15R)-5-({2-chloro-5H,6H,7H,8H,9H-pyrimido[4,5-d]azepin-4-yl}oxy)-15- methyl-11-thia-3,6,14,17-tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸] octadeca-1(10),2(7),3,5,8,12(18)- hexaen-13-one (73.4 mg, 1 eq, 92.9 µmol) in methanol (2 mL) at room temperature was added formaldehyde (0.5 mL, 37% in water) and acetic acid (0.1 mL). The reaction mixture was stirred at 25 ℃ for 0.5 hour. Then, to the reaction mixture was added sodium cyanoboranuide (20.4 mg, 3.5 eq, 325 µmol) at 25 ℃. The mixture was stirred at 25 ℃ for 1 hour. LCMS analysis showed the starting material was consumed completely and the desired product was detected. The reaction mixture was filtered, and the filtrate was purified by prep-HPLC to give 8.4 mg (18.2%) of (15R)-5-({2-chloro-7-methyl-5H,6H,7H,8H,9H- pyrimido[4,5-d]azepin-4-yl}oxy)-15-methyl-11-thia-3,6,14,17- tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸] octadeca-1(10),2(7),3,5,8,12(18)-hexaen-13-one as a yellow solid. LCMS: Rt = 0.434 min, m / z =496.1 (M+H)+.1H NMR (400 MHz, CDCl3) δ 8.94 (br s, 1H), 8.74 (s, 1H), 8.08 (d, J = 8.9 Hz, 1H), 7.89 (d, J = 8.9 Hz, 1H), 5.95 (br s, 1H), 3.98 – 3.70 (m, 2H), 3.61 (ddd, J = 3.3, 6.2, 13.4 Hz, 1H), 3.32 – 3.04 (m, 4H), 2.80 – 2.57 (m, 4H), 2.45 (s, 3H), 1.41 (d, J = 6.8 Hz, 3H). EXAMPLE 7 – Synthesis of 2-chloro-4-{[(15R)-15-methyl-13-oxo-11-thia-3,6,14,17- tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-5-yl]oxy}- 5H,7H,8H-6λ⁶-thiopyrano[4,3-d]pyrimidine-6,6-dione (I-7) 120ny-2716015Attorney Docket No.30864-20005.40

[0316] To a solution of (15R)-5-hydroxy-15-methyl-11-thia-3,6,14,17- tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-13-one (35.6 mg, 1 eq, 119 µmol) in dimethyl sulfoxide (1 mL) was added cesium carbonate (77.2 mg, 2 eq, 237 µmol). The mixture was stirred at 25 ℃ for 5 minutes. To the mixture was added 2,4- dichloro-5H,7H,8H-6λ⁶-thiopyrano [4,3-d]pyrimidine-6,6-dione (30 mg, 1 eq, 119 µmol) at 25 ℃. The reaction mixture was stirred at 25 ℃ for 1 hour. LCMS showed the starting material peak was consumed and the major peak was detected. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC to afford 10 mg (21.59%) of 2-chloro-4-{[(15R)-15- methyl-13-oxo-11-thia-3,6,14,17-tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸] octadeca- 1(10),2(7),3,5,8,12(18)-hexaen-5-yl]oxy}-5H,7H,8H-6λ⁶-thiopyrano[4,3-d]pyrimidine-6,6- dione as an orange solid. LCMS (ESI+): Rt = 1.505 min, m / z 517.0 (M+H)+.1H NMR (400 MHz, DMSO-d6) 9.09 (s, 1H), 8.82 – 8.77 (m, 1H), 8.36 (d, J = 9.0 Hz, 1H), 8.01 (br d, J = 4.1 Hz, 1H), 7.96 (d, J = 9.0 Hz, 1H), 4.63 (s, 2H), 3.74 – 3.64 (m, 3H), 3.64 – 3.57 (m, 2H), 3.47 (br t, J = 6.4 Hz, 2H), 1.22 (d, J = 6.6 Hz, 3H). 121ny-2716015Attorney Docket No.30864-20005.40 EXAMPLE 8 – Synthesis of (R)-3-((2-chloro-5,6,7,8-tetrahydropyrido [4,3-d]pyrimidin- 4-yl)oxy)-10-methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f] quinoxalin-8-one (I-8)

[0317] Step 1. Preparation of tert-butyl 2-chloro-4-{[(15R)-15-methyl-13-oxo-11-thia- 3,6,14,17-tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-5-yl] oxy}-5H,6H,7H,8H-pyrido[4,3-d]pyrimidine-6-carboxylate. To a solution of tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[4,3-d]pyrimidine-6-carboxylate (101 mg, 2 eq, 333 µmol) in dimethyl sulfoxide (2.5 mL, 34.9 mmol) was added (15R)-5-hydroxy-15-methyl-11-thia- 3,6,14,17-tetraazatetracyclo[8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen-13-one (50 mg, 1 eq, 166 µmol) and potassium carbonate (46 mg, 2 eq, 333 µmol) at 25 ℃. The reaction mixture was heated to 60 ℃ and stirred at 60 ℃ for 1 hour. LCMS showed the starting material peak was consumed and the desired peak was detected. Three additional reactions were set up as described above. After cooling to 20 ℃, all four reaction mixtures were combined, diluted with water (20 mL), and filtered. The filter cake was dried under reduced pressure to afford 200 mg of crude tert-butyl 2-chloro-4-{[(15R)-15-methyl-13-oxo- 11-thia-3,6,14,17-tetraazatetracyclo [8.8.0.0²,⁷.0¹²,¹⁸]octadeca-1(10),2(7),3,5,8,12(18)-hexaen- 5-yl]oxy}-5H,6H,7H,8H-pyrido[4,3-d]pyrimidine-6-carboxylate as an orange solid. LCMS (ESI+): Rt = 0.545 min, m / z 568.2 (M+H)+.

[0318] Step 2. Preparation of (R)-3-((2-chloro-5,6,7,8-tetrahydropyrido [4,3- d]pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12-tetrahydro-8H- [1,4]diazepino[5’,6’:4,5]thieno[3,2-f] quinoxalin-8-one. A solution of tert-butyl (R)-2- 122ny-2716015Attorney Docket No.30864-20005.40 chloro-4-((10-methyl-8-oxo-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2- f]quinoxalin-3-yl)oxy)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate (0.2 g, crude) in formic acid (2 mL) was stirred at 25 ℃ for 0.5 hour. LCMS showed the starting material peak was consumed and the desired peak was detected. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep- HPLC to give 35 mg (21.24%) of (R)-3-((2-chloro-5,6,7,8-tetra-hydropyrido [4,3- d]pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino [5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one as an orange solid. LCMS: Rt = 0.536 min, m / z = 468.2 (M+H)+.1H NMR (400 MHz, DMSO-d6) 9.32 – 9.22 (m, 1H), 9.07 (d, J = 2.3 Hz, 1H), 8.80 (br s,’1H’, 8.38 (dd, J = 2.3, 8.8 Hz, 1H), 8.03 (br s, 1H), 7.99 – 7.92 (m, 1H), 4.47 (br s, 2H), 3.70 – 3.66 (m, 1H), 3.64 – 3.59 (m, 2H), 3.55 (br s, 2H), 3.14 (br s, 2H), 1.29 – 1.14 (m, 3H). EXAMPLE 9 – Synthesis of (R)-3-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d] pyrimidin-4-yl) oxy)-10-methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5] thieno[3,2-f]quinoxalin-8-one (I-5)

[0319] To a solution of (R)-3-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 10-methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one (20 mg, 1 eq, 42.7 µmol) in methanol (0.5 mL) was added triethylamine to adjust the pH to 7 at 25 ℃. To the reaction mixture was added a solution of formaldehyde in water ^37% w / w, 26 µL, 1 eq, 42.7 µmol), acetic acid (0.2 µL, 1 eq, 4.27 µmol), and sodium cyanoborohydride (5.37 mg, 2 eq, 85.5 µmol) at 25 ℃. The reaction mixture was stirred at 25 ℃ for 1 hour. LCMS showed the starting material peak was consumed and the desired peak was detected. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC to afford 5.5 mg (21.59%) of (R)-3-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl) oxy)- 10-methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one as an orange solid. LCMS (ESI+): Rt = 0.628 min, m / z 482.1 (M+H)+.1H NMR (400 MHz, CD3CN ) 8.90 (br s, 1H), 8.84 (s, 1H), 8.18 (d, J = 9.0 Hz, 1H), 7.91 (d, J = 8.9 Hz, 1H), 6.49 123ny-2716015Attorney Docket No.30864-20005.40 (br s, 1H), 4.66 – 4.31 (m, 2H), 3.82 – 3.75 (m, 1H), 3.72 – 3.55 (m, 4H), 3.26 (br d, J = 6.4 Hz, 2H), 3.03 (s, 3H), 1.31 (d, J = 6.8 Hz, 3H). EXAMPLE 10 – Synthesis of (R)-3-((2-chloro-7,8-dihydro-5H-pyrano[4,3-d] pyrimidin- 4-yl)oxy)-10-methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]

[0320] To a solution of 2,4-dichloro-7,8-dihydro-5H-pyrano[4,3-d]pyrimidine (20.5 mg, 1 eq, 99.9 µmol) in dimethyl sulfoxide (1 mL) was added (R)-3-hydroxy-10-methyl-9,10,11,12- tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one (30 mg, 1 eq, 99.9 µmol) and potassium carbonate (27.6 mg, 2 eq, 0.2 mmol) at 25 ℃. The reaction mixture was heated to 60 ℃ and stirred at 60 ℃ for 1 hour. LCMS showed the starting material peak was consumed and the desired peak was detected. After cooling to room temperature, the reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (3 × 3mL). The organic phase was combined, washed with brine (5 mL), and dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC to afford 14.7 mg (31.38%) of (R)-3-((2-chloro-7,8-dihydro-5H-pyrano[4,3-d] pyrimidin-4-yl)oxy)-10-methyl- 9,10,11,12-tetrahydro-8H-[1,4]diazepino [5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one as an orange solid. LCMS (ESI+): Rt = 0.452 min, m / z 469.2 (M+H)+.1H NMR (400 MHz, DMSO-d6) 9.08 (s, 1H), 8.80 (t, J = 3.9 Hz, 1H), 8.35 (d, J = 8.8 Hz, 1H), 8.01 (d, J = 4.4 Hz, 1H), 7.96 (d, J = 9.0 Hz, 1H), 4.85 (s, 2H), 4.05 (t, J = 5.6 Hz, 2H), 3.71 – 3.65 (m, 1H), 3.60 (br s, 2H), 2.94 (t, J = 5.5 Hz, 2H), 1.21 (d, J = 6.6 Hz, 3H). EXAMPLE 11 – Synthesis of (R)-3-((2-chloro-5,7-dihydrofuro[3,4-d]pyrimidin-4- yl)oxy)-10-methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino[5’,6’:4,5]thieno[3,2- f]quinoxalin-8-one (I-10) 124ny-2716015Attorney Docket No.30864-20005.40

[0321] To a solution of (R)-3-hydroxy-10-methyl-9,10,11,12-tetrahydro-8H-[1,4]diazepino [5’,6’:4,5] thieno[3,2-f]quinoxalin-8-one (45 mg, 1 eq, 150 µmol) in dimethyl sulfoxide (1 mL) was added 2,4-dichloro-5,7-dihydrofuro[3,4-d]pyrimidine (28.6 mg, 1 eq, 150 µmol) and potassium carbonate (41.4 mg, 2 eq, 0.3 mmol,) at 25 ℃. The reaction mixture was heated to 60 ℃ and stirred at 60 ℃ for 1 hour. LCMS showed the starting material peak was consumed and the desired peak was detected. After cooling to room temperature, the reaction mixture was quenched with water (10 mL) and extracted with ethyl acetate (3 × 3 mL). The organic phase was combined, washed with brine (5 mL), and dried over anhydrous sodium sulfate. The mixture was filtered, and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC to afford 20 mg (29.94%) of (R)-3- ((2-chloro-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)oxy)-10-methyl-9,10,11,12-tetrahydro-8H- [1,4]diazepino [5’,6’:4,5]thieno[3,2-f]quinoxalin-8-one as an orange solid. LCMS (ESI+): Rt = 0.662 min, m / z 455.1 (M+H)+.1H NMR (400 MHz, DMSO-d6) 9.09 (s, 1H), 8.80 (t, J = 3.6 Hz, 1H), 8.35 (d, J = 9.0 Hz, 1H), 8.01 (d, J = 4.6 Hz, 1H), 7.95 (d, J = 9.0 Hz, 1H), 5.16 (t, J = 2.1 Hz, 2H), 5.11 – 5.04 (m, 2H), 3.67 (ddd, J = 3.2, 4.1, 7.2 Hz, 1H), 3.64 – 3.55 (m, 2H), 1.21 (d, J = 6.8 Hz, 3H). EXAMPLE 12 – Synthesis of 3’-((2-chloro-6-methyl-5,6,7,8-tetrahydropyrido[4,3-d] pyrimidin-4-yl)oxy)-11’,12’-dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5] thieno[3,2-f]quinoxalin]-8’(9’H)-one (I-25)

[0322] To a solution of 3’-((2-chloro-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl)oxy)- 11’,12’-dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]- 125ny-2716015Attorney Docket No.30864-20005.40 8’(9’H)-one (80 mg, crude) in methanol (1 mL) was added formaldehyde (36.6 mg, 1 eq, 167 µmol, 37%) and sodium cyanoborohydride (21 mg, 2 eq, 333 µmol) at 25 ℃. The reaction mixture was stirred at 25 ℃ for 1 hour. LCMS showed the starting material peak was consumed and the desired peak was detected. The mixture was filtered, and the filtrate was purified by prep-HPLC to afford 2 mg (2.43%) of 3’-((2-chloro-6-methyl-5,6,7,8- tetrahydropyrido[4,3-d] pyrimidin-4-yl)oxy)-11’,12’-dihydrospiro[cyclopropane-1,10’- [1,4]diazepino[5’,6’:4,5]thieno [3,2-f]quinoxalin]-8’(9’H)-one as an orange solid. LCMS (ESI+): Rt = 0.513 min, m / z 494.3 (M+H)+.1H NMR (400 MHz, DMSO-d6) 9.08 (s, 1H), 8.93 – 8.85 (m, 1H), 8.36 (d, J = 8.9 Hz, 1H), 8.24 (s, 1H), 7.96 (d, J = 8.8 Hz, 1H), 3.64 (s, 2H), 3.60 (br s, 2H), 2.99 – 2.91 (m, 2H), 2.78 (br t, J = 5.5 Hz, 2H), 2.46 (s, 3H), 0.96 (br s, 2H), 0.87 (br s, 2H). EXAMPLE 13 – Synthesis of 3’-((2-chloro-5,6,7,8-tetrahydropyrido [4,3-d]pyrimidin-4- yl)oxy)-11’,12’-dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f] quinoxalin]-8’(9’H)-one (I-26)

[0323] Step 1. Preparation of tert-butyl 2-chloro-4-((8’-oxo-8’,9’,11’,12’-tetrahydrospiro [cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-3’-yl)oxy)-7,8- dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate. To a solution of 3’-hydroxy-11’,12’- dihydrospiro[cyclopropane-1,10’-[1,4]diazepino [5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)- one (60 mg, 1 eq, 192 µmol) in dimethyl sulfoxide (1 mL) was added tert-butyl 2,4-dichloro- 7,8-dihydropyrido[4,3-d]pyrimidine-6(5H) -carboxylate (58.4 mg, 1 eq, 192 µmol) and cesium carbonate (125 mg, 2 eq, 384 µmol) at 25 ℃. Then resulting mixture was stirred at 126ny-2716015Attorney Docket No.30864-20005.40 25 ℃ for 3 hours. LCMS showed the starting material peak was consumed and the desired peak was detected. The reaction mixture was diluted with water (1 mL) and filtered. The filter cake was dried under reduced pressure to afford 120 mg (78.62%) of tert-butyl 2- chloro-4-((8’-oxo-8’,9’,11’,12’-tetrahydrospiro [cyclopropane-1,10’- [1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-3’-yl)oxy)-7,8-dihydropyrido[4,3- d]pyrimidine-6(5H)-carboxylate as an orange solid. LCMS (ESI+): Rt = 0.559 min, m / z 580.1 (M+H)+.

[0324] Step 2. Preparation of 3’-((2-chloro-5,6,7,8-tetrahydropyrido [4,3-d]pyrimidin-4- yl)oxy)-11’,12’-dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f] quinoxalin]-8’(9’H)-one. To a solution of tert-butyl 2-chloro-4-((8’-oxo-8’,9’,11’,12’- tetrahydrospiro[cyclopropane-1,10’- [1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-3’- yl)oxy)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate (50 mg, 1 eq, 86.2 µmol) in dichloromethane (1 mL) was added trifluoroacetic acid (0.1 mL) at 25 ℃. The reaction mixture was stirred at 25 ℃ for 2 hours. LCMS showed the starting material peak was consumed and the desired peak was detected. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC to afford 4 mg (7.67%) of 3’-((2-chloro-5,6,7,8-tetrahydropyrido [4,3-d]pyrimidin-4-yl)oxy)-11’,12’- dihydrospiro[cyclopropane-1,10’-[1,4]diazepino[5’,6’:4,5]thieno[3,2-f]quinoxalin]-8’(9’H)- one as an orange solid. LCMS (ESI+): Rt = 0.320 min, m / z 480.0 (M+H)+.1H NMR (400 MHz, DMSO-d6) 9.06 (s, 1H), 8.90 (t, J = 3.9 Hz, 1H), 8.35 (d, J = 9.0 Hz, 1H), 8.25 (s, 1H), 7.96 (d, J = 8.9 Hz, 1H), 3.96 (s, 2H), 3.59 (br d, J = 3.3 Hz, 2H), 3.09 (br t, J = 5.6 Hz, 2H), 2.81 (br t, J = 5.4 Hz, 2H), 0.99 – 0.92 (m, 2H), 0.86 (br s, 2H). 127ny-2716015Attorney Docket No.30864-20005.40 EXAMPLE 14 – Synthesis of Additional Compounds

[0325] The compounds in Table 2 were prepared using procedures analogous to those described herein above. TABLE 2.128 ny-2716015Attorney Docket No.30864-20005.40129 ny-2716015Attorney Docket No.30864-20005.40EXAMPLE 15 – Analysis of Biological Activity

[0326] Exemplary assays for evaluating the biological activity of compounds described herein are described below. 130 ny-2716015Attorney Docket No.30864-20005.40 MK2 Biochemical Assay

[0327] An ADP-Glo™ Kinase Assay can be used to monitor MK2 kinase activity by measuring effects on MK2 phosphorylation of a peptide substrate, HSP27tide (RRLNRQLSVA-amide). The kinase reaction is conducted in a 384-well, low-flange, white, flat-bottomed polystyrene nonbinding surface plate. MK2 is diluted to 0.625 nM in the BSA- containing assay buffer (40 mM Tris pH 7.5, 20 mM MgCl2, 0.125 mg / ml BSA, 0.5 mM TCEP) and 6 mL is added to each well. Subsequently, test compounds dissolved in the DMSO or the DMSO alone (as control) are diluted to 5% DMSO in BSA-free assay buffer (40 mM Tris pH 7.5, 20 mM MgCl2, 0.5 mM TCEP) and a 3 mL aliquot is added to each well. The plate is incubated at room temperature for 1 hour. The reaction is initiated by adding 3 mL of 50 mM ATP and 3 mL of 1 mg / mL substrate. The plate is incubated on the shaker at room temperature for 1 hour at 300 rpm. The reaction is terminated, and the remaining ATP depleted by adding 15 mL of ADP-Glo™ Reagent to each well. The plate is incubated for 40 minutes at room temperature. Lastly, 30 mL of the Kinase Detection Reagent is added to each well, and the plate is incubated for another 30 minutes at room temperature. The luminescence of each well is measured by EnVision® (PerkinElmer).

[0328] The above procedure was performed for the compounds in Table 3, for which the results are provided. The symbol “+++” indicates a IC50less than 5 nM. The symbol “++” indicates an IC50 in the range of 5 nM to 100 nM. The symbol “+” indicates a IC50 greater than 100 nM. TABLE 3.131ny-2716015Attorney Docket No.30864-20005.40HeLa Cell HSP27 S78 Phosphorylation Assay

[0329] Phospho HSP27 ELISA and total HSP27 ELISA may be performed with PathScan® Phospho-HSP27 (Ser78) Sandwich ELISA Kit (Cell Signaling: 7290) and PathScan® Total HSP27 Sandwich ELISA Kit (Cell Signaling: 7295), respectively. HeLa cells (ATCC: CCL- 2) are cultured in DMEM with 10% heat-inactivated fetal calf serum and 100 U / mL Penicillin- Streptomycin at 37 ℃ and 5% CO2. A day before the assay, HeLa cells are plated at 0.25x105 / well in a 96-well plate. On the following day, the cells are incubated with test compounds in the culture media at 37 ℃ (100 mL / well). After 1 hour incubation, the cells are treated with IL-1b (10 ng / mL) for 20 minutes at 37 ℃ (200 ml / well). After incubation, cells are washed with PBS 1x and lysed with 200 mL of lysis buffer (from ELISA kit) containing phosphatase inhibitor cocktail to each well, and incubated on ice for 5 minutes. Subsequently, cell lysates are centrifuged for 10 min (x3,000 g) at 4 ℃. The supernatant samples are assayed by ELISA for the presence of 132hosphor HSP27 S78 and total HSP27. PBMCs (Peripheral Blood Mononuclear Cells) TNF-a Release Assay

[0330] TNF-α ELISA may be performed with Human TNF alpha ELISA Kit (Abcam: ab181421). PBMCs are cultured in RPMI 1640 Medium with 10% heat-inactivated fetal calf serum and 100 U / mL Penicillin-Streptomycin at 37 ℃ and 5% CO2. PBMCs are plated at 1x105 / well in a 96-well plate and incubated with test compounds in the culture media at 37 ℃ (100 ml / well). After 1 hour incubation, the cells are treated with lipopolysaccharide (LPS, 100 132ny-2716015Attorney Docket No.30864-20005.40 ng / ml) for 4 hours at 37 ℃ (200 mL / well). After incubation, the supernatant samples are assayed by the ELISA for the presence of TNF-α.

[0331] The above procedure was performed for the compounds in Table 4, for which the results are provided. The symbol “+++” indicates a IC50 less than 20 nM. The symbol “++” indicates an IC50in the range of 20 nM to 100 nM. The symbol “+” indicates a IC50greater than 100 nM. TABLE 4.133ny-2716015Attorney Docket No.30864-20005.40 INCORPORATION BY REFERENCE

[0332] The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes. EQUIVALENTS

[0333] The invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting the invention described herein. Scope of the invention is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein. 134ny-2716015

Claims

Attorney Docket No.30864-20005.40 Claims:

1. A compound represented by Formula I’:(I’) or a pharmaceutically acceptable salt thereof, wherein: R1and R2are independently hydrogen or C1-4alkyl; or R1and R2are taken together with the carbon atom to which they are attached to form a 3-7 membered saturated carbocyclic ring or a 3-7 membered heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of R6; R3and R4are independently hydrogen or C1-4 alkyl; R5is -O-(9-11 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7); R6is C1-4 alkyl or C1-4 haloalkyl; R7is C1-4alkyl, C1-4deuteroalkyl, C1-4haloalkyl, -(C1-3alkylene)-C1-4alkoxy, or oxo; or two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring; X is -N(R8)-, -O-, or -CH2-; R8is hydrogen or C1-4alkyl; and n is 0, 1, 2, or 3.

2. The compound of Formula I’, wherein the compound is represented by Formula I:135ny-2716015Attorney Docket No.30864-20005.40 (I) or a pharmaceutically acceptable salt thereof, wherein: R1and R2are independently hydrogen or C1-4 alkyl; or R1and R2are taken together with the carbon atom to which they are attached to form a 3-7 membered saturated carbocyclic ring or a 3-7 membered heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of R6; R3and R4are independently hydrogen or C1-4alkyl; R5is -O-(9-11 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7); R6is C1-4 alkyl or C1-4 haloalkyl; R7is C1-4 alkyl, C1-4 deuteroalkyl, C1-4 haloalkyl, -(C1-3 alkylene)-C1-4 alkoxy, or oxo; or two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring; X is -N(R8)-, -O-, or -CH2-; R8is hydrogen or C1-4alkyl; and n is 0, 1, or 2.

3. The compound of claim 1 or 2, wherein the compound is a compound of Formula I.

4. The compound of any one of claims 1-3, wherein X is -N(R8)-.

5. The compound of any one of claims 1-4, wherein R8is hydrogen.

6. The compound of any one of claims 1-4, wherein R8is methyl.

7. The compound of any one of claims 1-3, wherein X is -O-.

8. The compound of any one of claims 1-3, wherein X is -CH2-.

9. The compound of claim 1 or 2, wherein the compound is a compound of formula Ia:136ny-2716015Attorney Docket No.30864-20005.40 or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 or 2, wherein the compound is a compound of formula Ib:or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 or 2, wherein the compound is a compound of formula Ic:or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 or 2, wherein the compound is a compound of formula Id:or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 or 2, wherein the compound is a compound of formula Ie: 137ny-2716015Attorney Docket No.30864-20005.40or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 or 2, wherein the compound is a compound of formula If:or a pharmaceutically acceptable salt thereof.

15. The compound of claim 1 or 2, wherein the compound is a compound of Formula I-A:(I-A) or a pharmaceutically acceptable salt thereof, wherein: R1and R2are independently hydrogen or C1-4alkyl; or R1and R2are taken together with the carbon atom to which they are attached to form a 3-7 membered saturated carbocyclic ring or a 3-7 membered heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of R6; R3and R4are independently hydrogen or C1-4 alkyl; 138ny-2716015Attorney Docket No.30864-20005.40 R5is -O-(9-11 membered bicyclic chloroheteroaryl containing 1, 2, or 3 heteroatoms selected from nitrogen, oxygen, and sulfur, wherein the heteroaryl is substituted with n occurrences of R7); R6is C1-4alkyl; R7is C1-4alkyl, C1-4deuteroalkyl, C1-4haloalkyl, -(C1-3alkylene)-C1-4alkoxy, or oxo; or two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring; and n is 0, 1, or 2.

16. The compound of claim 15, wherein the compound is a compound of Formula I-A.

17. The compound of any one of claims 1-8, 15, or 16, wherein each of R3and R4is hydrogen.

18. The compound of claim 1 or 2, wherein the compound is a compound of Formula I-B:(I-B) or a pharmaceutically acceptable salt thereof, wherein: R1and R2are independently hydrogen or C1-4alkyl; or R1and R2are taken together with the carbon atom to which they are attached to form a 3-7 membered saturated carbocyclic ring or a 3-7 membered heterocyclic ring containing 1 or 2 nitrogen atoms, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of R6;, wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclic ring is substituted with n occurrence of R7. R6is C1-4alkyl; 139ny-2716015Attorney Docket No.30864-20005.40 R7is C1-4alkyl, C1-4deuteroalkyl, C1-4haloalkyl, -(C1-3alkylene)-C1-4alkoxy, or oxo; or two R7groups attached to the same carbon atom are taken together with the carbon atom to form a 3-7 membered saturated carbocyclic ring; and n is 0, 1, or 2.

19. The compound of claim 18, wherein the compound is a compound of Formula I-B.

20. The compound of any one of claims 1-8 or 15-19, wherein R1is C1-4 alkyl.

21. The compound of any one of claims 1-8 or 15-19, wherein R1is methyl.

22. The compound of any one of claims 1-8 or 15-21, wherein R2is hydrogen.

23. The compound of any one of claims 1-8 or 15-19, wherien R1is methyl, and R2is hydrogen.

24. The compound of any one of claims 1-8 or 15-19, wherein R1and R2are taken together with the carbon atom to which they are attached to form a 3 membered saturated carbocyclic ring substituted with 0 or 1 occurrences of methyl.

25. The compound of any one of claims 1-8 or 15-19, wherein R1and R2are taken together with the carbon atom to which they are attached to form a 4 membered saturated carbocyclic ring or a 4 membered heterocyclic ring containing 1 nitrogen atom, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of methyl.

26. The compound of any one of claims 1-8 or 15-19, wherein R1and R2are taken together with the carbon atom to which they are attached to form a 6 membered saturated carbocyclic ring or a 6 membered heterocyclic ring containing 1 nitrogen atom, wherein the carbocyclic ring and the heterocyclic ring are substituted with 0 or 1 occurrences of methyl.

27. The compound of any one of claims 1-8 or 15-19, wherein R1and R2are taken together with the carbon atom to which they are attached to form a ring selected from, ,wherein * represents the carbon atom. 140ny-2716015Attorney Docket No.30864-20005.40 28. The compound of any one of claims 1-27, whereinwherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclic ring is substituted with n occurrences of R7.

29. The compound of any one of claims 1-27, wherein, wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclic ring is substituted with n occurrences of R7.

30. The compound of any one of claims 1-27, wherein, wherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, and wherein the heterocyclic ring is substituted with n occurrences of R7.

31. The compound of any one of claims 1-27, whereinwherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclic ring is unsubstituted.

32. The compound of any one of claims 1-27, whereinwherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclic ring is substituted with 1 occurrence of R7. 141ny-2716015Attorney Docket No.30864-20005.40 33. The compound of any one of claims 1-27, whereinwherein A is a 5-7 membered heterocyclic ring containing 1 heteroatom selected from oxygen, nitrogen, and sulfur, wherein the heterocyclic ring is substituted with 2 occurrences of R7.

34. The compound of any one of claims 1-33, wherein R7is methyl, -CHF2, -CH2CHF2, or oxo.

35. The compound of any one of claims 1-33, wherein n is 2, the two R7groups are attached to the same carbon atom, and the two R7groups are taken together with the carbon atom to which they are attached to form a cyclopropyl ring.

36. The compound of any one of claims 1-33, wherein n is 0.

37. The compound of any one of claims 1-34, wherein n is 1.

38. The compound of any one of claims 1-34, wherein n is 2. ,. 142ny-2716015Attorney Docket No.30864-20005.40 40. The compound of any one of claims 1-27, wherein R5is selected from,41. A compound in Table 1 herein, or a pharmaceutically acceptable salt thereof.

42. A pharmaceutical composition comprising a compound of any one of claims 1-41 and a pharmaceutically acceptable carrier.

43. A method for treating a disease or condition mediated by MK2, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of any one of claims 1-41 to treat the disease or condition.

44. The method of claim 43, wherein said disease or condition mediated by MK2 is an inflammatory disorder.

45. The method of claim 43, wherein said disease or condition mediated by MK2 is ankylosing spondylitis, rheumatoid arthritis, psoriasis, chronic graft-versus-host disease, acute graft-versus-host disease, Crohn’s disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren’s syndrome, scleroderma, ulcerative colitis, asthma, uveitis, psoriatic arthritis, hidradenitis suppurativa, cryopyrin-associated periodic syndromes, or juvenile idiopathic arthritis.

46. The method of claim 43, wherein said disease or condition mediated by MK2 is ankylosing spondylitis, rheumatoid arthritis, psoriasis, Crohn’s disease, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, Celiac Sprue, idiopathic thrombocytopenic thrombotic purpura, myasthenia gravis, Sjogren’s syndrome, scleroderma, ulcerative colitis, or asthma.

47. The method of claim 43, wherein said disease or condition mediated by MK2 is rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, hidradenitis suppurativa, cryopyrin-associated periodic syndromes, or juvenile idiopathic arthritis. 143ny-2716015Attorney Docket No.30864-20005.40 48. The method of claim 43, wherein said disease or condition mediated by MK2 is cancer.

49. The method of claim 43, wherein said disease or condition mediated by MK2 is a cancer selected from pancreatic cancer, colorectal cancer, multiple myeloma, lung cancer, gastric cancer, breast cancer, nasopharyngeal cancer, skin cancer, bladder cancer, prostate cancer, head and neck cancer, or glioblastoma.

50. The method of claim 43, wherein said disease or condition mediated by MK2 is pancreatic cancer.

51. The method of any one of claims 43-50, wherein the subject is a human.

52. A method of inhibiting the activity of a MK2, comprising contacting a MK2 with an effective amount of a compound of any one of claims 1-41 to inhibit the activity of said MK2.

53. A method of covalently modifying a MK2, comprising contacting a MK2 with an effective amount of a compound of any one of claims 1-41 to covalently modify the MK2.

54. A covalently modified MK2 formed by the method of claim 53. 144ny-2716015

Citation Information

Patent Citations

  • MK2 inhibitors and uses thereof

    US20160075720A1

  • Heteroaryl compounds useful as MK2 inhibitors

    US20200102325A1

  • MK2 degraders and uses thereof

    WO2023278759A1

  • Diazepino-thieno-quinoxaline compounds and their use in therapy

    WO2024044731A1